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The African pharmaceutical industry lacks the capacity to adequately supply the continent with 
essential medicines to combat the heavy disease burden that is grappling the continent. As a 
result, Africa relies heavily on imported medicines and vaccines to meet the growing needs of 
the population. Local pharmaceutical production promises to provide a sustainable solution to 
public health, industrial development and socio-economic issues on the continent. However, 
local pharmaceutical production does not make economic sense if the industry is unable to 
competitively produce quality medicine at prices that are comparable to or better than those of 
imported medicine. The aim of this study was to evaluate whether locally filling a multivalent 
vaccine used in paediatric immunization is economically viable when compared to the same 
vaccine currently imported semi-finished for labelling, packaging and distribution. Can a South 
African vaccine manufacturer produce the same vaccine cheaper than it currently imports? The 
objectives were to determine the production costs for both semi-finished product and local 
vaccine filling operations and to assess which option makes economic sense to pursue. The sub-
objectives were to establish the extent and impact of the market size and demand for this vaccine 
on the decision to pursue local production versus importation. A case study approach was 
adopted as a research method to gain an in-depth understanding of the economic and production 
factors within the context of vaccine manufacturing with The Biologicals and Vaccines Institute 
of Southern Africa (Biovac) as a unit of analysis. Multiple sources of data were used to collect 
data for analysis. The study found that local production of this vaccine is economically viable 
and more favourable over imported product at current annual demand of 4.5 million doses. 
Local vaccine filling operations break-even point was found to be at 1.3 million doses when 
compared to 2.6 million doses for imported semi-finished product Whilst economies of scale 
cannot be disregarded for long-term profitability, this study found that economic viability can 
be achieved with an annual demand of 4.5million doses.  The aim of this study was 
accomplished. This study contributes to the body of knowledge on local pharmaceutical 
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 CHAPTER ONE: Introduction 
1.1 Introduction 
The reliance on imported medicines in Africa remains unsustainably high with an estimated 25 
to 30 percent of essential medicines consumed in Africa being produced within the continent 
(African Development Bank, 2014). As a result of low production capacity the continent is 
susceptible to drug supply shortages, limited access to essential medicine and inability to swiftly 
respond to pandemic disease outbreaks. The disproportionate number of deaths due to acute 
shortage of the influenza vaccine in Africa during the 2009 H1N1 flu pandemic outbreak 
(Dawood et al., 2012) and the recent Ebola outbreaks in North and West Africa are examples 
demonstrating the unpreparedness to respond to epidemic outbreaks and heavy reliance on 
imported medicines. 
Local production of medicines on the African continent promises to reduce dependency on 
imported drugs, improve access to medicines and create a sustainable response to drug supply 
shortages (African Union and UNIDO, 2012). To effectively reduce import dependency and 
address drug supply shortages in Africa, the continent must create a competitive, sustainable 
pharmaceutical industry that can reliably supply quality, affordable medicine. However, in light 
of current competition from foreign manufacturers, the viability of the local pharmaceutical 
industry lies in price competition (Wilson et al., 2012) and the ability of the industry to produce 
quality products at costs that are less than, or at least competitive, to those of foreign 
manufactures (Taylor et al., 2009).  
The decision whether to produce locally or to continue with importation is complex (Kaplan 
and Laing, 2005) and requires a thorough assessment of the feasibility of either option. This is 
to  ensure that such an undertaking will be economically viable given that local manufacturing 
may not necessarily be cheaper than importation (UNCTAD, 2011). This case study assesses 
the economic viability of a locally produced vaccine when compared to the same vaccine 
currently imported semi-finished for labelling, packaging and distribution.  
The rest of this chapter is divided into the following sections: Section 1.2 discusses the 
motivation for the study, which is followed by Section 1.3 summarising the focus of the study; 
Section 1.4 discusses the problem statement; Section 1.5 states the objectives of the study; 
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Section 1.6 states imitations of the study and Section 1.7 will summarise this chapter and give 
an overview of the dissertation. 
1.2 Motivation for the Study: 
South Africa aims to improve its preparedness to respond to pandemic disease outbreaks 
(Dulnier, 2010) and reduce the dependency on imported vaccines by resuscitating vaccine 
manufacturing capability through the establishment of The Biologicals and Vaccines Institute 
of Southern Africa (Biovac). Over the past decade Biovac has sourced, imported and distributed  
vaccines for the national immunization programme  and is now preparing to  integrate the 
formulation and filling operations into the current importing and distribution business model 
(Dulnier, 2010).   
This study had to be conducted because the current costing model for Biovac is based on 
sourcing and distribution of imported vaccines. No formal cost-analysis study has been 
conducted by Biovac on local vaccine filling activities from formulated bulk liquid product. 
Biovac will use the information from this study to develop a costing model for fill/finish 
operations. With the Company attracting technology transfer partners for collaboration in 
various projects, understanding the vaccine production costs and associated market dynamics 
will enable Biovac to make informed decisions on which strategy, if pursued, will be 
economically viable.  
The decision on which imported vaccines are to be prioritised for local production can be made 
with more certainty if the production costs and market dynamics of either option is better 
understood. Because of limited human vaccine manufacturing operations in South Africa, there 
is a gap in the available literature on the production costs and capability to manufacture 
affordable, high quality vaccines. The extent to which the input costs are applicable to the 
viability of local production is not well defined and therefore there is limited reference to use 
as a baseline in the manufacturing of vaccines within the South African context.      
 There are different views regarding the feasibility of local vaccine manufacturing. According 
to Kaplan and Laing (2005), local manufacturing may not be feasible in all developing countries 
if the economies of scale of production are insufficient. However, the extent of the requirement 
for economies of scale is not well defined in the literature. It has been estimated that up to 60 
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% of vaccine production costs are fixed and requires economies of scale to recoup some of the 
costs (Baumann, 2009). Again there is no distinction whether this figure refers to the production 
of monovalent or polyvalent vaccines or whether these are high cost or low cost vaccines.   
1.3 Focus of the Study: 
This study will focus on the production and infrastructural costs to assess whether Biovac can 
competitively produce quality vaccines more favourably than imported vaccines. The input 
costs associated with producing a single unit of vaccine from imported formulated bulk were 
analysed and compared to the costs of importing a fully finished vaccine for labelling and 
distribution. Direct and indirect costs of production as well as fixed and variable costs were 
identified and assessed to determine the extent to which they have an effect on the final price 
of a vaccine under different market conditions.  
Since Biovac processes do not currently include antigen production and formulation, the costs 
of producing the antigens or the effect of locally producing vaccines from the antigen stage to 
finished product was not assessed as part of this study. The distribution and marketing costs of 
either a locally produced or imported vaccine is the same as the finished product is stored and 
packed in the same configuration therefore the study will not focus on these common costs.   
1.4 Problem Statement: 
Despite the dominant status of the South African pharmaceutical industry in Africa, in terms of 
annual production and the number of pharmaceutical manufacturers in the country (SEATINI 
and CEHURD, 2013), there is no human vaccine manufacturing capability in South Africa. As 
a result, South Africa  remains the only member of the group of developing countries among 
them Brazil, Russia, India, China and South Africa (BRICS) to import all vaccines to support 
the national immunization programme (Kaddar et al., 2014). Despite having no vaccine 
manufacturing capability, South Africa is considered an early adopter of  new vaccines financed 
by national government mainly through taxation (Blecher et al., 2012). It can therefore be 
expected that as newer vaccines are adopted by government for the immunization programme, 
there will be more pressure on the allocated vaccine budget. 
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Establishing vaccine manufacturing capability in South Africa could reduce trade deficit 
resulting from importation of pharmaceuticals, however such an investment undertaking 
requires a thorough assessment to determine its viability and profitability. When calculating the 
cost of a single unit of vaccine one must take into account the input costs such as the costs of 
establishing a vaccine manufacturing facility (Bate, 2008), developmental and production costs, 
cost and skill of labour, shipping and raw material (Lee and McGlone, 2010). Taking all of the 
above into account, the following pertinent questions remain to be answered:   
 Is local vaccine manufacturing a viable option in South Africa?  
 Can Biovac locally produce quality vaccines at a more favourable cost than currently 
imported? 
1.5 Objectives of the Study 
The aim of this study was to evaluate economic viability of Locally Filled Vaccine (LFV) when 
compared to imported, Semi-finished product for packaging and distribution (SFP).  
The objectives of this study were: 
i. To ascertain the manufacturing costs of a LFV versus SFP;  
ii. To determine the level of economic activity for which LFV is preferred when compared 
to SFP; 
iii. To determine the desirable market size for which one option is preferred over the other; 
iv. To determine the level of investment needed for both options – LFV vs. SFP; and 
v. To determine the effect of changing the key variables such as the selling price and the 
cost of imported product (SFP or formulated bulk) on the viability of either option.  
1.6 Limitations of the Study  
The LFV that was used to collect data was a technology transfer product candidate that is 
currently not commercially available in the South African market but has undergone stability 
testing and awaits approval by the regulatory authority. This means that this product has 
undergone the full manufacturing cycle, however, the costs of the primary and secondary 
packaging materials may change by the time the product is registered on the market. The SFP 
that was used for comparison in this study is registered and available in the market.  
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The cost price used is the current price of the product in the market on the government tender.   
1.7 Summary and Overview of the Dissertation  
This chapter discussed the motivation for the study, the problem statement and the focus of the 
study. The objectives and the limitations of the study were also stated in this chapter. 
The next chapter, Chapter 2, will discuss the literature review of local pharmaceutical 
production. In particular, the drivers for local production and key considerations for successful 
local pharmaceutical production are discussed with more emphasis on vaccine manufacturing.   
Chapter 3 outlines the case study research methodology that was employed in this study as well 
as data collection methods, data analysis tools and finally the issues of validity and reliability. 
Chapter 4 presents and analyses the findings obtained using the methodology in Chapter 3.  
Chapter 5 summarises the findings, makes recommendations and conclusion. 





CHAPTER TWO: Literature Review 
2.1 Introduction 
Many solutions have been proposed to solve the issues of access to affordable, quality medicine, 
which is a threat to public health and budgets of national governments in Africa. Local 
pharmaceutical production emerges as one of the key solutions that promise benefits that are 
beyond access to medicine. It is therefore not surprising that local production is receiving 
support from political heads and multilateral organizations (UNCTAD, 2011;UNIDO, 2013) as 
a sustainable solution to reduce heavy reliance on imported medicines. Currently, affordability 
and quality of medicine remain a challenge for many African countries to the extent that they 
rely on donor funding to access medicine. This is particularly evident when it comes to vaccines 
donated by the Global Alliance on Vaccination and Immunizations (GAVI) and the funding of 
medicines needed to treat malaria, HIV and AIDS. 
Despite the benefits that stand to be realized, there are key challenges that need to be overcome 
and considerations that must be taken into account in order for local production to be viable. 
These considerations relate to cost disadvantages and competitiveness of the pharmaceutical 
industry across the continent, the capability and capacity to embark on such an undertaking.  
The focus of this review will be on the key drivers behind the support to boost local production 
capacity and the key considerations for the successful establishment of local production in 
Africa within the context of South Africa.  
The aim of this study was to evaluate economic viability of locally produced vaccines in South 
Africa as opposed to importing them semi-finished for sale and distribution. Although there are 
varying degree of pharmaceutical production across the African continent, vaccine production 
is almost non-existent with Senegal as the only human vaccine manufacturer producing a single 
vaccine against Yellow Fever for the domestic market. Therefore, there is limited literature 
available on local vaccine manufacturing in Africa. As a result, this chapter begins with the 
background on the issues surrounding local production and local production overview and 
definition. This is followed by the drivers and key considerations for establishing local 
production in the context of this study. A summary will conclude this chapter.   
7 
 
2.2 Background   
The support for the developing countries to increase public access to essential medicine and 
reduce the dependency on imported medicine through local production is broadening. In Africa, 
the adoption of the Pharmaceutical Manufacturing Plan for Africa (PMPA) by the Heads of 
African Governments is a clear indication of the political commitment to boost local production 
capacity of essential medicine on the continent (African Union and UNIDO, 2012; African 
Development Bank, 2014). From a political and policy levels, establishing local pharmaceutical 
production promises to improve public health by increasing the security of drug supply and 
access to affordable medicines (WHO, 2011); promote industrial development and socio-
economic stimulation through economic diversification from agricultural production and 
mineral extraction (UNIDO, 2013).  
Despite the benefits and the high level support, competitive pharmaceutical production is 
complex and capital intensive (GlaxoSmithKline, 2011) and therefore requires careful 
consideration before embarking on such an investment undertaking. The primary considerations 
relate to investment cost associated with setting up a GMP-compliant manufacturing facility, 
access to technology and "know-how", skilled labour force, setting up a quality assurance 
system and the long lead times from drug discovery to commercialisation which can take 
approximately 10 – 15 years (IFPMA, 2011). With all these factors taken into consideration, 
the issue of cost of medicine and affordability cannot be ignored when considering the vast 
economic disparities between African countries (World Bank, 2014).  
It is against this background that Kaplan and Laing (2005) supported by Bate (2008) have 
argued that local production may not be a viable option for all countries despite the benefits. 
Whilst other countries can manufacture, others should focus on streamlining their procurement 
and supply chain processes  (Kaplan and Laing, 2005). This sentiment is shared by Bate (2008) 
who also concluded that it is difficult to sustain the argument for local production given the 
lack of resources and technical capacity to competitively produce affordable, high quality 
medicines in most developing countries.  
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2.3 Local Production Overview 
2.3.1 Defining Local Production  
According to the World Health Organization report (WHO, 2011), local production  may be 
defined and better understood in terms of territorial location and ownership of the 
manufacturing facility. Under the territorial definition, it is implied that production of medicine 
takes place in a developing or least-developed country and is subject to national jurisdiction 
irrespective of who owns the facility. For example; the manufacturing operations of a foreign 
owned company, such as Pfizer (American company) or Sanofi-Aventis (French-owned), 
operating in South Africa maybe considered “local” irrespective of where it is controlled or the 
location of its headquarters.     
The second definition of local production is in terms of ownership. Under this definition, it is 
implied that production operations will be considered “local” if the nationals have more than a 
majority of ownership in the firm. This definition has limitations in that the operations of a 
foreign owned company are excluded and considered foreign yet they take place within the said 
country. For the purposes of this study the territorial definition of local production has been 
adopted as it takes into account all manufacturing operations taking place in a country 
irrespective of ownership.  
2.3.2 Forms of Local Production 
Local production occurs at different levels of sophistication and hence the categorization of 
different forms is done in terms of simplicity of operations undertaken. There are three broad 
categories used to describe different forms of local production; namely tertiary, secondary and 
primary levels of production (WHO, 2011). Tertiary manufacturing is the simplest of all 
production categories that generally involves the labelling and packaging of formulated or SFP. 
This form of local production is commonly found in the least developed or low-income 
countries. Secondary manufacturing is more sophisticated than tertiary as it involves the mixing 
of raw materials and formulation of different dosage forms. This form of manufacturing is most 
prevalent in the so-called middle-income countries. However, the raw materials used in 
secondary manufacturing are usually produced by the industrialized and large developing 
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countries such as India and China where significant levels of the primary manufacturing take 
place.  
The primary manufacturing involves the manufacturing of active pharmaceutical ingredients, 
intermediaries and excipients. According to the World Health Organization (WHO, 2011, 
pg12), the primary production used to be concentrated in just five industrialized countries – The 
United States of America, Germany, France, The United Kingdom and Japan. However, the 
picture has changed with China and India’s competitive ability to produce API’s. Other smaller 
developing countries like South Africa have some capability to produce certain raw materials. 
Although South Africa has some capability to produce raw materials, the majority of the raw 
materials used in formulating medicines are imported from countries abroad (Bennet, 2014).   
2.3.3 Local Production of medicine in Africa  
Literature review of the African pharmaceutical Industry confirms the presence of local 
production activities across the continent  that are dominated by a handful of countries (Abbott, 
2011)  supplying a combined output of 25 to 30% of the continent’s needs (Iñarra, 2015). 
According to the summary by Abbott (2011), based on the International Finance Corporation 
(IFC) annual report (World Bank, 2007),  the African pharmaceutical industry is dominated by 
South Africa, Ghana, Nigeria, Kenya and North Africa. The South African pharmaceutical 
industry is considered as the most developed in the Sub-Saharan region and North Africa 
(Bennet, 2014) with South Africa alone responsible for the large majority of the manufacturing 
output (Abbott, 2011). This indicates vast differences in the capabilities of local production 
between the African countries and their abilities to provide essential medicines that will satisfy 
the needs of the population.   
Despite Africa being described in the McKinsey Report (Holt et al., 2015, p2) as the world’s 
fastest –growing economic region, the pharmaceutical industry remains weak and is biased to 
produce  generic medicines (Holt et al., 2015) and copy drugs under licence (WESGRO, 2012). 
This weakness is evident when taking into account that, in global terms, the African 
pharmaceutical industry  was worth an estimated US $23.1 billion in 2011 or less than 2% of 
the global market (African Development Bank, 2014, p1). To put this number into perspective, 
The  European Federation of Pharmaceutical Industries and Associations estimated that Africa 
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combined with Asia and Australia – excluding Japan – contributed to global sales of only 13.7% 
in 2012 (EFPIA, 2012)  and 16.6%  in 2014 (EFPIA, 2015). The small size of the 
pharmaceutical industry in Africa may be interpreted as a good indication of the potential 
economic growth when considering that the disease pattern is expected to shift from 
communicable to chronic or  “lifestyle” diseases  over the next decade (de-Graft Aitkins et al., 
2010). Based on the current situation; if the disease burden actually shifts as expected, it is 
difficult to imagine how the industry will be able to cope with additional demand and 
competition from cheaper medicines imported from India.    
The above scenario presents some worrying scenarios. Firstly, too much focus on the 
production of generics and copy drugs indicates more emphasis on treatment rather than 
prevention of diseases through vaccination. Secondly, the production of generics at a large scale 
implies that the local producers are paying less attention to the research and development of 
new drugs to fight diseases that are more prevalent or disproportionately affect Africa. This 
could be interpreted to mean that the local industry is dependent on research expertise from 
outside the continent. With most countries limited to secondary and tertiary manufacturing – 
formulation, packaging and labelling – the transition to primary manufacturing could prove to 
be costly even if countries are interested in pursuing more sophisticated forms of production. 
Thirdly, limited research and development leaves Africa unable to respond the pandemic 
disease outbreaks as there could be slow progress with research on drugs to combat diseases 
affecting Africa. The shortages of the H1N1 influenza vaccine in 2009 (Dawood et al., 2012) 
and the unavailability of vaccine against the recent deadly Ebola outbreaks in West Africa(Holt 
et al., 2015)  precisely demonstrate this point.   
Finally, the African continent presents some unique disparities in local production.  According 
to the African Development Bank (2015), the importation rate in Senegal is 80% with the 
majority of imports coming from India. Interestingly, Senegal is the only African country that 
has human vaccine manufacturing ability yet the country with the most developed 
pharmaceutical production capability (South Africa) does not produce vaccines for human use. 
As a result of producing a limited range of pharmaceuticals against a rising disease and shifting 
disease burden profile (de-Graft Aitkins et al., 2010), the local pharmaceutical industry will 
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continue to lack the adequate capacity to meet the growing needs of the continent. This leaves 
Africa heavily reliant on life-saving medicines and vaccines imported from abroad.  
2.3.4 Local Production and the Pharmaceutical Industry in South Africa 
South Africa is home to both local and multinational pharmaceutical manufactures that produce 
a wide range of pharmaceuticals for local demand and export (WESGRO, 2012). The 
multinational pharmaceuticals in the country include Pfizer (USA), Fresenius-Kabi (Germany), 
Sanofi (France), Johnson & Johnson (USA) and GlaxoSmithKline (United Kingdom) whilst 
the top local manufacturers include Aspen and Adcock Ingram (Kudlinski, 2013). The country 
has a well-developed pharmaceutical industry with all forms of local production – mainly 
secondary and tertiary with limited primary production – taking place. South Africa has the 
largest pharmaceutical market in Africa although multinationals continue to dominate the 
industry according to the Gauteng Growth Development Agency (GGDA, 2014).   
South Africa is a net importer of pharmaceuticals and this places a heavy burden on the trade 
balance. Previously, the pharmaceutical industry catered for about 64% of the local medicine 
requirements and this has decreased due to an increase in imported medicine (GGDA, 2014). 
The Department of Trade and Industry (DTI) estimated that South Africa imported more than 
65% of its pharmaceuticals and this was the 5th largest contributor to the South African trade 
deficit in 2013 (Kudlinski, 2013) The figures are startling in that, according to DTI, 85% of the 
imported pharmaceuticals in 2011 were in finished dosage form from India, Germany, United 
Kingdom, France and Italy (Kudlinski, 2013). Over the past decade, the reliance on imported 
medicine has continued to grow and this is a concern to government as it increases the risk to 
security of supply.      
Like in many African countries that promote local production, the pharmaceutical industry in 
South Africa is mainly focused on the production of generic medicine (Zhan, 2014) and copy 
drugs  under licence (WESGRO, 2012). According to the WESGRO report (2012), in 2011 the 
generic drug sales accounted for 29% in revenue and more than 50% in volume whilst patented 
drugs accounted for 59% of revenue. There is expectation that the market for generic drugs will 
continue to grow having grown at an average compounded annual growth rate of 22.3% 
between 2004 and 2011 (Holt et al., 2015).     
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Although South Africa dominates the African pharmaceutical industry in both annual 
production and the number of pharmaceutical manufacturers in the country (SEATINI and 
CEHURD, 2013), the country lags behind its peers in the BRICS group of countries (Brazil, 
Russia, India, China, South Africa)  particularly when it comes to vaccine manufacturing. Until 
1993 South Africa produced vaccines locally using out-dated technology and in 2014 South 
Africa remained the only member of the BRICS countries to import all vaccines for the national 
immunization programme (Kaddar et al., 2014). Meanwhile, in the corresponding period, the 
Chinese vaccine industry had developed rapidly to more than 40 vaccine manufacturers in 2010 
(Hendriks et al., 2010). This is a far cry when considering that South Africa has the most 
developed pharmaceutical industry in Africa.   
This section on local production overview suggests that the African pharmaceutical industry is 
weak and is focusing on generic medicines with limited research and development into diseases 
endemic to the continent. The local pharmaceutical industry is under pressure from competition 
from imports which are coming from India and other industrialized countries because of the 
growing reliance on imported medicine.   
2.4 Drivers behind Local Production in Africa  
Although arguments  against the promotion of local production in every country  have been 
presented (Kaplan and Laing, 2005) there is a strong support for local production in hope that 
it will improve public health (WHO, 2011), promote industrial development (UNIDO, 2013)  
and economic growth (Taylor et al., 2009). This section will discuss disease burden, access to 
affordable medicine, security of supply and socio-economic benefits as drivers behind the 
promotion of local production.   
2.4.1 Disease Burden  
While there are many diseases that affect Africa, specific diseases such as Malaria, HIV/AIDS, 
Tuberculosis, Cholera, Ebola and other tropical diseases are more prevalent or 
disproportionately affect Africa than any other part of the world. The disease burden is severe 
across the continent and there is no indication that the situation is getting better (de-Graft 
Aitkins et al., 2010). The continent is faced with a dual burden of disease due to an increase in 
both communicable and chronic disease (IHME, 2013). It is estimated that about 75% of 
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HIV/AIDS cases and 90% of deaths due to malaria occur in Africa (African Development Bank, 
2014) including “more than 50% of the global deaths of children under the age of five” (African 
Union and UNIDO, 2012, page12). HIV/AIDS, Malaria and TB account for more than 5 million 
deaths per year, or about 50 % of all infectious disease deaths (Foster et al., 2006).  
As recent as a decade ago, predictions of higher diabetes prevalence were rife that, by 2020, the 
disease burden will shift from infectious diseases to chronic or so-called lifestyle diseases 
(Foster et al., 2006) owing to Africa’s widespread economic growth and the rise of the middle 
class (Bennet, 2014). Recent studies have confirmed that the disease burden is already shifting 
from communicable to chronic and lifestyle diseases such as diabetes, cardiovascular, cancers 
and depression (de-Graft Aitkins et al., 2010). A study conducted by the Institute of Human 
Metrics and Evaluation (IHME, 2013) confirmed an increase in the prevalence of non-
communicable diseases between 1990 and 2010. The study found that incidents of diabetes, 
low back pain and depression increased by 88%, 65% and 61% respectively during this period. 
It is therefore not surprising that the South African pharmaceutical industry focusing on 
producing generic medicines against lifestyle diseases such as cardiovascular diseases, diabetes 
and antiretroviral (Kudlinski, 2013). 
The shift in disease pattern will also require a shift of focus for many governments especially 
taking into account that many rely on foreign aid to combat diseases such as malaria, HIV/AIDS 
and national immunization programmes. The emergence of chronic diseases on the African 
continent will put a financial strain on many national governments as more medicine will need 
to be imported. Whilst this may be welcome news for the local industry as it will stimulate 
growth and unlock untapped markets, it is unlikely to be welcome by governments in poorer 
countries. In sub-Saharan Africa the prevalence of chronic diseases could not have come at a 
worst time as the region is faced with both  communicable and non-communicable diseases (de-
Graft Aitkins et al., 2010).  
2.4.2 Access to affordable medicine  
According to the World Health Organization, at least 30 percent of the world’s population lacks 
access to essential medicines and in some countries in Africa, the number may be as high as 50 
percent (Bate, 2008). The lack of access to essential medicines and vaccines in developing 
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countries is one of the reasons for the efforts to encourage local production of essential 
medicines that are either in short supply or treat other poverty related, tropical and neglected 
diseases (UNCTAD, 2011). With this approach there will be more assurance that essential 
medicines are produced closer to where they are needed.  
Access to medicine and affordability of medicine may have different meanings and thus must 
be tackled separately. Access is concerned with physically getting the right medicine to the 
right person for the treatment of a properly diagnosed ailment. Affordability is concerned with 
the ability to pay for the required medicine. Many factors may be attributable to a lack of access 
to medicine. For example, the basic transport infrastructure may be lacking and thus the medical 
facilities become unreachable or medicine cannot reach the people who need it. Even worse, 
where it does reach the people, the quality can no longer be guaranteed as with a case with 
vaccines. In certain instances, people have to travel long distances to reach public health 
facilities.  
Most importantly, limited access to medicine and high prices may fuel the presence of 
counterfeit medicines (Alfadl et al., 2013) which has been a serious problem in Africa for many 
years (Laroche et al., 2005). The issue of high prices is sometime difficult to comprehend 
because it is not directly linked to manufacturers charging high prices. Other forces are at play. 
For example, taxes, duties, transport costs and mark-ups by middlemen add to the cost of 
medicine even when manufacturers have lowered their prices (Bate, 2008).  It is estimated that 
about 30% of medicines on the African continent are counterfeits with an estimated 100,000 
people losing their lives because of counterfeit medicines (Leon, 2014, pg1). The dangers are 
life threatening and devastating when taking into account, for example, that a patient taking 
counterfeit malaria tablets stand to lose their lives when infected with the virus.  
The other aspect limiting access to medicine is affordability of imported medicine by national 
governments. This is the ability of the governments to pay for the medicines to reach the people 
who need them. Vaccines for national immunization programmes illustrate this concept well. 
The African economies are vastly different in that there are those countries that are classified 
by the World Bank as upper middle income countries who can afford to pay for vaccines 
through taxation (Blecher et al., 2012). On the other hand, the poorest countries rely on funding 
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to supply the vaccines to their populations from organizations such as the Global Alliance for 
Vaccine and Immunization (GAVI) if they meet the stipulated requirements (Brenzel et al., 
2006) such as the country’s gross national income per capita of  less than $1500. The dilemma 
facing countries on the verge of graduating from the donation programmes is how best to fund 
these vaccines and not put their populations at risk when the funding dries out and most 
importantly how best to prepare themselves for the transition from donor funding to self-
procurement. 
2.4.3 Security of Supply  
Heavy reliance on imported medicine is the biggest threat to access to medicine and continuous 
drug supply. In Africa, essential drug supply shortages are a real threat because even when the 
country can afford to pay for the required medicines or vaccines, there is no assurance that the 
medicine will be available when needed. Even when the medicine eventually becomes 
available, it can take longer for it to reach the end user due to long supply chains among other 
things. Local production may alleviate the problem of medicine supply shortages and allow 
Africa to take course towards breaking away from depending on imported medicine to treat 
diseases that are grappling the continent. Manufacturing closer to home may shorten the lead 
times and supply chains to ensure the medicine reach the patients on time.  
The target for many countries is to be self-sufficient with regards to supplying locally produced 
medicines and less reliance on imported medicines. However, the reality is that self-sufficiency 
is rare and very few countries can supply more than 85% of their market needs through local 
production (Kaplan and Laing, 2005). Arguably, it may be worth the effort for many developing 
countries to target and aim to supply at least 50% of their market through local production or 
to target to purchase from neighbouring countries as opposed to importing from overseas.  
Despite the target of self-sufficiency, drug shortages continue to occur and affect many 
countries across the globe. These shortages are mainly attributable to manufacturing or 
production problems (Palmer, 2014), companies leaving the marketplace and changes in 
manufacturing recommendations such as implementation of stringent cGMP (NNII, 2006). 
Therefore, even if the vaccines were locally manufactured, production problems could still 
affect drug supply. Drug supply shortages become even more critical in pandemic situations 
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such as the shortage of influenza vaccines in 2006 (Ulmer et al., 2006) and again in 2010 during 
the H1N1 influenza outbreak. The Ebola outbreak in 2014 demonstrated three critical points; 
1) Africa is totally dependent on foreign aid; 2) the medicine to treat tropical diseases that 
predominantly affect Africa are unavailable and; 3) the African governments are not prepared 
nor are able to effectively deal with pandemic situations. This had a devastating effect on the 
economies of the affected countries (Holt et al., 2015).    
Although local production promises to improve the security of supply, the argument for self-
sufficiency remains difficult to sustain especially with Africa largely dependent on imported 
raw material supply.  
2.4.4 Socio-economic Benefits  
The African Union’s Action Plan for the Accelerated Industrial Development of Africa (African 
Union, 2007) highlights the link between industrial development, economic growth and social 
development.  The report also highlights the challenge of transforming African economies from 
resource-dependent to dynamic, diversified industrial economies.  This sentiment is evident in 
the UNIDO’s Industrial Development Report (IDR, 2013) which also promotes 
industrialization and economic diversification from agricultural and mineral extraction 
economies.    
 Local production is seen as a means to promote industrialization which presents the opportunity 
to diversify the economy and introduce other service sectors that will contribute towards a wide 
employment base (IDR, 2013). Local pharmaceutical production offers a mix of jobs and 
employment opportunities on a wide scale between low-end technology in packaging 
operations to high-end technology in research and development. Because high end jobs require 
skills in mathematics, science and engineering (IDR, 2013), there is a strong argument that local 
production will encourage investment in skills development and education as the manufacturing 
industry matures and becomes more sophisticated. This in turn has a potential to stimulate 
economic growth and create a substantial domestic market (IDR, 2013).   
The African Union has emphasized that the industrialization in Africa must be anchored on 
building human capacity by investing in health, education and training. There is also 
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recognition that industrial development policies should be designed to enhance the science, 
technology and innovative capacity which is lacking in many African countries (African Union, 
2007).  As industrialization matures, it can be expected that there will be more exports generated 
which will have a positive impact on the balance of trade.   
2.5 Considerations for Establishing Local Production Capacity  
There are two major conflicting views regarding local pharmaceutical production in Africa. 
Firstly, there is a view by the Heads of State and Governments (African Union and UNIDO, 
2012), the World Health Organization (WHO, 2011) and its allied organizations (UNCTAD, 
2011, UNIDO, 2013)  that the promotion of local production is a sustainable means to address 
the public health and socio-economic issues that are grappling the continent. The second 
opposing view as presented by Kaplan and Laing (2005) and supported by Bate (2008) puts 
forward the argument that local production may not be feasible for every country to pursue. 
This section discusses key considerations that must be in place in order for local production to 
be viable.  
2.5.1 Infrastructural Development and Funding 
The competitiveness and viability of local production rests on the availability of an efficient 
infrastructure (roads, communications, water and electricity) and financing. However, basic 
infrastructure on the continent is either lacking or inadequate hence the infrastructural 
development has been a priority of the African Union for more than a decade (African Union, 
2007). Reliable supply of water and electricity are the cornerstone of pharmaceutical 
manufacturing such that any disruption in either of these utilities immediately results in a loss 
of competitiveness. Complex pharmaceutical formulations and cleaning regimes require 
availability of high quality water and electricity to run the sophisticated machinery.  
The delivery of manufacturing supplies as well and final product to the patients demands 
adequate road infrastructure. Not only is the lack of basic infrastructure a problem for the 
manufactures, poor road and transport infrastructure will hinder access to medicine if the 
patients are unable to access healthcare facilities. Unreliable supply of electricity means the 
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manufacturers must have back-up power supply through the use of generators and pay for 
additional fuel costs.    
Financing is key to industrial development (African Union, 2007) and a major consideration in 
the development of physical infrastructure required to set up local production operations – that 
is, the construction of the manufacturing facility. However, financing still remains a major 
constraint to the industrial development in Africa particularly for small and medium enterprises 
who are perceived to be risky by the formal banking systems (UNESC et al., 2013). The start-
up costs of building a pharmaceutical plant that complies with international quality standards 
could cost millions of dollars and is therefore considered a major investment undertaking (Bate, 
2008).  
Once the facility has been built, additional costs to actually run and maintain the facility must 
be taken into account. Secondly, the hidden costs of maintaining the plant during the initial time 
of non-productivity whilst waiting for the regulatory authorities to assess and approve the 
facility as well as those products expected to be produced in that facility must be considered. 
Finally, consideration must be made to the allocation of funding for research and development 
to ensure a pipeline of drugs to be produced in the years to come. However, taking into account 
lead times from discovery to registration may take between 10 – 15 years and cost up to USD 
1.38 billion to develop a single medicine (IFPMA, 2011), it is not unexpected that Africa lags 
behind in this regard. It is for this reason that Kaplan and Laing (2005), Bate (2008) and Slamet 
(2012) have argued that local production may not be feasible for certain countries.     
Without adequate funding it is difficult to imagine any progress with regards to infrastructural 
development. With Africa being home to some of the poorest countries in the world, according 
to the World Bank classification system, and funding being hard to come by; the argument for 
local production becomes difficult to sustain (Bate, 2008). It is therefore not surprising that 
most countries in Africa concentrate their efforts on simple formulations which involve 
labelling and packaging.  
Funding remains a big challenge in Africa and a stumbling block to local production (SEATINI 
and CEHURD, 2013). Despite the challenges with funding on the African continent, each 
country must evaluate its own situation and make an informed investment decision whether or 
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not local production is a viable option. South Africa already has a well-developed 
pharmaceutical industry, a robust banking system and a stable political climate which suggests 
that it may be more favourable to embark on local production than it would be in poorer 
countries such as Lesotho or Swaziland.     
2.5.2 Human Resource Constraints  
Although local production promises socio-economic benefits of employment and skill 
development, pharmaceutical manufacturing is complex and capital intensive as opposed to 
labour intensive. The processes involved in pharmaceutical production require specialized, 
highly trained personnel which are in short supply in many African countries 
(GlaxoSmithKline, 2011). The expected increase in employment rates is unlikely to be realized 
by the masses because of the specialization requirements of the pharmaceutical industry. 
Therefore in order for the industry to be competitive, careful consideration must be given to the 
availability of appropriately skilled personnel to carry out sophisticated tasks required in 
pharmaceutical production (Saleh, 2014).  
The issue of skills availability and skills development becomes more critical as the industry 
evolves from tertiary to primary production where strong skills in research science, engineering 
and business management are required (IDR, 2013). Skills development for primary 
manufacturing is crucial; however, as mentioned in the previous section, funding is required for 
research and development. According to GlaxoSmithKline (2011) highly specialized staff is 
necessary to carry out research and development as well as high-tech manufacturing. Sadly, the 
World Health Report of 2006 (WHO, 2006 ) reported a crisis in human health in more than 57 
countries especially in pharmaceutical health. The availability of scientific research skills and 
infrastructure cannot be overemphasized.  
Central to the issue of availability of skilled personnel is whether the country has university 
faculties that are producing graduates with qualifications in the sciences particularly 
pharmacy/pharmacology, chemistry, microbiology, engineering and management (IDR, 2013, 
Kaplan and Laing, 2005). The quality of science education is crucial in ensuring that graduates 
are able to support research and development as the industry matures and moves towards 
primary production. South Africa is home to some of the world renowned universities with a 
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strong base in science, business and research. These include the Rhodes University School of 
Pharmacy, The University of Cape Town, Wits University, University of KwaZulu-Natal and 
a number of technology universities across the country all of which excel in the fields of science 
and research.   
Because skills development takes time and effort (IDR,2013), technology transfer may be a 
solution in boosting local production capacity and facilitation of technical “know-how” transfer 
(GlaxoSmithKline, 2011).  Technology has many benefits in that the recipient of technology 
transfer gains expertise, support and inherits a quality system from an established manufacturer. 
As beneficial as it may be to use technology transfer as a vehicle to accelerate skills transfer, 
careful attention must be paid to selecting a partner with a mutual benefit.  For example, 
technology transfer partners may impose market/territory restrictions which may hamper the 
profitability of the local manufactures. Secondly, technology transfer is lengthy and may be 
expensive depending on the nature and complication of the technology being transferred.  The 
costs of technology transfer may include travelling costs for training, new equipment, trial 
material and material for validation.  All these costs are usually incurred before any product 
can be approved for sale to the market and someone has to pay for it.  
2.5.3 Quality of Medicine and Regulatory Oversight  
The quality of medicine and regulatory oversight go hand-in-hand as poor regulation of 
medicine pose a serious threat to public health and may result in the presence of sub-standard 
or counterfeit medicine on the market (Kaplan and Laing, 2005). It is the responsibility of the 
regulatory agencies to verify compliance with good manufacturing practices by manufacturers; 
to oversee the drug registration process and to ensure that drugs that are not registered or 
produced in GMP-compliant facilities do not reach the market (UNCTAD, 2011). The 
regulatory agency conducts facility inspections, reviews registration dossiers and issues 
licences and give market authorization to the manufacturers. Sadly, in many developing 
countries, including Africa, the regulatory oversight is not up to the required standard despite 
the presence of regulatory agencies in almost all countries (WHO, 2012).   
Weak regulatory oversight in many countries results in the presence of sub-standard or 
counterfeit medicine finding their way into the market and have a devastating effect on human 
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health, economic relations and quality of life (Leon, 2014). A weak regulatory framework and 
a lack of access to medicine due to high prices are some of the reasons that are responsible for 
counterfeit medicine on the market. The problem of counterfeit medicine is not only an African 
problem as it also affects countries with the most robust regulatory systems; however,  Africa 
is estimated to have over 25 percent of counterfeit medicine in circulation (Leon, 2014, pg1). 
Weak regulatory oversight also results in many countries not complying with GMP principles 
sighting costs associated with upgrading to GMP inadvertently compromising on quality 
standards.  
There is a lack of regulatory harmonization across the African continent resulting in each 
country stipulating its own regulatory requirements which can also act as a barrier to registering 
medicines on the African continent (Narsai et al., 2012). Because of weak or poor regulation, 
many countries in Africa do not subscribe to internationally recognized quality standards such 
as those stipulated by the World Health Organization (WHO) for prequalification; the African 
countries are unable to benefit from economies of scale by selling to the WHO. It is for this 
reason that the African Union has recognized that inability to meet international standards is 
hampering competitiveness of the local industry as well as global competitiveness  (African 
Union, 2007). The AU further recognizes that failure to meet global standards is a barrier to 
taking advantage of the benefits of market access for processed and manufactured goods.     
2.5.4 Market Dynamics and Competitiveness  
Arguments against local production in developing countries, particularly in Africa, suggest that 
the market size does not justify the investment undertaking. This argument is strongly supported 
by Kaplan and Laing (2005) who have indicated that countries with smaller economies should 
abandon local production ambitions due to a lack of economies of scale.  From an investment 
perspective, the companies  need to break even and generate profits to be able to recoup their 
investment (GlaxoSmithKline, 2011). The argument further suggests that small companies in 
small economies cannot enjoy economies of scale that large companies in developed countries 
do hence they cannot compete in price or quality (Kaplan and Laing, 2005). According to this 
argument, the suggestion is that smaller countries should rather abandon the idea of local 
manufacturing altogether and purchase medicines from large developing countries such as 
Brazil and India. 
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The above argument almost sounds convincing but is loosely constructed with a few loopholes 
that are left hanging. Firstly, the definition of a small economy and small company does not 
come through from the above argument. If African pharmaceutical manufacturers are producing 
essential medicines to satisfy the needs of their population, they do not have to be as big as the 
multinationals. Given the infrastructural and financial constraints facing the African 
manufacturers, the argument to remain within limits of your resources seems more plausible.  
Secondly, it is widely acknowledged that manufacturing medicines locally may not always be 
cheaper than importing them (UNCATD, 2011). However, with an increasing “dual burden of 
diseases” in Africa (IDR, 2013) the point at which local manufacturing will be more beneficial 
over importation is fast approaching and this has not yet been explored. Finally, the suggestion 
that African economies should buy from countries with large economies is a step in the wrong 
direction as it suggests that Africa will never break free from importation dependence. It also 
defeats the purpose of establishing local production to stimulate industrial development on the 
continent.   
 A simulation study conducted in Ghana showed that economies of scale are not an absolute 
necessity and that countries with smaller economies can generate profits despite certain cost 
disadvantages (Chaudhuri, 2013). According to Chaudhuri (2013), producing with cost 
disadvantages does not lead to higher prices of neither medicine nor does it render local 
production to be unviable. The most startling conclusion from this study is that the role of 
economies of scale is over-exaggerated. According to the United Nations Conference on Trade 
and Development (UNCTAD, 2011) cost disadvantages may be improved by introduction of 
incentives such as tax breaks, duty-free importation on active raw materials and tax holidays 
until profitability sate has been reached.  
2.6 Chapter Summary  
High disease burden, heavy reliance on imported medicines and the desire by many African 
countries to become self –sufficient with regards to medicine supply are key factors driving the 
support local pharmaceutical production.  Whilst there is a case for supporting local production, 
there are strong arguments that seem to suggest that local production may not be a viable option 
for many African countries to an extent that each country needs to assess its case based on merit 
and circumstances affecting individual countries.  
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Literature reveal that Africa lacks the capacity to produce human vaccines for paediatric 
immunization programmes. There are numerous cost disadvantages that must be addresses for 
local production to be successful. These include the availability of basic infrastructure (water 
and electricity); availability of skilled staff  with relevant skills in subjects such as chemistry, 
pharmacy and business management; fragmented and weak regulatory framework in many 
countries has an impact on the availability of high quality of medicines; relatively small markets 
and high production input costs result in low profit margins that may discourage potential 
investors; lack of funding for research and development results in heavy reliance on imported 
active raw materials for secondary production which encourages the pharmaceutical companies 
to focus more attention on producing generic medicines.  
Whilst many factors affect the viability of local production, this study will focus on the 
production costs and market dynamics to ascertain whether local production of vaccines can be 
carried out in South Africa more favourably than importing SFP.   
Taking into account the factors discussed in this review, Chapter 3 will describe the 
methodology that was employed in determining economic viability of a locally produced 
vaccine when compared to imported semi-finished.   
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CHAPTER THREE: Research Methodology 
3.1 Introduction 
This chapter presents the research methodology used in the study. The chapter begins by 
restating the aims and objectives of the study followed by the description of the research design 
and methodology; the location of the study, sampling, data collection and data analysis 
methods. The chapter concludes with a discussion of the measures taken to enhance the validity 
and reliability of the study.  
3.2 Aim and Objectives of the study  
The aim of this study was to evaluate economic viability of LFV when compared to SFP.  
The objectives of this study were: 
i. To ascertain the manufacturing costs of LFV versus SFP;  
ii. To determine the level of economic activity for which LFV is preferred when compared 
to SFP; 
iii. To determine the desirable market size for which one option is preferred over the other;  
iv. To determine the level of investment needed for both options – LFV vs. SFP;      
v. To determine the effect of changing the key variables such as the selling price, cost of 
labour, raw materials and bulk product on the viability of either option.   
3.3 Location of the Study and Selection of Participants  
3.3.1 Location of the Study 
The study was conducted at The Biologicals and Vaccines Institute of Southern Africa (Biovac) 
in Cape Town.  Biovac is a Public Private Partnership (PPP) entity that was established in 2003 
to revive the development and manufacture of vaccines and biological products in South Africa.  
The Company employs more than 180 employees at its plant in Cape Town across the following 
departments: Manufacturing, Quality Control, Quality Assurance, Supply Chain, Regulatory 
Affairs, Business Development, Finance and Human Resources. 
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With no human vaccine manufacturing capacity in South Africa, vaccines that support the 
Extended Programme on immunization (EPI) are sourced abroad and imported either fully-
finished or semi-finished for local packaging and distribution into the South African public 
market. To date, Biovac has made significant progress in re-establishing vaccine manufacturing 
capability by investing in world-class infrastructure and skills development. This has enabled 
Biovac to enter into technology transfer agreements with various international vaccine 
manufactures to locally produce vaccines in the newly commissioned multipurpose 
manufacturing facility in Cape Town.   
The approval of the locally produced vaccines will enable Biovac to become the only approved 
human vaccine manufacturer in the Southern African region.  
3.3.2 Selection of the Participants   
The manufacturing of LFV and SFP requires input from seven (7) business units which include 
Production, Quality Assurance, Quality Control, Supply Chain, Regulatory Affairs, Finance 
and Human Resources departments. In order to achieve the objectives of this study, individuals 
possessing intimate knowledge and understanding of the vaccine manufacturing and support 
processes as they pertain to Biovac were selected to provide specific information. The Heads 
of each operational department were approached by the researcher to identify individual(s) 
within their departments who were knowledgeable in Biovac processes and systems and could 
be considered subject matter experts. The role of the identified participant was to provide the 
required information to be analysed by the researcher and to identify key informants for the 
research. Individuals from each department formed the basis of a focus group. The core of the 
focus group was made up of Section Heads (middle managers) from 7 business units who 
possessed both the process knowledge and authority to second subordinates to provide 
information to the researcher.  
Non-probability, purposive sampling using the judgement technique was used to select the 
participants of this study. Purposive sampling design is used to obtain information confined in 
a specific target group or type of people either because they are the only ones who have it or 
they conform to a criteria set out by the researcher (Sekaran and Bougie, 2013). Within the 
context of this study, few participants could be selected based on their experience in vaccine 
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manufacturing and knowledge of the Biovac processes. The judgement technique was utilized 
to select the participants who were in the best position to provide the required information 
necessary.  
Although, according to Sekaran and Bougie (2013), judgement sampling may limit the 
generalizability of the findings, it is the only viable sampling method when the required 
information can only be sourced from a handful of individuals who are subject matter experts.  
In this study the judgement sampling technique was used specifically because very few 
individuals, within Biovac, could provide the required information on the specific inputs 
required to support vaccine production processes.  
Although the information pertaining to the manufacturing and support services was obtained 
from the section heads, or designates, these individuals were themselves not the subjects of the 
study since the aim of the study was to assess the costs associated with manufacturing and 
support operations.  
3.4 Research Design and Methodology  
3.4.1 Purpose of the Study  
The purpose of this study was to explore and gain an in-depth understanding of the Biovac 
production cost factors associated with LFV and SFP operations. In order to conduct this study, 
the costs of a multivalent SFP were compared to the costs of LFV produced from formulated 
bulk product (antigen).  This study had to be conducted because the current costing model for 
Biovac is based on sourcing and distribution of imported vaccines. No formal cost analysis 
study has been conducted by Biovac on LFV activities.  
3.4.2 Research Approach 
A single case study approach was selected as the research strategy for this study to explore and 
gain an in-depth understanding of the Biovac production processes and associated costs.  
This case study follows a qualitative approach to solve the research question. The qualitative 
approach is exploratory in nature and is used when the researcher wants to gain a deeper 
understanding of the problem within a specific setting through first-hand experience (Sekaran 
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and Bougie, 2013). According to Rowley (2014) single case studies are appropriate to use where 
the case is extreme or unique and Biovac is a unique case where single case study is applicable.  
Case study research is defined as an in-depth study of a particular situation, or event, or problem 
within its real-life context where the researcher utilizes multiple sources for data collection but 
has little or no control over the events as they unfold (Yin, 1994). In a case study the “case” 
may be an individual, or a group, or the organization, or a department within the organization 
that the researcher is interested in (Rowley, 2014, Sekaran and Bougie, 2013). In the case study 
methodology, the researcher selects the case and conducts a detailed contextual analysis to gain 
an in-depth understanding of the phenomenon to be studied as opposed to making generic 
statistical conclusions based on quantitative data.  
Case studies have a prominent place in management studies and organizational theory as a form 
of data collection and a type of unstructured analysis (Schnell, 1992) and are particularly useful 
for analysing and solving practical business problems in their contextual setting (Dul and Hack, 
2008). The case study approach was deemed appropriate to apply in this research as the aim 
was not to make statistical inferences about the vaccine manufacturing industry costs but to 
gain a holistic view of the cost factors as they pertain specifically to Biovac as a business.  
The advantages of using case study as a research method lies is the ability to use multiple data 
sources to collect both qualitative and quantitative data for analysis and interpretation of the 
problem within its environment with minimal interference from the researcher (Sekaran and 
Bougie, 2013). Sources of data may include but not limited to archival records, interviews, 
physical artefacts, direct observations, and participant-observation with each data source 
contributing to the researcher’s understanding of the phenomenon (Baxter and Jack, 2008). The 
captured qualitative accounts may reveal and explain complexities that may not be captured 
through experimental and survey research (Zainal, 2007).  
Case study research approach is not without criticism. Critics of this methodology have argued 
that case studies may provide little basis for scientific generalisation because of the dependency 
from a single case  and may lack rigour because the researcher may have allowed bias views to 
influence the direction of the findings (Yin, 1994). It has also been argued that conducting case 
studies may be time consuming and generate too much data that may prove to be a challenge to 
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analyse. Whilst scientific generalizability is an important factor in research, this study aimed at 
finding information about one specific organization, Biovac. Using multiple sources of data 
collection methods has enhanced the credibility of this study to deal with the issue of bias within 
the study. Finally, focusing the attention to the research question has allowed collection of 
relevant, manageable data. 
3.4.3 Data Collection Strategies 
The qualitative nature of this study called for a combination of data collection strategies to 
provide insight into the research problem from different angles. Both primary (first-hand) and 
secondary (existing) sources were used in data collection.  
Data were collected using 1) Focus group discussions and interviews with a total of 6 “key 
informants”; 2) Document Studies; and 3) Observation methods.   
3.4.3.1 Focus Group Discussions and Interviews with individuals 
The focus group was formed by departmental section heads or designates (middle management) 
representing Production, Quality Assurance, Finance, Supply Chain and Project Management 
Office. The participants in the focus group  were selected using a judgemental sampling method 
(Sekaran and Bougie, 2013) based on their experience and intimate knowledge of the vaccine 
manufacturing operations; the authority level as managers to be able to provide the required 
information and give direction to their subordinates to provide further details required in the 
study.   
A total of 3 Team meetings were scheduled at monthly intervals with the members of the Focus 
group with additional ad hoc meetings with individuals from the group to provide clarity and 
specific information. Group meetings took place at the Company premises during normal 
working hours whilst individual interviews took place at a mutual venue as agreed. The Focus 
Group discussions provided first hand opinions and interpretation of the overview of Biovac 
production processes. Interviews with “key informants” (individual employees) were 
conducted to provide detailed information on the process overview obtained from the Focus 
Group discussions and to allow for further follow up to clarify concepts and check for reliability 
of data.  
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3.4.3.2 Document Studies  
Existing Company records were studied to extract information to enable process analysis on 
manufacturing and packaging operations, in-bound transportation cost factors. The records 
consulted included: 
 Manufacturing and Packaging Records – batch records, standard operating procedures, 
log books and work instructions 
 Financial Databases – Financial records with data on costs of raw materials, salary bands 
per job category, equipment depreciation, budgets and actual spent for the years 2014 
and 2015 
 Project financial information – to supplement and correlate information supplied by 
various departments. 
Sensitive business information was handled with care in order to ensure confidentiality and 
ethical considerations.   
3.4.3.3 Observation Methods  
Observation methods provide a useful tool to collect data on actions and behaviour (Sekaran 
and Bougie, 2013). Observations require the researcher to go into the field to collect first-hand 
data. In this study, observations were made within the production environment in order to gain 
insight into manufacturing inputs required in the study. The aim of using this method was to 
observe and record the production processes; to confirm the components and labour used in 
manufacturing as provided by the participants of the focus group and key informants; and to 
gain an in-depth understanding and confirm the accuracy of the Biovac production processes.  
Both forms of observation methods – participant and non-participants – were used in this study. 
As a participant, the researcher made arrangements to spend time with production operators 
inside the manufacturing facility learning various aspects of the production processes whilst 
making notes of the critical operational information. This method of observation was utilised 
specifically when vial filling operations similar to those of the case study vaccines were 
undertaken.  As a non-participant, the researcher observed the manufacturing processes using 
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the closed circuit cameras installed for this purpose as and when it was required to verify 
process information such as start and finish times of certain processes. The cameras are always 
switched on and the operators are aware that anyone could be watching at any given time. This 
provided the opportunity for the researcher to request permission to observe the operations as 
and when required.  
3.5 Data Collection Procedure  
Data collection was conducted with the research objectives in mind to ensure a logical flow of 
information from the first objective to the last objective. As a result, more time was allocated 
to understanding and capturing the various processes within the vaccine value chain in order to 
fulfil objective 1 (determination of production costs). The information obtained here was used 
to fulfil objective 2 (determination of favourable option to pursue based on economic activity) 
and objective 3 (determination of the desirable market size to generate revenue), as well as 
objective 5 (evaluation of the effect of changing key variables on profitability). Objective 4 
(Cost of investment) was independent of data collected from objective 1.  
3.5.1 Objective 1: Determination of the manufacturing costs of LFV and SFP 
Process Flow Mapping  
Data used to describe, analyse and cost the manufacturing processes were collected using a 
combination of sources, namely:  focus group, interviews, company records and observations. 
Group discussions and interviews were critical in mapping the production processes and 
identifying which records to be studied as well as to confirm which processes to be observed 
for data collection. The extraction of information from Company financial records and process 
observation provided the key numerical information that was required to evaluate the economic 
viability of locally produced vaccines.   
Initially, three Focus group meetings were scheduled over the period of 3 months to provide 
the overview of the manufacturing processes as they pertain to semi-finished imported vaccines 
and local formulation and filling activities. The aim of the first meeting was to initiate the group 
discussion to describe and give an overview of the operational activities at Biovac. The second 
meeting was scheduled by the researcher to present the initial results to the participants of the 
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focus group based on the discussions from the first meeting. This presented the opportunity for 
both the researcher and the subject matter experts to check if the information from the first 
meeting was captured accurately and for the group to ratify the process information first hand. 
A third meeting with the focus group was scheduled to present the final framework to be used 
in collecting detailed data and to present the picture that had emerged from the initial analysis. 
Between the first and the third meeting, interviews with the identified key informants, 
observations and archival data were collected by the researcher. After the third meeting the 
research focussed mainly on the Company record extraction and observation techniques to 
collect numerical data.  
The information on process maps was grouped into various cost centres based on the activities 
mapped and was verified through focus group discussions, manufacturing records review and 
individual interviews. 
Collection of Batch Processing Data  
The collection of batch processing data for both LFV and SFP was necessary in order to 
understand the total duration of each operation. Relevant data was collected from the 
discussions with the Focus Group and verified by studying the manufacturing batch records as 
well as through process observations. This data enabled the researcher to calculate the 
theoretical production capacity of this facility; the calculation of direct labour; the batch size to 
be filled and packed; the components required for each operation which in turn will enable the 
computation of raw materials required per batch. Data was collected on component preparation 
and cleaning times; components used in filling and packaging operations; labour usage and 
requirements for each process stage; theoretical capacity of the manufacturing site; equipment 
filling speeds and in-bound transportation costs of bulk liquid and finished product. 
The duration of processing a single batch was computed by using data collected for a standard 
batch size of imported formulated bulk (83 Litres) for filling into single-dose glass vials using 
the automated vial filling machine at 10,000 units per hour and a manual packaging process 




The following assumptions were made in the calculation:  
 Out of the 52 weeks in a year; there are 8 days a month allocated to weekends which 
translates to approximately 96 days per annum (equivalent to 13 weeks). With the 
exclusion of public holidays, approximately 38 working weeks available for production.   
 Only a single product is filled in vials at this site over 38 weeks;  
 All available resources are channelled to producing this product;   
 The manual packaging operational capacity is fixed at 350 units packed per operator per 
hour for either LFV or SFP;  
 The quantity of the product filled is equal to the product to be packed;  
Collection of Process costing data 
Data on the cost of components used in manufacturing (filling and packaging); equipment costs 
and depreciation; manufacturing overheads and labour costs were collected by the researcher 
through interviews and extracted from company financial and project records.  
Cost of Production   
The method used to calculate the costs of producing a single unit (dose) of LFV was similar for 
the SFP although the inputs varied. Variable costs per unit (dose) were calculated by dividing 
the costs per batch by the number of units per batch; fixed costs were computed per annum.  
Total Fixed Costs were computed by adding direct costs (transportation, raw materials, etc.) 
and indirect costs (costs of labour, electricity, water, etc.). 
Total Fixed costs per dose were calculated based on the known total annual demand of this 
product at 4.5 million doses per year. Different scenarios were simulated under different 
demands such as at theoretical capacity of Biovac.   
Locally produced vaccine cost inputs  
The cost of formulated bulk transportation, the cost of formulated bulk, the cost of raw 
materials, cost of product testing, equipment depreciation as supplied by the Finance Manager, 
direct and indirect labour and energy costs per batch including the packaging operations were 
taken into account in this calculation.  
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The cost of product per batch was calculated using the contract price per litre in the supplier’s 
foreign currency and converted into South African Rands (ZAR) to obtain the cost of bulk 
product per litre. With the known delivered volume of bulk product, the total cost per batch was 
calculated by multiplying the volume and the ZAR product per litre. To variable cost per dose 
was calculated by dividing the total cost per batch with the average number of units per batch 
as calculated in Table 4.5 above.  
The depreciation costs of critical equipment used in production were extracted from the 
company financial records.  
The overhead costs were computed by extracting financial information on indirect costs related 
to manufacturing as supplied by the finance manager. From the focus group interviews, a 
percentage activity was allocated to production with the final overhead rate expressed as a 
percentage of the total indirect costs.   
Imported SFP cost inputs 
The costs of SFP, transportation, raw materials, product testing, direct and indirect labour 
costs were taken into account when calculating the input costs.  Depreciation on the 
equipment used in the manual packaging of the SFP was not calculated as the equipment used 
was more than 10 years old and the remaining value was negligible to have a significant 
impact on the cost of production.  
The unit cost of SFP was provided by the finance department and was multiplied by the 
average batch size of 119,000 units to calculate the estimated total cost of product.   
A similar approach was followed when calculating the overhead costs relevant to SFP.  
3.5.2 Objective 2: Determination of favourable option to pursue for LFV and SFP  
Point of indifference or Pivot Point 
This is the point at which the total cost to produce a certain number of doses is irrelevant of 
whether the vaccine is manufactured locally or imported semi-finished. This point is significant 
in that it could be used to determine which option is more favourable under different market 
conditions (low or high market demand). On either side of this point one option (LFV or SFP) 
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is expected to be more favourable than the other.  In this study, the researcher is interested to 
determine the number of doses required to reach the point of indifference and extrapolate 
whether the point at which the LFV option is economically more viable than the SFP option.  
To determine this point, variable costs per dose and fixed costs (Total Cost) of each unit 
produced up to 5 million doses were calculated. A chart depicting Total Cost (y-axis) vs. 
Number of doses (x-axis) was plotted on the same axis for both LFV and SFP using the formula:  
Y = mx + c, where Y = Total Cost of production; m = variable cost per dose (Slope);      
         x = number of doses and c = Fixed Cost (y-intercept);  
The point at which the two curves cross each other is the indifference point.  
3.5.3 Objective 3: Determination of the desirable market size for each option  
Break-even Point Analysis 
The desirable market size will be determined by the number of doses required to break-even. 
The break-even point is a neutral point where the cost of production equals the revenue 
generated. It is used to determine the point at which the number of units sold will cover the 
operational expenses and generate a profit.  The selling price of the SFP and LFV was assumed 
to be the same as this is the single exit price on tender. The break-even point was calculated 
using the variable cost per dose and fixed costs which in turn were used to compute the 
contribution margin.  
Using the contribution margin and total fixed costs, the Total Profit gained from each unit 
produced up to 5 million doses was calculated. A chart depicting Profit (y-axis) vs. Number of 
doses (x-axis) was plotted on the same axis for both LFV and SFP using the formula:  
Y = mx + c, where Y = Total Profit; m = Contribution Margin (Slope); x = number of doses 
and c = Total Fixed Cost (y-intercept);  
The break-even point was reached at a point where each curve crossed the horizontal axis.  
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3.5.4 Objective 4: Determination of the level of investment required for LFV & SFP 
The investment requirements for locally filled and imported vaccines differ. This section will 
estimate the cost of setting up a facility from the ground up. With the Company having first 
built a facility suitable for imported vaccines (Cold Storage, Packaging and quality Control 
testing) then built a new facility for formulation and filling; the actual cost was accurately 
calculated from the data that was collected from the archival projects and financial records.  
The cost of bringing the product into the facility was estimated from technology transfer 
projects with external partners by analysing the actual project expenditure on each project from 
inception to submission of a product dossier for registration. In particular, the costs were 
analysed and grouped according to the following categories: 
 Infrastructural Costs – Physical Buildings (Packaging, Formulation, Utilities, Warehouse 
and Cold Room Storage and Quality Control Laboratories) 
 Plant & Equipment – Automated Filling Machines, Washers, Autoclaved and Utilities   
 Technology Transfer Components – Product-specific Equipment, Qualification & 
Validation, Regulatory, Bulk Product Transportation and Consultant Fees  
The foreign currency fluctuations and today’s cost of borrowing were not taken into account 
3.5.5 Objective 5: Assessment of the effect of changing variables on profitability  
Objectives 1 to 3 were concerned about understanding the production cost and market dynamics 
under static conditions. This objective aimed to test the resilience of either LFV or SFP 
operations by introducing the stress factors which are known to occur in the vaccine business. 
Firstly, the SFP and formulated bulk are imported from a European supplier and are therefore 
subject to currency fluctuations between the South African Rand and the Euro. The resilience 
to external forces had to be tested for the most favourable option as per objectives 2 and 3. 
Secondly, the prices of vaccines are known to drop either due to entry of competitor products 
or due to unaffordable prices (Spier and Milstien, 2009). It was therefore critical that both semi-
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finished and LFV were subjected to these external factors and assess the impact on profitability 
and to determine which option is able to better withstand these factors.  
By using the production cost information from objectives 1 to 3, the cost of product (Formulated 
bulk and SFP) was increased by 25% while the selling price which is currently known was 
reduced by 20% and the effects on profitability and resilience were analysed. The percentage 
manipulations were adjusted in parallel up to a point where only one option indicated viability 
under duress.     
3.6 Data Analysis 
The data collected from multiple sources had to be coded and categorized to give 
meaningfulness. Data selection, coding and categorization is known as data reduction (Sekaran 
and Bougie, 2013). It helps to give ideas on how data may be displayed as well as to draw 
conclusions based on patterns. Once the data has been coded, the next stage in the analysis is 
data presentation as a matrix or graphical form to illustrate the patterns as they are developing.  
Data Coding 
The unit of analysis in this study was the entire organization as this was a case study. As a 
result, an insurmountable amount of data was collected. Relevant data was selected and coded 
as either direct or indirect cost. These direct and indirect costs were further classified into either 
fixed or variable costs.  
Data Categorization 
The second stage of analysis was the mapping of the manufacturing processes for both SFP and 
LFV with the production costs associated with both processes described and classified into cost 
centres. Through repetition of data from multiple sources, the main cost drivers emerged as 
transportation of SFP or formulated bulk costs (for LFV), raw materials, labour, equipment 
depreciation, utility and product testing costs.  
During this stage of data analysis, patterns and relationships between the data began to emerge 




Data Display and Analysis 
The data that had been coded and categorised into cost pools was captured and displayed in a 
tabular matrix using Microsoft Excel Spreadsheet.  With further analysis, formulae and graphs 
were computed from the data to easily read patterns and make conclusions.  
Data Stress testing  
In order to test the robustness of the model, the cost of formulated product and the selling price 
were deliberately increased and decreased by between 10 and 25%. Further analysis was 
conducted on the effect of this manipulation. 
3.7 Issues of Trustworthiness  
Although case study research methodology is widely used in management studies and 
organizational theory (Schnell, 1992) because of its flexibility in the use of multiple sources of 
data to enhance credibility (Baxter and Jack, 2008, Yin, 2012), the method may be subject to 
criticism. The researcher took careful consideration when conducting this study to ensure the 
credibility of the study.  
To enhance the credibility of this study, the researcher used multiple sources of data to converge 
them into the research. Within the context of this study, a focus group made up of company 
section heads that are familiar with the intricacies of vaccine production was formed. This group 
provided valuable information on the overview of the processes. Because of the level of 
authority within this middle management group, each member was able to select individuals 
from their teams who could be interviewed or guide the researcher into the facility to observe 
the processes as they unfold. The information that was provided by members of the focus group 
was verified through observations and review of manufacturing and financial records for 
accuracy.  
A series of meetings with the focus groups were setup as well as presentations to the research 
and development team (academic team) were used as a means to interrogate the robustness of 
the research methodology and approach. Data relating to costs were collected from projects and 
verified against archived financial records whilst data on processes and process maps were 
verified through approved standard operating procedures and observation of the processes. An 
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audit trail of the presentation slides to various groups (focus groups, management and research 
and development team), the meeting requests and summary of discussions were kept by the 
researcher for reference and as part of the audit trail. This team provided valuable input on the 
best approach and course to be taken in order to ensure the researcher remained within the scope 
of the study.   
3.8 Ethical Considerations  
Ethical considerations were observed at all times when this research was conducted. Active 
research only commenced after the Ethical Clearance Certificate was issued by the University 
of KwaZulu-Natal. Permission to conduct the study was sought and granted in writing by the 
Chief Executive Officer of Biovac.  In conducting this research study within a commercial 
entity, the researcher had to take great care not divulge company secrets such as supplier 
information, trade secrets and sensitive information without explicit permission to do so.  The 
permission letter reiterated that access to confidential Company information needed to be 
treated in a confidential and appropriate manner as outlined in the Company’s Policies and 
procedure. 
 As this was a case study research, observations took place within the work setting and it was 
imperative to demonstrate respect to the production schedule and request for permission to have 
access to restricted areas within the facility, Company records and time for interviews. 
Although this was a case study on the entity, key informants and the focus group members had 
the option not to participate and this was emphasized during on-going progress report-back 
meetings.  
3.9 Limitations of the Study  
Assumption that only one product is produced on the site annually. The effect on the production 
costs if more products are added onto the facility was not assessed.  
The effect of foreign exchange currency fluctuations on the original cost when the equipment 
was purchased was not taken into account. Instead, the cost of production and other related 
costs will be reported in the local currency (the South African Rand).  
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3.10 Summary  
This chapter discussed the case study research methodology that was employed by the 
researcher when conducting this study. The selection of middle managers as subject matter 
experts proved to be invaluable in ensuring the accuracy and the robustness of data collection 
procedures. Multiple sources of data from company financial and project records, standard 
operating procedures, individual interviews as well as direct and indirect observations were 
used in the study to collect and verify information provided by the Focus Group members as 
well as the key informants.  
The presentations to various groups within the organization enhanced the credibility of the 
study. Ethical considerations were also employed by first obtaining permission to conduct the 
study at the Company site and undertaking to maintain confidentiality of sensitive information 
that the researcher may have obtained special access such as personnel salaries and Company 
supplier database and trade secrets (contracts).  
Chapter 4 will present the findings resulting from data collected in this chapter. The findings 




CHAPTER FOUR: Findings 
4.1 Introduction 
The aim of this study was to evaluate whether local production of vaccines, in South Africa, is 
economically viable when compared to imported vaccines using Biovac as a case study.  This 
chapter presents and discusses the results of the data analysis from Chapter 3.  This study 
entailed the collection and sifting through tremendous amounts of data from different sources 
over a period of 4 months in order to achieve the goals and objectives of the study.  
The results are narrated and presented in tabulation and graphical form as appropriate.    
This chapter is organized with the research problem in mind and with the findings presented 
in accordance to research questions raised in Chapters 1 and 3 as follows:   
 Section 4.2.1 will report on the demographics of the Unit of Analysis 
 Section 4.2.2 will report the findings on the unit cost of production; 
 Section 4.2.3 will report findings on the point where LFV is favourable over SFP (The 
point of indifference); 
 Section 4.2.4 will report on the findings relating to market size for which one option 
is desirable over the other (Break-even Analysis); 
 Section 4.2.5 will report the investment costs required for each option – LFV and SFP;   
 Section 4.2.6 will report the findings on the effects of changing key variables such as 
the cost of product and a drop in price on the profitability of either of the options.  
 Section 4.2.7 will summarise the findings of this chapter and introduce Chapter 5. 
4.2 Presentation of Findings 
4.2.1 Demographics of the Unit of Analysis  
The Biologicals and Vaccines Institute of Southern Africa (Biovac) is a pharmaceutical 
manufacturing company based in Cape Town with a workforce of approximately 180 
employees. The core business of Biovac is vaccine manufacturing. The company was formed 
in 2003 as a Public Private Partnership (PPP) between the South African Government and The 
Biovac Consortium. Since 2003, more than R700 million has been invested in infrastructural 
and skills development in order to realize the company’s ambitions of becoming a fully-fledged 
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vaccine manufacturer on the African continent. Since inception, Biovac has recruited a wide 
mix of skilled personnel to support the current operations of vaccine distribution, basic 
Research and Development as well as future expansion operations. By 2014, the skill set was 
mixed with Company employing 9 personnel with PhD qualifications on the high end and 30 
with matriculation and below as summarised in Table 4.1 below. 
Table 4.1: Biovac Skill Set in 2014 (Permanent Employees)  
Qualifications  No. of people  
Matric & Below 30 
Certificates & Diplomas 34 
Bachelor’s Degree 20 
Honours Degree 10 
Master Degree 13 
PhD 9 
Source: Adapted from Biovac Presentation: Retention Policies and Models for the Local 
Workforce 
The headcount per department is shown in figure 4.1 below. The figure shows that the highest 
numbers of people are employed in Production, Quality Control, Logistics, Engineering and 
Research and Development departments.  
    
Figure 4.1: Biovac Headcount per Department  





















Biovac Headcount per Dept - 2014
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4.2.2 Objective 1: Unit Cost of Production  
The determination of the unit cost of production was conducted in a multistep approach 
involving: 1) process flow mapping and identifying the relevant cost centre (pools), cost 
activities and classification; 2) Batch process information and theoretical capacity for aseptic 
filling and manual packaging operations; 3) Computation of cost activities and classification; 
4) Indirect cost allocation of manufacturing and administrative overheads and; 5) the cost of 
producing a single unit of vaccine under various demand scenarios.   
 Process Flow Mapping and Cost Categories  
The manufacturing process overview was developed from the description and identification of 
activities involved in both local filling and semi-finished importation operations. Due to the 
complexity of the vaccine manufacturing operations, data collected was reduced and 
categorized into main cost centre activities and further subdivided into relevant costs per 
activity. Each cost activity was classified as either fixed or variable as described in Table 4.2 
below.  
Table 4.2: Process Steps for SFP and LFV 
Semi-Finished Product   Locally Filled Vaccine   
Cost Centre/ Pool Cost Centre/ Pool Cost Activities Cost Classification  
   
Finished Product 
Handling 
Bulk  Liquid Handling  
Transportation  Variable 
Raw Materials Variable 
Labour  Fixed 
  Aseptic Filling 
Raw Materials  Variable 
Labour  Fixed 





Labour  Fixed  
Equip. Depr. Fixed 
Labeling & Packaging  Labeling & Packaging  
Raw Materials Variable 
Labour  Fixed  




Quality Control Quality Control 
Consumables Variable 






There are four steps involved in the processing of an imported vaccine and five for a locally 
produced vaccine. These steps are grouped vertically into cost centres. The manufacturing steps 
are similar between LFV and SFP operations with the additional aseptic filling step for the LFV.  
The cost centres for SFP are product handling from supplier to Biovac; product inspection; 
labelling and packaging and quality control testing. The LFV cost centres were found to be 
same as in SFP with the addition of the aseptic filling cost centre. In both SFP and LFV the 
common cost activities were: 
 Transportation Costs – Freight Charges, Customs Clearance and Agents Fees 
 Raw Materials (SFP or Formulated Bulk Liquid) – Cost of Product and Insurance 
 Direct Electricity – power consumption required to power the equipment  
 Quality Control Testing – consumables and testing commissioned testing 
 Labour Costs – all labour costs across the cost centres including indirect labour 
 Equipment Depreciation – Significantly costly equipment depreciation (Automated 
filling lines, washers and autoclaves)        
Batch Process Information and Theoretical Capacity Calculations 
Aseptic Filling  
The company subscribes to batch manufacturing method of operation. In order to fill one batch 
of product, a single batch of formulated bulk liquid must be dispensed into single, sterile vials. 
The formulated bulk product for LFV is shipped sterile to Biovac in a sealed stainless steel tank 
with a volume of 83 litres (L) which is dispensed to single vials with a target 0.68 millilitres 
per vial. 
A single batch of finished product filled from 83 litres of formulated bulk into single dose vials 
at a rate of 10,000 vials per hour is expected to have a theoretical yield of approximately 
122,000 unit doses. A 2% rejection rate allowed to account for start-up samples, product testing 
(quality control), in-process checks, product lost due to start-up and the product left in the 3-
meter line between the formulated bulk tank and the filling line, the final quantity expected to 
be transferred to packaging is approximately 119,000 doses. Although the actual filling time 
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required to fill and empty the formulated bulk tank is approximately 12 hours, the total batch 
processing time (filling operations) is 19 hours as shown in Table 4.3 below.  
Table 4.3: Batch Process Information (Aseptic Filling)  
Batch Process Information (Aseptic Filling) 
Formulated Bulk Size 83 Litres 
Fill Volume per dose 0.68 mL 
Batch Size  122059 units  
Batch Size (2% Scrap) 119618 units  
Filling Capacity 10000 units/hour 
Filling time 12 hours  
Setup Time 4 hours  
Cleaning Time  3 hours  
Total Process Time 19 hours  
It takes approximately 4 hours to prepare for the aseptic filling of a batch. This is the time it 
takes to perform the cleaning and sanitisation of the filling line, the aseptic connections between 
the filling line and the formulated bulk product and the time to allow the filling suite to return 
to a state of “rest”. Upon completion of the filling process, the disposable filling components 
are discarded as per approved procedures. The filling machine and the filling suite are cleaned 
over a period of 3 hours.   
Theoretical Annual Filling Capacity 
The filling line has a theoretical capacity of 63.8 million batches per year at 10,000 vials per 
hour. This capacity is achieved over 38 production weeks and takes into account the machine 
will not be utilised during planned maintenance shutdown, Christmas holiday time and on 
public holidays. As presented in Table 4.4 below, 63.8 million doses equate to a total of 523 






Table 4.4: Theoretical Filling Capacity 
Theoretical Filling Capacity 
Production Weeks   38 Weeks 
Production Days 266 Days per Annum 
Production Hours 6384 Hours per Annum 
Annual Filling Capacity 63,840,000  Doses per Annum 
No. of batches/annum 523 batches 
The annual demand for this product is 4.5 million doses which equates to a spare capacity of 
59.3 million doses under the study assumptions. The annual demand of 4.5 million doses is 
equivalent to 38 batches to be filled per annum versus a maximum theoretical capacity of 523 
batches. Based on the theoretical capacity of the filling line and the stated demand, the 
utilization capacity of this filling line is approximately 7% per annum for this product.   
Packaging Operations 
The manual packaging process for both LFV and the current SFP is the same and take the same 
duration to complete both operations. Each unit filled or imported has to undergo a manual 
visual inspection before it can be labelled and packed. Table 4.5 below summarises the duration 
of the packaging process 
Table 4.5: Batch Process Information (Manual Packaging) 





Quantity   
Unit of 
measure 
Batch Size    119 618 Doses 
Visual Inspection  
Capacity/hour 
2100 14 hours 
Labeling Capacity/hour  6000 5 hours 
Packaging Capacity/hour 1750 9 hours 
Total Process Time   28 hours 
Batch processing Days   4 days 
 The visual inspection process is performed by 7 operators at an average of 300 vials viewed 
per hour and takes approximately 14 hours to complete. This equates to 2 working days on a 
single shift of 7 working hours (Excludes tea and lunch breaks). The labelling is carried out 
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using an old automatic labelling machine which has the capability to encode the batch and 
expiry date at an output of 6000 vials per hour over 5 hours.  
The packaging operation takes approximately 9 hours when carried out by 8 operators with an 
average packaging rate of 250 vials per hour. The total average packaging time is approximately 
4 days for a single batch of product.  
Cost Activity and Computation of Unit Cost of Production  
From data collection and process overview, the main cost drivers for both LFV and SFPs were 
transport, raw materials, product cost (either formulated bulk or SFP), quality control testing 
and labour costs. Of these cost drivers, the cost of transport, raw materials and cost of product 
emerged the highest.  Table 4.6 below presents a detailed account of the various costs associated 
with LFV and SFPs as per data collected.   
Table 4.6: Summary Costs behaviour per batch and per dose  
Summary Cost Behaviour  
Cost Drivers Locally Filled Vaccine Costs Semi-Finished Vaccine Costs  













Transport  Variable  R 192,287 R 1.58   R 403,725 R 3.31   
Raw Materials Variable  R 280,340 R 2.34   R 63,566 R 1.06   
Cost of Product  Variable  R 11,961,765 R 100.00   R 8,779,971 R 157.00   
Direct Energy  Variable  R 4,979 R 0.04         
QC Testing  Variable  R 90,738 R 0.74   R 22,392 R 0.18   
Depreciation  Fixed     R 3,097,307       
All Labour   Fixed     R 8,023,794     R 5,069,243 
Total variable Cost per Dose R 104.70     R 161.55   
Total Direct Fixed  Cost     R 11,121,101    R 5,069,243 
 Manufacturing Overheads     R 14,065,742     R 2,168,850 
Administration Overheads    R 84,269,765     R 54,318,980 
Total indirect cost     R 98,335,506     R 56,487,830 
Total Fixed Costs R 109,456,607     R 61,557,073 
Total Fixed Costs/dose (4.5 million doses) R 24.32   
  
  R 13.68   
Total Fixed Costs/dose (2 million doses) R 54.73   R 30.78   
Total Fixed Costs/dose (76 million doses) R 1.71     R 0.96   
Source: Author compiled using data from Biovac documents and interviews: 
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 The cost of transporting 83L formulated bulk from a supplier in Europe to Cape Town was 
R192, 287 whilst the cost of transporting SFP from the same supplier was R403, 725. The 
cost of transporting SFP is more than double the cost of transporting 83 Litres of formulated 
bulk for LFV operations because it is more complex and expensive to transport SFP in vials 
packed into shippers and airfreighted from Europe to South Africa. The sheer weight and 
volume of shipping a full container under cold-chain conditions with SFP is expected to cost 
substantially more than transporting a single, stainless steel tank containing 83 Litres of 
product from Europe to South Africa (R1.58 per dose bulk product when compared to R3.31 
for SFP). The cost of transport is made up of freight charges, customs clearance fees and 
agent forwarding charges. 
The cost of raw materials required to process a batch of a LFV was R280, 340 whilst the cost 
of raw materials required for a SFP was R63, 566. The costs of raw materials for a LFV are 
more than four times the costs of raw materials required to complete a SFP. The raw material 
costs for a LFV are R2.34 per dose whilst for a SFP the raw material costs are R1.06. This is a 
difference of only 50% between the dosage forms however; this is expected at a dose level since 
the raw material costs of a LFV are in addition to those of an imported product. The cost of raw 
materials for SFP included the labels, cartons, package inserts and shippers. In addition, the raw 
materials for a LFV includes glass vials, gamma irradiated rubber stopper and the aluminium 
seal cap. All these items are imported into the country.  
At the time of conducting the study, the cost price of a single dose of SFP was R157 before 
processing. This translates to R8, 779, 971 per batch of 119,000 units. The cost of purchasing 
formulated bulk (83L) was calculated to be R11, 961,765 per batch which translates to R100 
per dose filled locally. The unit cost per dose of a SFP costs at least 50% more (at R157) than 
a LFV at R100 per dose when compared to the SFP at R157 per dose as per contract price. For 
both options of this product, the product cost accounted for more than 90% of the variable cost 
per dose.   
Direct energy costs to drive the filling line, autoclaves and automated washers were found to 
be significantly low at less than 5 cents per dose. Direct energy was only calculated for the LFV 
48 
 
and not on the manual packaging operation as there is only one low capacity labelling line used 
in this process and the power consumption is considered insignificant. 
The cost of quality control testing of a LFV was four times that of a SFP. It cost R90, 738 to 
test a batch of a locally produced vaccine (R0.74 per dose) when compared to R22, 392 to test 
a batch of a SFP (R0.18 per dose). The quality control testing for LFV includes full batch testing 
whilst the SFP batch includes selected tests which are limited.  
Fixed depreciation costs using a straight-line method for the major equipment used directly 
during the filling process were calculated as fixed costs at R3 million whilst the total cost of 
labour that is directly involved in the production of the batch was R8 million for the LFV and 
R5 million for the SFP. This is a cost difference of R3 million (60% difference) that is required 
per annum to produce vaccines locally.   
The total variable cost per dose for a LFV is R104.70 when compared to R161.55 for the SFP. 
This is a cost difference of R56.85 per unit between a LFV and the imported product. However, 
the total fixed costs for a LFV are R109 million when compared to R61.5 million for the SFP. 
The total fixed costs per dose for the LFV at annual demand of 4.5million doses were R24.32 
when compared to R13.68 for the SFP. This is a difference of almost 80% between the two 
products. At full theoretical capacity of 63.8 million doses per year, the fixed cost per dose 
drops from R24.32 to R1.71 for the LFV and R13.68 to R0.96 for the imported vaccine. The 
fixed cost per dose for both products drop significantly with an increase in the number of doses 
produced. At 2 million doses (approximately half the annual demand), the fixed cost per dose 
are more than double those of the annual demand.  
4.2.3 Objective 2: Level of economic activity favourable to LFV vs. SFP  
The second objective of this study was to determine the level of economic activity for which 
LFV option is preferred when compared to SFP. This was achieved by first determining the 
point at which the total cost of producing a LFV is less than the total cost of producing a SFP. 
Figure 4.2 below is a graphical representation of the total costs incurred in the production of 




Figure 4.2: Point of Indifference 
In figure 4.2 above, the cost behaviours of LFV and SFP are plotted on the same axis. The total 
cost of production is plotted along the Y-axis and the number of vaccine doses is plotted along 
the X-axis. The Y-intercept for each curve represents the respective fixed costs of each option. 
The curve depicting SFP is plotted in blue and labelled SFP whilst the curve depicting LFV is 
plotted in dark red and labelled LFV. The slopes of each of the curves represent the variable 
cost per dose which translates to the total cost of production for each vaccine sold. The variable 
cost per dose for SFP (R161.55) is higher than for LFV (R104.70) hence the cost of production 
increases at different rates which are shown by a steeper curve for the SFP when compared to 
the LFV curve.  
The black dotted line indicates the point at which the LFV and SFP curves intersect at 800,000 
doses. At this point, the costs of production for either option is the same. This point is also 
referred to as the point of indifference. It is observed from the curves that the total fixed cost of 
LFV is initially higher R109 million than the fixed cost of a SFP at R61.5 million up to 800, 
000 doses (point of indifference).  Beyond this point, the costs of LFV remain below the costs 







































produce the vaccine than to import it semi-finished. This does not mean that either option will 
generate positive revenue (profit) beyond 800, 000 doses.  
When taking into account the break-even analysis of each option as calculated in table 4.7 
below, the break-even point for LFV is 1.3 million doses and 2. 6 million doses for the SFP. 
Therefore, this confirms that at 800,000 doses sold the company would be operating at a loss 
for both options.  The profit maximising level of R109 million for LFV is reached at 2.4 million 
doses while the profit maximising level for SFP will never be realised within the annual demand 
of 4.5 million doses (see figure 4.7 below).   
4.2.4 Objective 3: Determination of the desirable market size (Break-even Point) 
The selling price for both LFV and SFP is the same at R185.00 per dose (current selling price 
of SFP). Table 4.7 summarises the break-even analysis for the LFV and the SFP. 
Table 4.7: Break-even Analysis of LFV vs. SFP 
  LFV SFP 
Sales/Dose R 185.00 R 185.00 
Variable cost/Dose R 104.70 R 161.55 
Contribution Margin  R 80.30 R 23.45 
Total Fixed Costs R 109,456,607 R 61,557,073 
 Doses to Break-even         1,363,150         2,625,234  
Total Costs per dose  (F+V) R 129.03 R 175.23 
Profit/Loss per Dose  
(2 million Doses) 
R25.57 -R7.30 
Profit/Loss per dose  
(at 4.5 million doses) 
R 55.97 R 9.77 
The variable cost per dose of LFV is significantly lower than for the SFP at R104.70 and 
R161.55 respectively. The lower variable cost per dose corresponds with a higher contribution 
margin of R80.30 for the LFV when compared to a much lower contribution margin of R23.45 
for the SFP. The total fixed costs for each option vary significantly with fixed costs accounting 
for R109.5million for LFV when compared to R61.5million for SFP.  The break-even point for 
both LFV and SFP was found to be below the annual demand of 4.5million doses.  
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The number of doses required to break-even for the LFV was 1.3million compared to 2.6million 
for the SFP. The total cost per dose for LFV was lower at R129.03 when compared to R175.23 
for the SFP. This resulted in a significant profit per dose of R55.97 per dose of locally produced 
unit when compared to R9.77 per dose if 4.5 million doses are produced. An analysis of 2 
million doses results in a loss of R7.30 per dose for the SFP and a profit of R25.57 per dose for 
the LFV as shown in table 4.7. 
Figure 4.3 below is a graphical presentation of the results on the effect of profit generated per 
dose sold for the LFV and the SFP.  
 
Figure 4.3: Break-even Analysis of LFV vs. SFP  
By plotting the curve depicting Profit on the Y-axis against the number of doses sold the curve 
above emerges. The Y-intercept for each curve represents the fixed costs. The slopes of each of 
the curves represent the contribution margin per dose which translates to profit generated with 
each sale. The break-even point for both LFV and SFP is the point where each of the curves 
cross the X-axis at zero as indicated in figure 4.3 above. Below the x-axis depicts LFV or SFP 











































for this product on the South African market is 4.5 million doses and this point is marked on by 
the red dotted line.   
The fixed costs for LFV are more than those of the SFP however; the slopes of each curve differ 
markedly. That is, the LVF curve is steeper than the SFP curve which means the higher the 
contribution margin, the steeper the curve and the faster the rate of profit generation. By 
observing the two curves, it takes less than a million doses for the LFV and SFP curves to cross 
each other and reach a point where the cost of importing the SFP equals the cost of producing 
locally. However, both LFV and SFP options are not profitable at this point. At the LFV break-
even point of 1.3million doses, the SFP option is not generating a profit and is still at a loss of 
approximately R30 million. When the SFP reaches break-even point at 2.6million doses, the 
LFV option has already generated a profit of approximately R90 million.  
At the annual demand of 4.5 million doses, the profit generated by the LFV is approximately 
R250 million compared to a profit of approximately R45million generated by the SFP option. 
4.2.5 Objective 4: Investment costs  
The analysis of the investment costs showed that R745 million has been invested over 10 years 
into establishing local manufacturing operations. A further breakdown of the costs reveals that 
R375 million is required for investment into SFP operations as opposed to a total of R745 
million required for LFV operations. From the findings, almost twice (1.98 times) the 
investment amount is required for LFV operations than semi-finished. The investment amounts 
exclude the cost of labour incurred from 2003 to 2014 for both manufacturing options. Because 
Biovac was established on an existing site (formerly, The State Vaccines Institute) the costs of 
acquiring the land, excavations and electrification is excluded from the calculated investment 
costs.   
The major investment costs for SFP were attributable to setting up of the Cold Room Storage 
infrastructure, Quality Control laboratories, Packaging Halls and the Administration buildings. 
Of these costs, the Quality Control laboratory constituted the bulk of the costs at R240 million 
whilst the construction of the warehouse building was the least.  The warehouse cost included 
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the refrigeration infrastructure for vaccine storage. The major investment costs are summarised 
in Table 4.8 below. 
Table 4.8: Investment Cost Summary 
Cost Category Item Description Item Cost 
Infrastructure 
API, Formulation & Filling  R300 million 
Quality Control Laboratories R240 million  
Packaging Hall 100 million  
Warehouse & Utility  R30 million  
Plant & Equipment  
Automated Filling Line R34 million  
Washers & Autoclaves R12.5 million  
Cleanroom Structures  R2.5 million 
Technology Transfer   Product for Local Filling  R17 million  
The investment cost of setting up local filling operations alone were R300 million excluding 
the equipment to be used inside the Cleanrooms. The cost of constructing the formulation and 
filling suites was more than the combined cost of setting up operations for a SFP. Of this amount 
(R300 million), approximately 10% was allocated to the purchasing of a high speed automated 
aseptic filling machine at a cost of R34 million. Less than 5% of the cost went to the purchasing 
of autoclaves and automatic washers which are crucial in ensuring consistent cleaning and 











4.2.6 Objective 5: Effect of changing Cost of Product and Selling Price      
Increasing Cost of Product 
Figure 4.4 below demonstrates the effect of increasing the cost of formulated bulk by 25% on 
the profitability of local vaccine filling operations.  
 
Figure 4.4: Effect of increasing Cost of Product on profitability for LFV  
The findings show that increasing the cost of formulated bulk for LFV by 25% moves the break-
even point curve to shift to the right from 1.3 million doses (break-even point 1: LFV) to 1.98 
million doses (break-even point 2: LFV). Notably, the new break-even point for LFV is reached 
before the break-even point for SFP (Break-even point 1: SFP) which occurs at 2.6 million 
doses.  
A 25% increase in the cost of formulated bulk product resulted in a drop in profit per dose for 
LFV from R55.97 to R30.97 which equates to a profit drop of R25 per dose (45% decline). This 
results in a net profit of 16% from local filling operations as opposed to a profit of 12% from 
SFP. Consequently, the effect on total profit from LFV operations drops to approximately R140 
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Figure 4.5 below shows the effect of increasing the cost of formulated bulk product by 25% on 
the point of indifference.  
 
Figure 4.5: Point of Indifference after increasing Cost of Product for LFV 
The effect of increasing the cost of formulated bulk product on the indifference point is a shift 
of the break-even point to the right from the original 800, 000 doses to 1.6 million doses. Not 
shown in the above curves, increasing results in a break-even point of 7.9 million doses which 
is beyond the annual demand of this product. This figure indicates that local filling operations 
are favourable over semi-finished operations even with a 25% increase in the cost of product at 
4.5 million doses. This supports earlier findings that LFV operations are more resilient to price 
fluctuations and are favourable over SFP if the demand is expected to be more than 1.6 million 
doses per annum.  
Reduction in Selling Price:  
The selling price of a SFP was R185 per dose. Findings showed that reducing the selling price 
of a SFP by 10% from R185 to R175.75 per dose resulted in 4.3 million doses to break even 
when compared to 2.6million doses if the selling price remained unchanged. The findings show 
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current annual demand of 4.5 million doses per annum. The price was only reduced by 10% for 
SFP, instead of 20%, to avoid analysing a result from a selling price per dose of R148 which is 
below the variable cost per dose of R161.55.  
A 20% reduction in the LFV selling price from R185 to R148 breaks even at 2.5 million doses 
resulting in profit of R18.97 per dose as shown in the break-even analysis in Table 4.9 and 
Figure 4.6 below.  
Table 4.9: Break-even Analysis after a drop in product selling price 
Break-even Analysis after Selling Price Reduction  
  LFV SFP 
Sales per Dose R 148.00 R 175.75 
Variable cost/Dose R 104.70 R 161.55 
Contribution Margin  R 43.30 R 14.20 
Total Fixed Costs R 109,456,607 R 61,557,073 
 Doses to Break-even 2,528,052         4,335,549  
Total Costs per dose  (F+V) R 129.03 R 175.23 
Profit per dose  
(4.5 million dose capacity) 
R 18.97 R 0.52 
The findings in Table 4.9 showed that the profit per dose generated by LFV operations after a 
20% reduction in the selling price is 32 times more than the profit per dose generated from SFP 
operations. The findings reveal that a 20% selling price reduction results is a drop of almost 
50% (from R80 to R43) for the LFV operations and remained profitable. This is in contrast to 
a drop of 60% in profit margin from only a 10% drop in the selling price for the SFP. These 
findings are consistent with those observed on the effect of increasing the cost of product in 
that in both instances in that LFV option is more resilient to price fluctuations. SFP is sensitive 





Figure 4.6 below illustrates the effect of reducing the selling price by 20% for LFV and 10% 
for SFP.  
 
Figure 4.6: Effect of reducing Selling Price on profitability  
Figure 4.6 shows that LFV operations break-even ahead of SFP operations.  
Reducing the selling price of SFP by 10% causes the curve to shift to the right resulting in a 
break-even of 4.3 million doses which reduced the profit per dose to R0.52 (R104,000 total 
profit) if 4.5 million doses are sold.   
Reducing the selling price of LFV by 20% causes the curve to shift to the right resulting in a 
break-even of 2.5 million doses which reduced the profit per dose to R18,97 if 4.5 million doses 
are sold.  Under the selling price scenarios above, LFV is preferred over SFP beyond a demand 
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4.3 Summary of Findings  
The major findings from this study show that LFV operations from formulated bulk product is 
more favourable than SFP beyond 800,000 doses sold when the estimated annual demand is 4.5 
million doses. The break-even point for LFV operations is reached at 1.3 million doses which 
is less than half the estimated annual demand of 4.5 million doses for this product. This is in 
stark contrast to the break-even point of SFP which is reached at 2.6 million doses. From the 
study, an estimated demand of 4.5 million doses per annum may be expected to generate a profit 
of approximately R250 million for LFV when compared to R50 million for the SFP. The study 
seems to suggest less reliance on large markets for LFV operations than SFP, at current annual 
demand, as demonstrated by the effect of price fluctuations on the break-even point and 
profitability of either of the options. 
The major cost factors for both options were identified to be inbound transportation and cost of 
product. The study found that there are more inherent cost disadvantages for SFP than LFV 
operations. The cost of transporting SFP is more than double the cost of transporting the 
formulated bulk for LFV production whilst SFP seemed to show more sensitivity to price 
fluctuations. For example, a 10% reduction in the selling price of SFP resulted in a 60% 
reduction in the contribution margin and a break-even point of 4.3 million doses when 
compared with a 20% reduction in the selling price of LFV which reached break-even point at 
2.6 million doses. This is particularly concerning for a product that is imported in foreign 
currency and may be subjected to future exchange rate fluctuations.  
The cost of product for both LFV and SFP options remain significantly high and accounts for 
more than 90% of the total variable cost per dose.  
The investment costs to set up LFV operations were calculated to be R745 million as opposed 
to R330 million required to set up SFP operations. 




CHAPTER FIVE:  Discussion 
5.1 Introduction  
The aim of this study was to evaluate economic viability of a LFV when compared to the same 
vaccine that is currently imported as a SFP for labelling, packaging and distribution. The 
objectives were to determine the production costs for both options followed by a thorough 
analysis on which option is favourable to pursue under which conditions. A case study approach 
was followed in conducting this study in order to gain an in-depth contextual analysis of the 
Biovac processes and cost factors using multiple sources of data. This chapter will discuss the 
findings in relation to the key consideration that were highlighted in the literature review in 
chapter 2 within the context of Biovac. In particular, the production costs, skills availability, 
economies of scale and their effect on profitability and finally the findings on the investment 
cost requirements will be discussed. The Chapter will conclude with a summary.  
5.1.1. Cost of Production and Price of Finished Product 
The literature review in Chapter 2 highlighted the drivers behind the support for local 
production as heavy disease burden, lack of access to affordable medicine, security of supply 
and the socio-economic benefits that stand to be realized. Those who argued against local 
production (Kaplan and Laing, 2005; Bate, 2008) cited lack of skilled personnel, economies of 
scale (small markets), cost disadvantages and lack of competitiveness of the local 
pharmaceutical industry. That is, the viability of local production rests on the ability of local 
manufacturers to produce quality medicine at competitive or better prices than imported 
medicine. Within the context of this study, the production costs of a LFV were compared to the 
costs of a SFP to determine the viability of local vaccine production in South Africa.  
In-bound Transport Costs 
The cost of transporting formulated bulk product is significantly less than the cost of 
transporting SFP.  Formulated bulk product is transported in a 100L stainless steel vessel that 
is inside a self-cooling container. On the other hand, the filed vials are packed in trays which 
are stacked inside insulated shipper boxes that are filled with dry ice. Dry ice is used to ensure 
that that cold chain is maintained from the supplier to Biovac. As a result, shipment of SFP is 
bulky and requires a standard shipping container. Because the packaging configuration of 
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formulated bulk takes up less space and requires less pre-shipment handling, it is expected that 
the shipment costs would be less.  
Cape Town is a port of entry for Formulated bulk and SFPs which are then transported for 15 
kilometres to Biovac in a refrigerated truck. The shipping costs would be expected to be more 
if either the formulated bulk or the SFP were to be delivered to a land-locked country. This 
additional cost of transport would be added to the price of medicine. All else being equal, it is 
likely that the cost of the same product in a landlocked country would be more than it would be 
in South Africa.  
Cost of Testing (Quality Control) 
The cost of testing LFV is substantially more than testing a SFP. The SFP is delivered with a 
certificate of analysis that confirms that all tests have been performed in accordance to 
procedure with only the potency and product identification that remain to be tested on finished 
product. Formulated bulk product requires additional testing steps from delivery to finished 
product. These steps include bulk sample testing, in-process and finished product testing which 
includes sterility testing and potency at each step of the process. It is therefore expected that the 
testing costs would be more for LFVs when compared to SFP. 
In instances where the laboratory infrastructure is not in place to complete all tests required, the 
Company may send certain samples to external, approved laboratories to conduct such tests on 
behalf of the Company. External testing comes at a cost, therefore, a cost-benefit analysis on 
which tests are to be carried out in-house or to be outsourced is usually done based on the 
available skill, complexity of the test, cost of equipment and frequency of the testing 
requirement.  
Raw Materials Costs  
The costs of raw materials that are required to process formulated bulk are twice as much as 
those required for processing SFP. SFP is delivered as naked vials (unlabelled product) and 
undergoes labelling and final packaging. Over and above, the LFV requires specialised type of 
glass vials, gamma-irradiated rubber stoppers and aluminium seals which are imported abroad 
in foreign currency. Once the product is filled, it undergoes the same process as a SFP. The cost 
of raw materials per dose is however not twice as much for LFV versus SFP because the total 
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cost is an average of total cost divided by the number of units filled. The importation of glass 
vials and rubber stoppers could be subject to foreign currency fluctuations resulting in annual 
cost variations 
Cost of Production – LFV vs. SFP 
When analysing the cost of product, the following becomes evident: The cost of SFP is R157 
per dose as per contract which translates to R8.7 million per batch. The cost of formulated bulk 
product is R11.9 million as per contract which translates to R100 per dose of filled product.   
SFP and LFV present different sets of challenges that may have an effect on the cost of each 
option. Firstly, the risks of product failure due to sterility and low potency remain with the 
supplier of the SFP up to the point of delivery to Biovac. Over and above, the product supplier 
would have incurred additional cost of quality assurance on the process as well as raw materials 
used in the product also remain with the supplier. Secondly, the same risk of batch failure due 
to sterility pose a major concern as the responsibility shifts from the product supplier to the 
manufacturer. Vaccine manufacturing requires aseptic handling which means there is no 
terminally sterilisation step once the product is in the final container. The manufacturer not only 
has to be vigilant about product handling to prevent loss of potency and product contamination 
during processing but also has to prove through validation that the product can be handled from 
delivery right through processing into finished product.  
Another finding that may appear as a cause for concern is the low utilization capacity of 7% 
which suggests that the filing suites will be utilized for a time equivalent to a few weeks in a 
year. Even when taking into account aseptic validation activities that take place during year, 
the utilisation capacity remains low. This presents an opportunity to bring additional products 
through contract manufacturing of other compatible products and indicates that the filling line 
is not a bottleneck. This will help to improve the higher utilisation capacity.     
5.1.2. Availability of Skilled Labour and Cost of Labour  
Personnel employed at Biovac possess a skill base that ranges from very low skill with no 
formal qualification all the way up to Master’s and PhD level. The spread of skill and expertise 
support the low tech, tertiary operations with semi-skilled personnel through to aseptic filling 
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operations with skilled personnel and research and development with highly skilled personnel 
with Honour’s, Master’s and PhD degrees. The Universities of Stellenbosch, Cape Town and 
the Western Cape are some of the tertiary institutions providing support to Biovac in skills 
development and other research collaborations.   
The labour requirements for SFP operations are less than those of LFV in terms of the operator 
skill and the simplicity of the operations. The skill requirement for tertiary production operators 
is low-tech and does not require a tertiary qualification. On the other hand, secondary 
production (aseptic formulation and filling) requires a higher level of expertise especially in 
microbiology background. This is evident in the mix of skill set that is utilised for local filling 
operations. As long as Biovac is able to recruit and retain the right kind of skilled personnel and 
continually train them in topics such as validation, aseptic processing, good manufacturing 
practices and quality assurance; local production operations will receive the required support 
and ensure that local filling operations remain sustainable.  
5.1.3. Economies of Scale on Profitability and Sustainability 
Under current conditions, local vaccine filling from imported bulk is favourable if the demand 
is estimated beyond 1.3 million doses. For the product under study, the demand for SFP is 
currently at 4.5 million doses per annum and therefore renders this option profitable. However, 
the SFP seemed to be more sensitive to selling price fluctuations as was shown that a 10% 
reduction in the selling price resulted in a break-even of 4.3 million doses which is not 
sustainable, unprofitable and risky in the long term. This is concerning when taking into account 
that this product is imported in foreign currency and hence is subject to currency fluctuations. 
Secondly, with vaccine prices known to drop with time as more competition enters the market 
(Spier and Milstien, 2009), the sensitivity of the SFP to price does not seem to favour this option 
for long term sustainability Therefore, the findings support local production of this vaccine.  
The economies of scale for this product appear to be exaggerated with profitability being 
achieved with 1.3 million doses which coincides with a point where the number of doses for 
imported vaccine is not even profitable.  This finding is in line with a study that was conducted 
in Ghana by Chaudhuri (2013) which also showed that local production in small countries with 
small markets can be profitable despite the cost disadvantages.  
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The findings of this study confirmed the issue of high fixed costs in vaccines (Baumann, 2009) 
in that the fixed cost per dose reduced with the increasing number of doses. This effect of this 
phenomenon was more noticeable with SFP. This suggest that although the definition of 
economies of scale is not very clear; when it comes to the profitability of SFP operations, the 
more doses that can be sold the lower the average fixed cost per dose that can be realised. 
Perhaps one way to improve profitability would be to expand to regional markets. For South 
Africa, expansion into the Southern African Developing Countries (SADC) region which 
includes Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, and Mozambique could 
potentially unlock untapped markets in the region and result in a higher annual demand for this 
product. In turn, this will could have a positive impact on the current equipment utilisation 
which is currently at 5.6%.  
5.1.4. Investment Costs 
 Infrastructural Costs 
The findings in Chapter 4 confirmed that there are different levels of investment requirements 
for secondary and tertiary production operations. The infrastructural investment began a decade 
ago and to date more than R700 million has been invested into the reestablishment of local 
vaccine manufacturing. The setup costs for tertiary operations (labelling and packaging) were 
substantially low at R375 million when compared to R745 million total investment cost for 
secondary and tertiary operations. This implies that the requirements for LFV operations are 
twice as much as the requirements for SFP operations. This was not surprising as the 
infrastructural cost of the formulation and filling suites alone were R300 million excluding plant 
and equipment. 
Vaccines are sensitive to heat and therefore the investment into the warehouse and cold room 
storage is required upfront before any labelling and packaging can take place. Being heat 
sensitive, testing for potency on delivery and of finished product is critical to prevent processing 
of product that may not meet the quality standard hence the quality assurance infrastructural 
requirement. Quality control laboratories require sophisticated equipment which also adds to 
the cost of the product.  
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The presence of the cold chain and testing infrastructure not only does it allow for labelling and 
packaging operations to continue but serve as building blocks for more products to be brought 
into the facility. In addition, it serves as a footprint for expansion into more complex operations 
such as formulation and filling whilst generating revenue. The model of backward integration 
which was adopted by Biovac showed that other countries who are interested in establishing 
local pharmaceutical manufacturing can begin by investing in simpler operations to generate 
revenue and increase the level of investment into more complex operations over time. 
The findings revealed that the profit margins from SFP operations are lower than those for LFV 
which may be an indication of the ability to recoup the investment costs from operations. The 
findings showed that importing SFP will generate a profit of 10%, excluding distribution and 
marketing costs, whilst the LFV operations can be expected to generate a profit of about 43% 
under the same conditions. It can be concluded from the findings that LFV operations, under 
current conditions, are more favourable for this product over the SFP. From an investment point 
of view, LFV operations indicate a better return on investment and a high probability to being 
able to recoup the investment costs. This means the formal banking sector is likely to fund this 
kind of operation.  
The finding that LFV operations provide a higher probability to recoup investment costs when 
compared to SFP is confirmed by the analysis into the effect of price fluctuations. This analysis 
showed lower profit margins of R9.77 per dose at 4.5 million doses sold for SFP and sensitivity 
to price fluctuations can be translated to mean that more than a decade that may be required to 
recoup the investment costs of simple tertiary production operations. LFV operations, on the 
other hand, are able to repay the investment costs in approximately 4 years with a profit margin 
of R55 per dose. Even when the selling price drops by 20%, LFV is still favoured over SFP.  
Technology Transfer Costs 
This refers to the costs associated with bringing a new product into the facility. There are three 
considerations to be taken into account when selecting a technology transfer partner to ensure 
a mutual benefit.  Firstly, the selection of the product(s) to be produced in the facility must be 
compatible with the available infrastructure in order to contain investment costs. Secondly, 
because pharmaceutical production is highly regulated, the product may not be sold to the 
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market before licensing and registration approval from the local regulatory agency has been 
obtained.  
Finally, whilst technology transfer may speed up the process knowledge and improve personnel 
skill level, it cost money and someone has to pay for it. Selecting a mutually compatible partner 
is critical to ensure fair distribution of costs. For example, this technology transfer required an 
investment of approximately R17 million. However, this cost could have been in excess of R30 
million without the technology transfer partner bearing the costs of active raw materials and 
training. Transferring technical know-how requires competent project management skills as this 
is an immense investment undertaking before the product can be sold into the market.  
5.2 Summary 
The break-even point for LFV operations is reached at 1.3 million doses sold when compared 
to SFP operations with a break-even point of 2.6 million doses. Taking into account the current 
annual demand of this product at 4.5 million doses, LFV operations can be expected to generate 
a profit of R250 million when compared to R50 million expected from SFP. The finding from 
the study seems to suggest that profitability can be achieved from relatively small markets.  
The investment requirements for setting up LFV were found to be approximately twice as much 
as those required to setup SFP operations, however the potentially higher profit margins justify 
such an investment undertaking. Whilst the SFP investment setup costs may seem favourable 
initially, the demonstrated sensitivity of this option to price fluctuations remains a concern for 
a product that is imported abroad and is subject to foreign exchange rate uncertainties. 
For Biovac, the option of LFV is preferred and must pursued in order to realise demonstrated 
profits. 
Chapter will highlight and discuss significant conclusions from this study and make 





CHAPTER SIX: Conclusions and Recommendations 
6.1 Introduction 
The aim of this study was to evaluate, using Biovac as a case study, whether LVF is 
economically viable when compared to SFP. The objectives were to determine the costs of 
production of each option and to assess which option was favourable under which conditions 
and to determine the investment requirements for each of the options. This Chapter provides 
the implications of this research as well as recommendations for future studies based on the 
findings.  
6.2 Significant Conclusions from the Study 
The major conclusion from this study is that LFV production may be economically viable and 
more preferable to imported SFP. The cost of formulated bulk and SFP constituted more than 
80% of the total cost of production however; the profit margins from LFV operations were 
shown to be substantially higher than those that stand to be realised from processing SFP.  For 
example, at 4.5 million doses, LFV operations can be expected to generate a profit of R250 
million when compared to R50 million profit that may be expected from SFP. As a result of 
low profit margins that are generated from SFP, this manufacturing option is the least 
favourable between the two and is sensitive to price fluctuations (10% story and currency 
effects). The conclusion is that SFP option may not be viable for long-term sustainability of the 
organization.  
The second conclusion from findings showed that LFV operations of high-end multivalent 
vaccines are economically viable even with low volumes of 4.5 million doses. Whilst pursuing 
LFV has been demonstrated to be cheaper and more profitable than SFP, it is important to take 
note that in this option; the risk of batch failure shifts from the overseas supplier to the local 
manufacturer. high batch failure rate may have negative financial implications which the local 
manufacturer may not have been exposed to when processing SFP. Therefore, significant 
amount of time in training and validation may be required to ensure the risk of batch failure due 
to process inconsistencies is minimised.  
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Although the study did not assess economic viability from antigen production and formulation, 
the findings suggest that LFV from locally produced antigens may be even cheaper. This takes 
into account that local production will eliminate transport and formulated bulk costs.  However, 
this level of operation requires additional product handling expertise and may expose the 
organization to even higher risks of batch failures at multiple levels of operation over and above 
the skill requirements for processing product at this level. It is within this context that a 
conclusion can be drawn that security of supply may take years to be realised, if not decades, 
as Africa continues to be dependent on imported formulated bulk to carry out local filling 
operations. This suggests that the African continent still remains vulnerable to supply shortages. 
This is contrary to the notion of establishing local manufacturing operations to reduce 
dependency on imports.   
6.3 Implications of this Research  
This study provides an assessment tool for Biovac management to use when assessing the 
viability of a project proposal from a potential technology transfer partner. With the production 
costs associated with processing SFP and LFV from formulated bulk known, determining the 
number of doses required to break-even (profitability) and the extent of the profitability (at 
anticipated demand) of the proposed option is now possible.  This will allow management to 
strategize on which vaccines or compatible products to pursue and more importantly which 
information to use in the assessment.  
The findings from this study suggest that economies of scale are a key consideration for profit 
generation and may not necessarily be an absolute requirement for countries or governments 
who want to produce locally to meet local demand. As shown by the findings, the break-even 
point of a locally produced vaccine with an annual demand of 4.5 million doses could be 
reached with 1.6 million doses sold. However, economies of scale cannot be disregarded as 
they can provide a cushion against external forces such as a drop in the selling price or an 
increase in the cost of product as per the findings on the resilience of the SFP option.  
With the African Union supporting local production across Africa as a means to stimulate 
industrial development and economic growth, other countries that may be interested in pursuing 
vaccine production and sterile manufacturing can use this study as a baseline to gauge the level 
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of investment required for such an undertaking. Other countries will be able to use findings 
from this study on manufacturing costs to make decisions which cost factors to subsidise in 
efforts to lower costs to the end user.      
6.4 Limitations and Recommendations for Future Studies   
This study was the first of its kind in South Africa with regards to human vaccine production 
with the findings and conclusions drawn from a single case study. Due to the general limitations 
of the case study and a single unit of analysis, the findings may be difficult to apply generically 
across other pharmaceutical manufacturing operations. Because this study focussed on the 
production costs to evaluate economic viability, perhaps other studies could focus on the impact 
of other types of costs such as opportunity and sunk costs on the profitability of the organization.  
Secondly, this case study focused on multivalent vaccine production to draw conclusion on the 
viability of LFV operations. This presented a limitation in that the study did not consider 
whether a low cost vaccine with a lower or higher demand will also be a viable option to pursue 
when compared with SFP. However, this study has laid a foundation for future similar studies 
on economic viability of any pharmaceutical operations. For Biovac to get a complete picture 
on which vaccines to continue importing or to consider for local manufacturing, through 
technology transfer, an internal study must be carried out to include monovalent and low cost 
vaccines. Carrying out a study of this nature will allow Biovac to develop a matrix of the type 
of products to be pursued for local production based on set of well-defined criteria. Such criteria 
could involve assessing the effect of adding other products on the existing infrastructure to 
increase the equipment utilization rates which are currently below 10%.  
Finally, the duration of the technology transfer for this product was almost 3 years due to 
regulatory requirements for validation prior to product licensing. Perhaps a study focussing on 
comparing the opportunity costs due to time lost while waiting for regulatory approval and 
licensing for either SFP or LFV may justify or prove to the contrary the viability of local 
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paper text: 
Abstract The African pharmaceutical industry lacks the capacity to adequately supply the 
continent with essential medicines to combat the heavy disease burden that is grappling the 
continent. As a result, Africa relies heavily on imported medicines and vaccines to meet the 
growing needs of the population. Local pharmaceutical production promises to provide a 
sustainable solution to public health, industrial development and socio- economic issues on the 
continent. However, Local pharmaceutical production does not make economic sense if the 
industry is unable to competitively produce quality medicine at prices that are comparable to or 
better than those of imported medicine. The aim of this study was to evaluate whether locally 
filling a multivalent vaccine used in paediatric immunization is economically viable when 
compared to the same vaccine currently imported semi-finished for labelling, packaging and 
distribution. Can a South African vaccine manufacturer produce the same vaccine cheaper than it 
currently imports? The objectives were to determine the production costs for both semi-finished 
product and local vaccine filling operations and to assess which option makes economic sense to 
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pursue. The sub-objectives were to establish the extent and impact to which the market size and 
demand for this vaccine on the decision to pursue local production versus importation. A case 
study approach was adopted as a research method to gain an in-depth understanding of the 
economic and production factors within the context of vaccine manufacturing with The 
1Biologicals and Vaccines Institute of Southern Africa (Biovac) as a  unit of 
analysis. Multiple sources of data were used to collect data which was analysed in detail. The 
findings from the study showed that local vaccine filling operations of this product were favourable 
over importation of semi-finished product when the demand exceeded 800,000 doses per annum. 
The local filling operations were found to be economically viable beyond 1.3 million doses as 
opposed to 2.6 million doses for semi-finished product. The aim of this study was accomplished. 
This study contributes to local production body of knowledge and serves as a baseline for 
economic evaluation of local vaccine production operations versus importation as no formal study 
has been conducted in Africa i CHAPTER ONE: Introduction 1.1 Introduction The reliance on 
imported medicines in Africa remains unsustainably high with an estimated 25 to 30 percent of 
essential medicines consumed in Africa being produced within the continent (African 
Development Bank, 2014). As a result of low production capacity the continent is susceptible to 
drug supply shortages, limited access to essential medicine and inability to swiftly respond to 
pandemic disease outbreaks. The disproportionate number of deaths due to acute shortage of 
the influenza vaccine in Africa during the 2009 H1N1 flu pandemic outbreak (Dawood et al., 
2012) and the recent Ebola outbreaks in North and West Africa are examples demonstrating the 
unpreparedness to respond to pandemic outbreaks and heavy reliance on imported medicines. 
Local production of medicines on the African continent promises to reduce dependency on 
imported drugs, improve access to medicines and create a sustainable response to drug supply 
shortages (African Union and UNIDO, 2012). To effectively reduce import dependency and 
address drug supply shortages in Africa, the continent must create a competitive, sustainable 
pharmaceutical industry that can reliably supply quality, affordable medicine. However, in light of 
current competition from foreign manufacturers, the viability of the local pharmaceutical industry 
lies in price competition (Wilson et al., 2012) and the ability of the industry to produce quality 
products at costs that are less than, or at least competitive, to those of foreign manufactures 
(Taylor et al., 2009). The decision whether to produce locally or to continue with importation is 
complex (Kaplan and Laing, 2005) and requires a thorough assessment of the feasibility of either 
option. This is to ensure that such an undertaking will be economically viable given that local 
manufacturing may not necessarily be cheaper than importation (UNCTAD, 2011). This case 
study assesses the economic viability of a locally produced vaccine when compared to the same 
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vaccine currently imported semi-finished for labelling, packaging and distribution. The 
19rest of this chapter is divided into the following sections: Section 1.2  
discusses the Motivation for the study, which 3is followed by Section 1.3 summarising  
the Focus of the study; Section 1.4 discusses the problem statement; Section 1.5  
States the Objectives of the 2 Study; Section 1.6 States Limitations of the Study and  
Section 1.7 which is the Summary of this Chapter  and an overview of the next 
Chapters to follow in the thesis. 1.2 Motivation for the Study: South Africa aims to improve its 
preparedness to respond to pandemic disease outbreaks (Dulnier, 2010) and reduce the 
dependency on imported vaccines by resuscitating vaccine manufacturing capability through the 
establishment 1of The Biologicals and Vaccines Institute of Southern Africa  
(Biovac). Over the past decade Biovac  has sourced, imported and distributed vaccines for 
the national immunization program and is now preparing to integrate the formulation and filling 
operations into the current importing and distribution business model (Dulnier, 2010). This study 
had to be conducted because the current costing model for Biovac is based on sourcing and 
distribution of imported vaccines. No formal cost-analysis study has been conducted by Biovac on 
local vaccine filling activities from formulated bulk liquid product. Biovac will use the information 
from this study to develop a costing model for fill/finish operations. With the Company attracting 
technology transfer partners for collaboration in various projects, understanding the vaccine 
production costs and associated market dynamics will enable Biovac to make informed decisions 
on which strategy, if pursued, will be economically viable. The decision on which imported 
vaccines are to be prioritised for local production can be made with more certainty if the 
production costs and market dynamics of either option is better understood. Because of limited 
human vaccine manufacturing operations in Africa, there is a gap in the available literature on the 
production costs and capability to manufacture affordable, high quality vaccines. The extent to 
which the input costs are applicable to the viability of local production is not well defined and 
therefore there is limited reference to use as a baseline in the manufacturing of vaccines within 
the South African context. There are different views regarding the feasibility of local vaccine 
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manufacturing. According to Kaplan and Laing (2005), local manufacturing may not be feasible in 
all developing countries if the economies of scale of production are insufficient. However, the 
extent of the requirement for economies of scale is not well defined in the literature. It has been 
estimated 3 that up to 60 % of vaccine production costs are fixed and requires economies of 
scale to recoup some of the costs (Baumann, 2009). Again there is no distinction whether this 
figure refers to the production of monovalent or polyvalent vaccines or whether these are high 
cost or low cost vaccines. 1.3 Focus of the study: This study will focus on the production and 
infrastructural costs to assess whether Biovac can competitively produce quality vaccines more 
favourably than imported vaccines. The input costs associated with producing a single unit of 
vaccine from imported formulated bulk were analysed and compared to the costs of importing a 
fully finished vaccine for labelling and distribution. Direct and indirect costs of production as well 
as fixed and variable costs were identified and assessed to determine the extent to which they 
have an effect on the final price of a vaccine under different market conditions. Since Biovac 
processes do not currently include antigen production and formulation, the costs of producing the 
antigens or the effect of locally producing vaccines from the antigen stage to finished product was 
not assessed as part of this study. The distribution and marketing costs of either a locally 
produced or imported vaccine is the same as the finished product is stored and packed in the 
same configuration therefore the study will not focus on these common costs. 1.4 Problem 
Statement: Despite the dominant status of the South African pharmaceutical industry across the 
continent in terms of annual production and the number of pharmaceutical manufacturers in the 
country (SEATINI and CEHURD, 2013), there is no human vaccine manufacturing capability in 
South Africa. As a result, South Africa remains the only member of the BRICS countries to import 
all vaccines to support the national immunization programme (Kaddar et al., 2014). Despite 
having no vaccine manufacturing capability, South Africa is considered an early adopter of new 
vaccines financed by national government mainly through taxation (Blecher et al., 2012). It can 
therefore be expected that as newer vaccines are adopted by government for the immunization 
program, there will be more pressure on the allocated vaccine budget. Establishing vaccine 
manufacturing capability in South Africa could reduce trade deficit resulting from importation of 
pharmaceuticals, however such an investment undertaking requires a thorough assessment to 
determine its viability and profitability. When calculating the cost of a single unit of vaccine one 
must take into account the input costs such as the costs of establishing a vaccine manufacturing 
facility (Bate, 2008), developmental and production costs, cost and skill of labour, shipping and 
raw material (Lee and McGlone, 2010). Taking all of the above into account, the following 
pertinent questions remain to be answered: ? Is vaccine manufacturing a viable option on the 
African continent? ? Can Biovac locally produce quality vaccines at a more favourable cost than 
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they are currently imported? 1.5 Objectives of the Study The objectives and the sub-objectives of 
this study were as follows: a. To ascertain the manufacturing costs of a locally produced vaccine 
(Fill and finish) and imported vaccine for labeling and packaging; b. To determine the level of 
economic activity for which local production is preferred compared to importation and distribution 
of finished vaccine product c. To determine the market size for which one option is preferred over 
the other; d. To determine the level of investment needed for both options – local production vs. 
importation; and e. To determine the effect of changing the key variables such as the selling price 
and the cost of imported product (Semi-finished or formulated bulk) on the viability of either 
option. 1.6 Limitations of the study The locally produced vaccine that was used to collect data 
was a technology transfer product candidate that is currently not commercially available in the 
South African market but has undergone stability testing and awaits approval by the regulatory 
authority. This means that this product has undergone the full manufacturing cycle, however, the 
costs of the primary 5 and secondary packaging materials may change by the time the product is 
registered on the market. The semi-finished product (SFP) that was used for comparison in this 
study is registered and available in the market. The cost price used is the current price of the 
product in the market on the government tender. 1.7 Summary This chapter discussed the 
12motivation for the study, the problem statement and the focus of the study.  
The objectives and the limitations of the study were also stated in  this chapter, The 
next chapter, Chapter 2, will discuss the literature review of local pharmaceutical production. In 
particular, the drivers for local production and key considerations for successful local 
pharmaceutical production are discussed with more emphasis on vaccine manufacturing. Chapter 
3 outlines the case study research methodology that was employed in this study as well as data 
collection methods, data analysis tools and finally the issues of validity and reliability. Chapter 4 
presents and analyses the findings obtained using the methodology in Chapter 3 Chapter 5 
summarises the findings, makes recommendations and conclusion. Chapter 6 will discuss the 
concluding remarks and make recommendations for future studies. CHAPTER TWO: Literature 
Review 2.1 Introduction Many solutions have been proposed to solve the issues of access to 
affordable, quality medicine, which is a threat to public health and budgets of national 
governments in Africa. Local pharmaceutical production emerges as one of the key solutions that 
promise benefits that are beyond access to medicine. It is therefore not surprising that local 
production is receiving support from political heads and multilateral organizations (UNCTAD, 
2011;UNIDO, 2013) as a sustainable solution to reduce heavy reliance on imported medicines. 
Currently, affordability and quality of medicine remain a challenge for many African countries to 
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the extent that they rely on donor funding to access medicine. This is particularly evident when it 
comes to vaccines donated by the Global Alliance on Vaccination and Immunizations (GAVI) and 
the funding of medicines needed to treat malaria, HIV and AIDS. Despite the benefits that stand 
to be realized, there are key challenges that need to be overcome and considerations that must 
37be taken into account in order for local production to be  viable. These 
considerations relate to cost disadvantages and competitiveness of the pharmaceutical industry 
across the continent, the capability and capacity to embark on such an undertaking. The focus of 
this review will be on the key drivers behind the support to boost local production capacity and the 
key considerations for the successful establishment of local production in Africa. The aim of this 
study was to evaluate economic viability of locally produced vaccines in South Africa as opposed 
to importing them semi-finished for sale and distribution. Although there are varying degree of 
pharmaceutical production across the African continent, vaccine production is almost non-existent 
with Senegal as the only human vaccine manufacturer producing a single vaccine against Yellow 
Fever for the domestic market. Therefore, there is limited literature available on local vaccine 
manufacturing in Africa. As a result, this chapter begins with the background on the issues 
surrounding local production and local production overview and definition. This is followed by the 
drivers and key considerations for establishing local production in the context of this study. A 
summary will conclude this chapter. 2.2 Background The support for the developing countries to 
increase public access to essential medicine and reduce the dependency on imported medicine 
through local production is broadening. In Africa, the adoption of the Pharmaceutical 
Manufacturing Plan for Africa (PMPA) by the Heads of African Governments is a clear indication 
of the political commitment to boost local production capacity of essential medicine on the 
continent (African Union and UNIDO, 2012; African Development Bank, 2014). From a political 
and policy levels, establishing local pharmaceutical production promises to improve public health 
by increasing the security of drug supply and access to affordable medicines (WHO, 2011); 
promote industrial development and socio-economic stimulation through economic diversification 
from agricultural production and mineral extraction (UNIDO, 2013). Despite the benefits and the 
high level support, competitive pharmaceutical production is complex and capital intensive 
(GlaxoSmithKline, 2011) and therefore requires careful consideration before embarking on such 
an investment undertaking. The primary considerations relate to investment cost associated with 
setting up a GMP-compliant manufacturing facility, access to technology and "know-how", skilled 
labour force, setting up a quality assurance system and the long lead times from drug discovery 
to commercialisation which can take approximately 10 – 15 years (IFPMA, 2011). With all these 
factors taken into consideration, the issue of cost of medicine and affordability cannot be ignored 
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when considering the vast economic disparities between African countries (World Bank, 2014). It 
is against this background that Kaplan and Laing (2005) supported by Bate (2008) have argued 
that local production may not be a viable option for all countries despite the benefits. Whilst other 
countries can manufacture, others should focus on streamlining their procurement and supply 
chain processes (Kaplan and Laing, 2005). This sentiment is shared by Bate (2008) who also 
concluded that it is difficult to sustain the argument for local production given the lack of 
resources and technical capacity to competitively produce affordable, high quality medicines in 
most developing countries. 2.3 Local Production Overview 2.3.1 Defining Local Production 
According to the World Health Organization report (WHO, 2011), local production may be defined 
and better understood in terms of territorial location and ownership of the manufacturing facility. 
Under the territorial definition, it is implied that production of medicine takes place in a developing 
or least-developed country and is subject to national jurisdiction irrespective of who owns the 
facility. For example; the manufacturing operations of a foreign owned company, such as Pfizer 
(American company) or Sanofi-Aventis (French- owned), operating in South Africa maybe 
considered “local” irrespective of where it is controlled or the location of its headquarters. The 
second definition of local production is in terms of ownership. Under this definition, it is implied 
that production operations will be considered “local” if the nationals have more than a majority of 
ownership in the firm. This definition has limitations in that the operations of a foreign owned 
company are excluded and considered foreign yet they take place within the said country. For the 
purposes of this study the territorial definition of local production has been adopted as it takes into 
account all manufacturing operations taking place in a country irrespective of ownership. 2.3.2 
Forms of Local Production Local production occurs at different levels of sophistication and hence 
the categorization of different forms is done in terms of simplicity of operations undertaken. There 
are three broad categories used to describe different forms of local production; namely tertiary, 
secondary and primary levels of production (WHO, 2011). Tertiary manufacturing is the simplest 
of all production categories that generally involves the labelling and packaging of formulated or 
semi-finished product. This form of local production is commonly found in the least developed or 
low-income countries. Secondary manufacturing is more sophisticated than tertiary as it involves 
the mixing of raw materials and formulation of different dosage forms. This form of manufacturing 
is most prevalent in the so-called middle-income countries. However, the raw materials used in 
secondary manufacturing are usually produced by the industrialized and large developing 
countries such as India and China where significant levels of the primary manufacturing takes 
place. The primary manufacturing involves the manufacturing of active pharmaceutical 
ingredients, intermediaries and excipients. According to the WHO World medicine report, the 
primary production used to be concentrated in just five industrialized countries – The 
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25United States of America, Germany, France, The United Kingdom and  
Japan.  However, the picture has changed with China and India’s competitive ability to 
produce API’s. Other smaller developing countries like South Africa have some capability to 
produce certain raw materials. Although South Africa has some capability to produce raw 
materials, the majority of the raw materials used in formulating medicines are imported from 
countries abroad (Bennet, 2014). 2.3.3 Local Production of medicine in Africa Literature review of 
the African pharmaceutical Industry confirms the presence of local production activities across the 
continent that are dominated by a handful of countries (Abbott, 2011) supplying a combined 
output of 25 to 30% of the continent’s needs (Iñarra, 2015). According to the International 
Finance Corporation (IFC) annual report (World Bank, 2007 ) as summarised by Abbott (2011), 
the pharmaceutical industry on the continent is dominated by South Africa, Ghana, Nigeria, 
Kenya and North Africa. The South African pharmaceutical industry is considered as the most 
developed in the Sub-Saharan region and North Africa (Bennet, 2014) with South Africa 
responsible for more than 70% of the manufacturing output (Abbott, 2011). This indicates vast 
differences in the capabilities of local production between the African countries and their abilities 
to provide essential medicines that will satisfy the needs of the population. Despite Africa being 
described in the McKinsey Report (Holt et al., 2015) as the world’s fastest –growing economic 
region, the pharmaceutical industry remains weak and is biased to produce generic medicines 
(Holt et al., 2015) and copy drugs under licence (WESGRO, 2012). This weakness is evident 
when taking into account that, in global terms, the African pharmaceutical industry was worth an 
estimated US $23.1 billion in 2011 or less than 2% of the global market (African Development 
Bank, 2014). To put this number into perspective, The European Federation of Pharmaceutical 
Industries and Associations estimated that Africa combined with Asia and Australia – excluding 
Japan – contributed to global sales of only 13.7% in 2012 (EFPIA, 2012) and 16.6% in 2014 
(EFPIA, 2015). The small size of the pharmaceutical industry in Africa may be interpreted as a 
good indication of the potential economic growth when considering that the disease pattern is 
expected to shift from communicable to chronic or “lifestyle” diseases over the next decade (de-
Graft Aitkins et al., 2010). Based on the current situation; if the disease burden actually shifts as 
expected, it is difficult to imagine how the industry will be able to cope with additional demand and 
competition from cheaper medicines imported from India. The above scenario presents some 
worrying scenarios. Firstly, too much focus on the production of generics and copy drugs 
indicates more emphasis on treatment rather than prevention of diseases through vaccination. 
Secondly, the production of generics at a large scale implies that the local producers are paying 
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less attention to the research and development of new drugs to fight diseases that are more 
prevalent or disproportionately affect Africa. This could be interpreted to mean that the local 
industry is dependent on research expertise from outside the continent. With most countries 
limited to secondary and tertiary manufacturing – formulation, packaging and labelling – the 
transition to primary manufacturing could prove to be costly even if countries are interested in 
pursuing more sophisticated forms of production. Thirdly, limited research and development 
leaves Africa unable to respond the pandemic disease outbreaks as there could be slow progress 
with research on drugs to combat diseases affecting Africa. The shortages of the H1N1 influenza 
vaccine in 2009 and the unavailability of vaccine against the recent deadly Ebola outbreaks in 
West Africa precisely demonstrate this point. Finally, the African continent presents some unique 
disparities in local production. According to the African Development Bank (2015), the importation 
rate in Senegal is 80% with the majority of imports coming from India. Interestingly, Senegal is 
the only African country that has human vaccine manufacturing ability yet the 36country  
with the most developed pharmaceutical production capability (South Africa)  does 
not produce vaccines for human use. As a result of producing a limited range of pharmaceuticals 
against a rising disease and shifting disease burden profile (de-Graft Aitkins et al., 2010), the 
local pharmaceutical industry will continue to lack the adequate capacity to meet the growing 
needs of the continent. This leaves Africa heavily reliant on life-saving medicines and vaccines 
imported from abroad. 2.3.4 Local Production and the Pharmaceutical Industry in South Africa 
South Africa is home to both local and multinational pharmaceutical manufactures that produce a 
wide range of pharmaceuticals for local demand and export (WESGRO, 2012). The multinational 
pharmaceuticals in the country include Pfizer (USA), Fresenius-Kabi (Germany), Sanofi (France), 
Johnson & Johnson (USA) and GlaxoSmithKline (United Kingdom) whilst the top local 
manufacturers include Aspen and Adcock Ingram (Kudlinski, 2013). The country has a well-
developed pharmaceutical industry with all forms of local production – mainly secondary and 
Tertiary with limited primary production – taking place. South Africa has the largest 
pharmaceutical market in Africa although multinationals continue to dominate the industry 
according to the Gauteng Growth Development Agency (GGDA, 2014). South Africa is a net 
importer of pharmaceuticals and this places a heavy burden on the trade balance. Previously, the 
pharmaceutical industry catered for about 64% of the local medicine requirements and this has 
decreased due to an increased in imported medicine (GGDA, 2014). According to the department 
of Trade and Industry (DTI), in 2013 South Africa imported 65% of its pharmaceuticals and this 
was the 5th largest contributor to the South African trade deficit (Kudlinski, 2013). The figures are 
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startling in that, according to DTI, 85% of the imported pharmaceuticals in 2011 were in finished 
dosage form from India, Germany, United Kingdom, France and Italy (Kudlinski, 2013). Over the 
past decade, the reliance on imported medicine has continued to grow and this is a concern to 
government as it increases the risk to security of supply. Like in many African countries that 
promote local production, the pharmaceutical industry in South Africa is mainly focused on the 
production of generic medicine (Zhan, 2014) and copy drugs under licence (WESGRO, 2012). 
According to the WESGRO report (2012), in 2011 the generic drug sales accounted for 29% in 
revenue and more than 50% in volume whilst patented drugs accounted for 59% of revenue. 
There is expectation that the market for generic drugs will continue to grow having grown 
32at an average compounded annual growth rate of 22.3% between 2004 and  2011 
(Holt et al., 2015). Although South Africa dominates the African pharmaceutical industry in both 
annual production and the number of pharmaceutical manufacturers in the country (SEATINI and 
CEHURD, 2013), the country lags behind its peers in 26the BRICS group of countries  
(Brazil, Russia, India, China, South Africa)  particularly when it comes to vaccine 
manufacturing. Until 1993 South Africa produced vaccines locally using out-dated technology and 
in 2014 South Africa remained the only member of the BRICS countries to import all vaccines for 
the national immunization programme (Kaddar et al., 2014). Meanwhile, in the corresponding 
period, the Chinese vaccine industry had developed rapidly to more than 40 vaccine 
manufacturers in 2010 (Hendriks et al., 2010). This is a far cry when considering that South Africa 
has the most developed pharmaceutical industry. This section on local production overview 
suggests that the African industry is weak and is focusing on generic medicines with limited 
research and development into diseases endemic to the continent. The local pharmaceutical 
industry is under pressure from competition from imports which are coming from India and other 
industrialized countries because of the growing reliance on imported medicine. 2.4 Drivers behind 
Local Production in Africa Although arguments against the promotion of local production in every 
country have been presented (Kaplan and Laing, 2005) there is a strong support for local 
production in hope that it will improve public health (WHO, 2011), promote industrial development 
(UNIDO, 2013) and economic growth (Taylor et al., 2009). This section will discuss disease 
burden, access to affordable medicine, security of supply and socio-economic benefits as drivers 
behind the promotion of local production. 2.4.1 Disease Burden While there are many diseases 
that affect Africa, specific diseases such as Malaria, HIV/AIDS, Tuberculosis, Cholera, Ebola and 
other tropical diseases are more prevalent or disproportionately affect Africa than any other part 
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of the world. The disease burden is severe across the continent and there is no indication that the 
situation is getting better (de-Graft Aitkins et al., 2010). The continent is faced with a dual burden 
of disease due to an increase in both communicable and chronic disease (IHME, 2013). It is 
estimated that about 75% of 9HIV/AIDS cases and 90% of deaths due to malaria  
occur in Africa including “more than 50% of the global deaths of children under the  
age of five”.18HIV/AIDS, Malaria and TB account for more than 5 million deaths  
per year,  or about 50 % of all infectious disease deaths (Foster et al., 2006). As recent as a 
decade ago, predictions of higher diabetes prevalence were rife that, by 2020, the disease 
burden will shift from infectious diseases to chronic or so-called “lifestyle diseases” (Foster et al., 
2006) owing to Africa’s widespread economic growth and the rise of the middle class (Bennet, 
2014). Recent studies have confirmed that the disease burden is already shifting from 
communicable to chronic and lifestyle diseases such as diabetes, cardiovascular, cancers and 
depression (de-Graft Aitkins et al., 2010). A study conducted by the Institute of Human Metrics 
and Evaluation (IHME, 2013) confirmed an increase in the prevalence of non-communicable 
diseases between 1990 and 2010. The study found that incidents 17of diabetes, low  
back pain and depression increased by 88%, 65% and 61% respectively  during 
this period. It is no longer a prediction, it is happening. The South African pharmaceutical industry 
is already focusing on producing generic medicines against cardiovascular diseases, diabetes 
and antiretroviral (Kudlinski, 2013). The shift in disease pattern will also require a shift of focus for 
many governments especially taking into account that many rely on foreign aid to combat 
diseases such as malaria, HIV/AIDS and national immunization programs. The emergence of 
chronic diseases on the African continent will put a financial strain on many national governments 
as more medicine will need to be imported. Whilst this may be welcome news for the local 
industry as it will stimulate growth and unlock untapped markets, it is unlikely to be welcome by 
governments in poorer countries. In sub-Saharan Africa the prevalence of chronic diseases could 
not have come at a worst time as the region is faced with both communicable and non-
communicable diseases (de-Graft Aitkins et al., 2010). 2.4.2 Access to affordable medicine 
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According to the 4World Health Organization, at least 30 percent of the world’s  
population lacks access to essential medicines and in some countries in Africa,  
the number may be as high as 50 percent  (Bate, 2008). The 38lack of  
access to essential medicines and vaccines in  developing countries is one of the 
reasons for the efforts to encourage local production of essential medicines that are either in 
short supply or treat other poverty related, tropical and neglected diseases (UNCTAD, 2011). 
With this approach there will be more assurance that essential medicines are produced closer to 
where they are needed. Access to medicine and affordability of medicine may have different 
meanings and thus must be tackled separately. Access is concerned with physically getting the 
right medicine to the right person for the treatment of a properly diagnosed ailment. Affordability is 
concerned with the ability to pay for the required medicine. Many factors may be attributable to a 
lack of access to medicine. For example, the basic transport infrastructure may be lacking and 
thus the medical facilities become unreachable or medicine cannot reach the people who need it. 
Even worse, where it does reach the people, the quality can no longer be guaranteed as with a 
case with vaccines. In certain instances, people have to travel long distances to reach public 
health facilities. Most importantly, limited access to medicine and high prices may fuel the 
presence of counterfeit medicines (Alfadl et al., 2013) which has been a serious problem in Africa 
for many years (Laroche et al., 2005). The issue of high prices is sometime difficult to 
comprehend because it is not directly linked to manufacturers charging high prices. Other forces 
are at play. For example, taxes, duties, transport costs and mark-ups by middlemen add to the 
cost of medicine even when manufacturers have lowered their prices (Bate, 2008). It is estimated 
that about 30% of medicines on the African continent are counterfeits with an estimated 100,000 
people losing their lives because of counterfeit medicines (Leon, 2014). The dangers are life 
threatening and devastating when taking into account, for example, that a patient taking 
counterfeit malaria tablets stand to lose their lives when infected with the virus. The other aspect 
limiting access to medicine is affordability of imported medicine by national governments. This is 
the ability of the governments to pay for the medicines to reach the people who need them. 
Vaccines for national immunization programs illustrate this concept well. The African economies 
are vastly different in that there are those countries that are classified by the World Bank as upper 
middle income countries who can afford to pay for vaccines through taxation (Blecher et al., 
2012). On the other hand, the poorest countries rely on funding to supply the vaccines to their 
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populations from organizations such as the Global Alliance for Vaccine and Immunization (GAVI) 
if they meet the stipulated requirements (Brenzel et al., 2006) such as the country’s gross 
national income per capita of less than $1500. The dilemma facing countries on the verge of 
graduating from the program is how best to fund these vaccines and not put their populations at 
risk when the funding dries out. Most importantly how best to prepare themselves for the 
transition from donor funding to self-procurement. 2.4.3 Security of Supply Heavy reliance on 
imported medicine is the biggest threat to access to medicine and continuous drug supply. In 
Africa, essential drug supply shortages are a real threat because even when the country can 
afford to pay for the required medicines or vaccines, there is no assurance that the medicine will 
be available when needed. Even when the medicine eventually becomes available, it can take 
longer for it to reach the end user due to long supply chains among other things. Local production 
may alleviate the problem of medicine supply shortages and allow Africa to take course towards 
breaking away from depending on imported medicine to treat diseases that are grappling the 
continent. Manufacturing closer to home may shorten the lead times and supply chains to ensure 
the medicine reach the patients on time. The target for many countries is to be self-sufficient with 
regards to supplying locally produced medicines and less reliance on imported medicines. 
However, the reality is that self- sufficiency is rare and very few countries can supply more than 
85% of their market needs through local production (Kaplan and Laing, 2005). Arguably, it may 
be worth the effort for many developing countries to target and aim to supply at least 50% of their 
market through local production or to target to purchase from neighbouring countries as opposed 
to importing from overseas. Despite the target of self-sufficiency, drug shortages continue to 
occur and affect many countries across the globe. These shortages are mainly attributable to 
manufacturing or production problems (Palmer, 2014), companies leaving the marketplace and 
changes in manufacturing recommendations such as implementation of stringent cGMP (NNii, 
2006). Therefore even if the vaccines were locally manufactured, production problems could still 
affect drug supply. Drug supply shortages become even more critical in pandemic situations such 
as the shortage of influenza vaccines in 2006 (Ulmer et al., 2006) and again in 2010 during the 
H1N1 influenza outbreak. The Ebola outbreak in 2014 demonstrated three critical points; 1) Africa 
is totally dependent on foreign aid; 2) the medicine to treat tropical diseases that predominantly 
affect Africa are unavailable and; 3) the African governments are not prepared nor are able to 
effectively deal with pandemic situations. This had a devastating effect on the economies of the 
affected countries (Holt et al., 2015). Although local production promises to improve the security 
of supply, the argument for self- sufficiency remains difficult to sustain especially with Africa 
largely dependent on imported raw material supply. 2.4.4 Socio-economic Benefits The 
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2African Union’s Action Plan for the Accelerated Industrial Development of  
Africa (African  Union, 2007) highlights the link between industrial development, economic 
growth and social development. The report also highlights the challenge of transforming African 
economies from resource-dependent to dynamic, diversified industrial economies. This sentiment 
is evident in the UNIDO’s Industrial Development Report (IDR, 2013) which also promotes 
industrialization and economic diversification from agricultural and mineral extraction economies. 
Local production is seen as a means to promote industrialization which presents the opportunity 
to diversify the economy and introduce other service sectors that will contribute towards a wide 
employment base (IDR, 2013). Local pharmaceutical production offers a mix of jobs and 
employment opportunities on a wide scale between low-end technology in packaging operations 
to high-end technology in research and development. Because high end jobs require skills in 
mathematics, science and engineering (IDR, 2013), there is a strong argument that local 
production will encourage investment in skills development and education as the manufacturing 
industry matures and becomes more sophisticated. This in turn has a potential to stimulate 
economic growth and create a substantial domestic market (IDR, 2013). The African Union has 
emphasized that the industrialization in Africa 2must be anchored on building human  
capacity by investing in health, education and training.  There is also recognition that 
industrial development policies should be designed to enhance the science, technology and 
innovative capacity which is lacking in many African countries (African Union, 2007). As 
industrialization matures, it can be expected that there will be more exports generated which will 
have a positive impact on the balance of trade. 2.5 Considerations for Establishing Local 
Production Capacity There are two major conflicting views regarding local pharmaceutical 
production in Africa. Firstly, there is a view by the Heads of State and Governments (African 
Union and UNIDO, 2012), the World Health Organization (WHO, 2011) and its allied 
organizations (UNCTAD, 2011, UNIDO, 2013) that the promotion of local production is a 
sustainable means to address the public health and socio-economic issues that are grappling the 
continent. The second opposing view as presented by Kaplan and Laing (2005) and supported by 
Bate (2008) puts forward the argument that local production may not be feasible for every country 
to pursue. This section discusses key considerations that must be in place in order for local 
production to be viable. 2.5.1 Infrastructural Development and Funding The competitiveness and 
viability of local production rests on the availability of an efficient infrastructure (roads, 
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communications, water and electricity) and financing. However, basic infrastructure on the 
continent is either lacking or inadequate hence the infrastructural development has been a priority 
of the African Union for more than a decade (African Union, 2007). Reliable supply of water and 
electricity are the cornerstone of pharmaceutical manufacturing such that any disruption in either 
of these utilities immediately results in a loss of competitiveness. Complex pharmaceutical 
formulations and cleaning regimes require availability of high quality water and electricity to run 
the sophisticated machinery. The delivery of manufacturing supplies as well and final product to 
the patients demands adequate road infrastructure. Not only is the lack of basic infrastructure a 
problem for the manufactures, poor road and transport infrastructure will hinder access to 
medicine if the patients are unable to access healthcare facilities. Unreliable supply of electricity 
means the manufacturers must have back-up power supply through the use of generators and 
pay for additional fuel costs. Financing is key to industrial development (African Union, 2007) and 
a major consideration in the development of physical infrastructure required to set up local 
production operations – that is, the construction of the manufacturing facility. However, financing 
still remains a major constraint to the industrial development in Africa particularly for small and 
medium enterprises who are perceived to be risky by the formal banking systems (UNESC et al., 
2013). The start-up costs of building a pharmaceutical plant that complies with international 
quality standards could cost millions of dollars and is therefore considered a major investment 
undertaking (Bate, 2008). Once the facility has been built, additional costs to actually run and 
maintain the facility must be taken into account. Secondly, the hidden costs of maintaining the 
plant during the initial time of non-productivity whilst waiting for the regulatory authorities to 
assess and approve the facility as well as those products expected to be produced in that facility 
must be considered. Finally, consideration must be made to the allocation of funding for research 
and development to ensure a pipeline of drugs to be produced in the years to come. However, 
taking into account lead times from discovery to registration may take between 10 – 15 years and 
cost up to USD 1.38 billion to develop a single medicine (IFPMA, 2011), it is not unexpected that 
Africa lags behind in this regard. It is for this reason that Kaplan and Laing (2005), Bate (2008) 
and Slamet (2012) have argued that for certain countries local production may not be feasible. 
Without adequate funding it is difficult to imagine any progress with regards to infrastructural 
development. With Africa being home to some of the poorest countries in the world, according to 
the World Bank classification system, and funding being hard to come by; the argument for local 
production becomes difficult to sustain (Bate, 2008). It is therefore not surprising that most 
countries in Africa concentrate their efforts on simple formulations which involve labelling and 
packaging. Funding remains a big challenge in Africa and a stumbling block to local production 
(SEATINI and CEHURD, 2013). Despite the challenges with funding on the African continent, 
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each country must evaluate its own situation and make an informed investment decision whether 
or not local production is a viable option. South Africa already has a well- developed 
pharmaceutical industry, a robust banking system and a stable political climate which suggests 
that it may be more favourable to embark on local production than it would be in poorer countries 
such as Lesotho or Swaziland. 2.5.2 Human Resource Constraints Although local production 
promises socio-economic benefits of employment and skill development, pharmaceutical 
manufacturing is complex and capital intensive as opposed to labour intensive. The processes 
involved in pharmaceutical production require specialized, highly trained personnel which are in 
short supply in many African countries (GlaxoSmithKline, 2011). The expected increase in 
employment rates is unlikely to be realized by the masses because of the specialization 
requirements of the pharmaceutical industry. Therefore in order for the industry to be competitive, 
careful consideration must be given to the availability of appropriately skilled personnel to carry 
out sophisticated tasks required in pharmaceutical production (Saleh, 2014). The issue of skills 
availability and skills development becomes more critical as the industry evolves from tertiary to 
primary production where strong skills in research science, engineering and business 
management are required (IDR, 2013). Skills development for primary manufacturing is crucial; 
however, as mentioned in the previous section, funding is required for research and development. 
According to GlaxoSmithKline (2011) highly specialized staff is necessary to carry out research 
and development as well as high-tech manufacturing. Sadly, the World Health Report of 2006 
(WHO, 2006 ) reported a crisis in human health in more than 57 countries especially in 
pharmaceutical health. The availability of scientific research skills and infrastructure cannot be 
overemphasized. Central to the issue of availability of skilled personnel is whether the country 
has university faculties that are producing graduates with qualifications in the sciences 
particularly pharmacy/pharmacology, chemistry, microbiology, engineering and management 
(IDR, 2013, Kaplan and Laing, 2005). The quality of science education is crucial in ensuring that 
graduates are able to support research and development as the industry matures and moves 
towards primary production. South Africa is home to some of the world renowned universities with 
a strong base in science, business and research. These include the Rhodes University School of 
Pharmacy, The University of Cape Town, Wits University, University of KwaZulu- Natal and a 
number of technology universities across the country all of which excel in the fields of science 
and research. Because skills development takes time and effort (IDR,2013), technology transfer 
may be a solution in boosting local production capacity and facilitation of technical “know-how” 
transfer (GlaxoSmithKline, 2011). Technology has many benefits in that the recipient of 
technology transfer gains expertise, support and inherits a quality system from an established 
manufacturer. As beneficial as it may be to use technology transfer as a vehicle to accelerate 
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skills transfer, careful attention must be paid to selecting a partner with a mutual benefit. For 
example, technology transfer partners may impose market/territory restrictions which may 
hamper the profitability of the local manufactures. Secondly, technology transfer is lengthy and 
may be expensive 30depending on the nature and complication of the technology  
being transferred. The  costs of technology transfer may include travelling costs for training, 
new equipment, trial material and material for validation. All these costs are usually incurred 
before any product can be approved for sale to the market and someone has to pay for it. 2.5.3 
Quality of Medicine and Regulatory Oversight The quality of medicine and regulatory oversight go 
hand-in-hand as poor regulation of medicine pose a serious threat to public health and may result 
in the presence of sub-standard or counterfeit medicine on the market (Kaplan and Laing, 2005). 
It is the responsibility of the regulatory agencies to verify compliance with good manufacturing 
practices by manufacturers; to oversee the drug registration process and to ensure that drugs 
that are not registered or produced in GMP-compliant facilities do not reach the market 
(UNCTAD, 2011). The regulatory agency conducts facility inspections, reviews registration 
dossiers and 21 issues licences and give market authorization to the manufacturers. Sadly, in 
many developing countries including Africa the regulatory oversight is not up to the required 
standard despite the presence of regulatory agencies in almost all countries (WHO, 2012). Weak 
regulatory oversight in many countries results in the presence of sub-standard or counterfeit 
medicine finding their way into the market and have a devastating effect on human health, 
economic relations and quality of life (Leon, 2014). A weak regulatory framework and a lack of 
access to medicine due to high prices are some of the reasons that are responsible for counterfeit 
medicine on the market. The problem of counterfeit medicine is not only an African problem as it 
also affects countries with the most robust regulatory systems; however, Africa is estimated to 
have as much as 30% of counterfeit medicine in circulation (Leon, 2014). Weak regulatory 
oversight also results in many countries not complying with GMP principles sighting costs 
associated with upgrading to GMP inadvertently compromising on quality standards. There is a 
lack of regulatory harmonization across the African continent resulting in each country stipulating 
its own regulatory requirements which can also act as a barrier to registering medicines on the 
African continent (Narsai et al., 2012). Because of weak or poor regulation, many countries in 
Africa do not subscribe to internationally recognized quality standards such as those stipulated by 
the World Health Organization (WHO) for prequalification; the African countries are unable to 
benefit from economies of scale by selling to the WHO. It is for this reason that the African Union 
has recognized that inability to meet international standards is hampering competitiveness of the 
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local industry as well as global competitiveness (African Union, 2007). The AU further recognizes 
that failure to meet global standards is 2a barrier to taking advantage of the benefits  
of market access for processed and manufactured goods.  2.5.4 Market Dynamics 
and Competitiveness Arguments against local production in developing countries, particularly in 
Africa, suggest that the market size does not justify the investment undertaking. This argument is 
strongly supported by Kaplan and Laing (2005) who have indicated that countries with smaller 
economies should abandon local production ambitions due to a lack of economies of scale. From 
an investment perspective, the companies need to break even and generate profits to be able to 
recoup their investment (GlaxoSmithKline, 2011). The argument further suggests that small 
companies in small economies cannot enjoy economies of scale that large companies in 
developed countries do hence they cannot compete in price or quality (Kaplan and Laing, 2005). 
According to this argument, the suggestion is that smaller countries should rather abandon the 
idea of local manufacturing altogether and purchase medicines from large developing countries 
such as Brazil and India. The above argument almost sounds convincing but is loosely 
constructed with a few loopholes that are left hanging. Firstly, the definition of a small economy 
and small company does not come through from the above argument. If African pharmaceutical 
manufacturers are producing essential medicines to satisfy the needs of their population, they do 
not have to be as big as the multinationals. Given the infrastructural and financial constraints 
facing the African manufacturers, the argument to remain within limits of your resources seems 
more plausible. Secondly, it is widely acknowledged that manufacturing medicines locally may not 
always be cheaper than importing them (UNCATD, 2011). However, with an increasing “dual 
burden of diseases” in Africa (IDR, 2013) the point at which local manufacturing will be more 
beneficial over importation is fast approaching and this has not yet been explored. Finally, the 
suggestion that African economies should buy from countries with large economies is a step in 
the wrong direction as it suggests that Africa will never break free from importation dependence. 
It also defeats the purpose of establishing local production to stimulate industrial development on 
the continent. A simulation study conducted in Ghana showed that economies of scale are not an 
absolute necessity and that countries with smaller economies can generate profits despite certain 
cost disadvantages (Chaudhuri, 2013). According to Chaudhuri (2013), producing with cost 
disadvantages does not lead to higher prices of neither medicine nor does it render local 
production to be unviable. The most startling conclusion is that the role of economies of scale is 
over-exaggerated. 8According to the United Nations Conference on Trade and  
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Development (UNCTAD,  2011) cost disadvantages may be improved by introduction of 
incentives such as tax breaks, duty-free importation on active raw materials and tax holidays until 
profitability sate has been reached. 2.6 Summary This chapter discussed local production from an 
African context and identified the key drivers behind the support to boost local production as well 
as key considerations to be taken into account for successful establishment of local production. 
Aim of this study was to evaluate whether it would be economically viable to produce vaccines in 
South Africa by comparing primary production costs (semi-finished imported) versus a secondary 
production cost (locally filled vaccine). Based on the literature review, the disease burden in 
South Africa is no different to other African countries and the same considerations for local 
production to be successful are applicable to vaccine manufacturing. Specific considerations are 
scarcity of skills, reliance on active raw materials for secondary production, funding for research 
and development, market dynamics and the cost of production. Taking into account the factors 
discussed in this review, Chapter 3 will describe the methodology that was employed in 
determining economic viability of a locally produced vaccine when compared to one that is 
imported semi-finished. 5CHAPTER THREE: Research Methodology 3.1  
Introduction This chapter presents the research methodology used in the  
study. The chapter begins by restating the  aims and objectives of the study followed by 
the 6description of the research design and methodology; the location of the  study, 
sampling, data collection and data analysis methods. The chapter concludes with a discussion of 
the measures taken to 10enhance the validity and reliability of the study.  3.2 
10Aim and Objectives of the study The aim of this study was to evaluate  
economic viability of  locally filled vaccine (LFV) when compared to imported, semi-finished 
vaccine for packaging and distribution (SFP). The objectives of this study were: i. To ascertain the 
manufacturing costs of a locally produced vaccine (LFV) versus imported vaccine for labeling and 
packaging (SFP); ii. To determine the level of economic activity for which local vaccine production 
is preferred when compared to importation and distribution of finished vaccine product; iii. To 
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determine the desirable market size for which one option is preferred over the other; iv. To 
determine the level of investment needed for both options – local production vs. importation of 
vaccines. v. To determine the effect of changing the key variables such as the selling price, cost 
of labour, raw materials and bulk product on the viability of either option. 3.3 Location of the Study 
and Selection of Participants 53.3. 1 Location of the Study The study was conducted  
at 1The Biologicals and Vaccines Institute of Southern Africa (Biovac)  in 
Pinelands, Cape Town. Biovac is a Public Private Partnership (PPP) entity that was established 
in 2003 to revive the development and manufacture of vaccines and biological products in South 
Africa. The Company employs more than 180 employees at its plant in Cape Town across the 
following departments: Manufacturing, Quality Control, Quality Assurance, Supply Chain, 
Regulatory Affairs, Business Development, Finance and Human Resources. With no human 
vaccine manufacturing capacity in South Africa, vaccines that support the Extended Program on 
immunization (EPI) are sourced abroad and imported either fully- finished or semi-finished for 
local packaging and distribution into the South African public market. To date, Biovac has made 
significant progress in re-establishing vaccine manufacturing capability by investing in world-class 
infrastructure and skills development. This has enabled Biovac to enter into technology transfer 
agreements with various international vaccine manufactures to locally produce vaccines in the 
newly commissioned multipurpose manufacturing facility in Cape Town. The approval of the 
locally produced vaccines will enable Biovac to become the only approved human vaccine 
manufacturer in the Southern African region. 3.3.2 Selection of the Participants The participants 
had to possess intimate knowledge and understanding of the vaccine manufacturing (formulation, 
filling and packaging), quality control & assurance, supply chain, financial controls and project 
management processes as they pertain to Biovac. The Section Heads of each operational 
department were approached to identify a subject matter expert within their department who was 
knowledgeable in Biovac processes and systems. The role of the identified participant was to 
provide the required information to be analysed by the researcher. Non-probability, purposive 
sampling using the judgement technique was used to select the participants of this study. 
Purposive sampling design is used to obtain information confined in a specific target group or 
type of people either because they are the only ones who have it or they conform to a criteria set 
out by the researcher (Sekaran and Bougie, 2013). Within the context of this study, few 
participants could be selected based on their experience in vaccine manufacturing and 
knowledge of the Biovac processes. The judgement technique was utilized to select the 
participants who were in the best position to provide the required information necessary. 
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Although, according to Sekaran and Bougie (2013), judgement sampling may limit the 
generalizability of the findings, it is the only viable sampling method when the required 
information can only be sourced from a handful of individuals who are subject matter experts. In 
this study the judgement sampling technique was used specifically because very few individuals, 
within Biovac, could provide the required information on the specific inputs required to support 
vaccine production processes. The selected participants (subject matter experts) represented the 
respective operational departments to provide the required information but were themselves not 
subjects of the study. 3.4 Research Design and Methodology 223.4.1 Purpose of the  
Study The purpose of this study was to  explore and gain an in-depth understanding 
of the Biovac production cost factors associated with local vaccine manufacturing (LFV) when 
compared to imported semi-finished vaccine operations. In order to conduct this study, the costs 
of manufacturing imported semi-finished multivalent vaccine (SFP) were compared to the costs of 
locally manufacturing the same vaccine from formulated bulk product. This study had to be 
conducted because the current costing model for Biovac is based on sourcing and distribution of 
imported vaccines. No formal cost analysis study has been conducted by Biovac on LFV 
activities. 3.4.2 Research Approach A single case study approach was selected as the research 
strategy for 8this study to explore and gain an in-depth understanding of the  
Biovac production processes and  associated costs. This case study follows a qualitative 
approach to solve the research question. The qualitative approach is exploratory in nature and is 
used when the researcher wants to gain a deeper understanding of the problem within a specific 
setting through first-hand experience (Sekaran and Bougie, 2013). According to Rowley (2014) 
single case studies are appropriate to use where the case is extreme or unique and Biovac is a 
unique case where single case study is applicable. Case study research is defined as an in-depth 
study of a particular situation, or event, or problem within its real-life context where the researcher 
utilizes multiple sources for data collection but has little or no control over the events as they 
unfold (Yin, 1994). In a case study the “case” may be an individual, or a group, or the 
organization, or a department within the organization 23that the researcher is  
interested in (Rowley, 2014, Sekaran and Bougie, 2013). In the case study  
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methodology the researcher selects the case and conducts a detailed contextual analysis 
6to gain an in-depth understanding of the phenomenon to  be studied as opposed to 
making generic statistical conclusions based on quantitative data. Case studies have a prominent 
place in 15management studies and organizational theory as a form of data  
collection and a type of unstructured analysis  (Schnell, 1992) and are particularly 
useful for analysing and solving practical business problems in their contextual setting (Dul and 
Hack, 2008). The case study approach was deemed appropriate to apply in this research as the 
aim was not to make statistical inferences about the vaccine manufacturing industry costs but to 
gain a holistic view of the cost factors as they pertain specifically to Biovac as a business. The 
advantages of using case study as a research method lies is the ability to use multiple data 
sources to 29collect both qualitative and quantitative data for analysis and  
interpretation of the problem  within its environment with minimal interference from the 
researcher (Sekaran and Bougie, 2013). Sources of data 16may include but not limited  
to archival records, interviews, physical artefacts, direct observations, and  
participant-observation with each data  source 28 21contributing to the  
researcher’s understanding of the phenomenon (Baxter and Jack, 2008).  The 
captured qualitative accounts may reveal and explain complexities that 20may not be  
captured through experimental and survey research (Zainal, 2007). Case study  
research  approach is not without criticism. Critics of this methodology have 
11argued that case studies may provide little basis for scientific generalisation  
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because of the  dependency from a single case and may lack rigour because the researcher 
may have allowed 11bias views to influence the direction of the findings  (Yin, 
1994). It has also been argued that conducting case studies may be time consuming and 
generate too much data that may prove to be a challenge to analyse. Whilst scientific 
generalizability is an important factor in research, this study aimed at finding information about 
one specific organization, Biovac. Using multiple sources of data collection methods has 
enhanced the credibility of this study to deal with the issue of bias within the study. Finally, 
focusing the attention to the research question has allowed collection of relevant, manageable 
data. 3.4.3 Data Collection Strategies The qualitative nature of this study called for a combination 
of data collection strategies to provide insight into the research problem from different angles. 
Both primary (first-hand) and secondary (existing) sources were used in data collection. Data 
were collected using 1) Focus group discussions and Interviews with “key informants”; 2) 
Document Studies; and 3) Observation methods. 3.4.3.1 Focus Group Discussions and 
Interviews with individuals The focus group was formed by departmental section heads (middle 
management) representing Production, Quality, Finance, Supply Chain and Project Management 
Office. The participants in the focus group were selected using a judgemental sampling method 
(Sekaran and Bougie, 2013) based on their experience and intimate knowledge of the vaccine 
manufacturing operations; the authority level as managers to be able to provide the required 
information and give direction to their subordinates to provide further details required in the study. 
Focus group discussions provided first hand opinions and interpretation of the overview of Biovac 
production processes. Interviews with “key informants” (individual employees) were conducted to 
provide detailed information on the process overview obtained from the Focus Group discussions 
and to allow for further follow up to clarify concepts and check for reliability of data. 3.4.3.2 
Document Studies Existing Company records were studied to extract information to enable 
process analysis on manufacturing and packaging operations, in-bound transportation cost 
factors. The records consulted included: ? Manufacturing and Packaging Records – batch 
records, standard operating procedures, log books and work instructions ? Financial Databases – 
Financial records with data on costs of raw materials, salary bands per job category, equipment 
depreciation, budgets and actual spent for the years 2014 and 2015 ? Project financial 
information – to supplement and correlate information supplied by various departments. Sensitive 
business information was handled with care in order to ensure confidentiality and ethical 
considerations. 3.4.3.3 Observation Methods Observation methods provide a useful tool to collect 
data on actions and behaviour (Sekaran and Bougie, 2013). Observations require the researcher 
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to go into the field to collect first- hand data. In this study, observations were made within the 
production environment in order to gain insight into manufacturing inputs required in the study. 
The aim of using this method was to observe and record the production processes; to confirm the 
components and labour used in manufacturing as provided by the participants of the focus group 
and key informants; and to gain an in-depth understanding and confirm the accuracy of the 
Biovac production processes. Both forms of observation methods – participant and non-
participants – were used in this study. As a participant, the researcher spent time with the 
operators learning various aspects of the production processes. As a non-participant, the 
researcher observed the processes using the closed circuit cameras installed for this purpose. 
The cameras are always switched on and the operators are aware that anyone could be watching 
at any given time. This provided the opportunity for the researcher to request permission to 
observe the operations as and when required. 3.5 Data Collection Procedure Data collection was 
conducted with the research objectives in mind to ensure a logical flow of information from the 
first objective to the last objective. As a result more time was allocated to understanding and 
capturing the various processes within the vaccine value chain in order to fulfil objective 1 
(determination of production costs). The information obtained here was used to fulfil objective 2 
(determination of favourable option to pursue based on economic activity) and objective 3 
(determination of the desirable market size to generate revenue), as well as objective 5 
(evaluation of the effect of changing key variables on profitability). Objective 4 (Cost of 
investment) was independent of data collected from objective 1. 3.5.1 Objective 1: Determination 
of the manufacturing costs of LFV and SFP Process Flow Mapping Data used to describe, 
analyse and cost the manufacturing processes were collected using a combination of sources, 
namely: focus group, interviews, company records and observations. Group discussions and 
interviews were critical in mapping the production processes and identifying which records to be 
studied as well as to confirm which processes to be observed for data collection. The extraction 
of information from Company financial records and process observation provided the key 
numerical information that was required to evaluate the economic viability of locally produced 
vaccines. Initially, three Focus group meetings were scheduled over the period of 3 months to 
provide the overview of the manufacturing processes as they pertain to semi-finished imported 
vaccines and local formulation and filling activities. The aim of the first meeting was to initiate the 
group discussion to describe and give an overview of the operational activities at Biovac. The 
second meeting was scheduled by the researcher to present the initial results to the participants 
of the focus group based on the discussions from the first meeting. This presented the 
opportunity for both the researcher and the subject matter experts to check if the information from 
the first meeting was captured accurately and for the group to ratify the process information first 
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hand. A third meeting with the focus group was scheduled to present the final framework to be 
used in collecting detailed data and to present the picture that had emerged from the initial 
analysis. Between the first and the third meeting, interviews with the identified key informants, 
observations and archival data were collected by the researcher. After the third meeting the 
research focussed mainly on the Company record extraction and observation techniques to 
collect numerical data. The information on process maps was grouped into various cost centres 
based on the activities mapped and was verified through focus group discussions, manufacturing 
records review and individual interviews. Collection of Batch Processing Data The collection of 
batch processing data for both LFV and SFP was necessary in order to understand the total 
duration of each operation. This data will enable the researcher to calculate the theoretical 
production capacity of this facility; the calculation of direct labour; the batch size to be filled and 
packed; the components required for each operation which in turn will enable the computation of 
raw materials required per batch. Data was collected on component preparation and cleaning 
times; components used in filling and packaging operations; labour usage and requirements for 
each process stage; theoretical capacity of the manufacturing site; equipment filling speeds and 
in-bound transportation costs of bulk liquid and finished product. The duration of processing a 
single batch was computed by using data collected for a standard batch size of imported 
formulated bulk (83 Litres) for filling into single-dose glass vials using the automated vial filling 
machine at 10,000 units per hour and a manual packaging process that is currently in place. 32 
The following assumptions were made in the calculation: ? Out of the 52 weeks in a year, there 
are 38 working weeks available for production when the public holidays, weekends and annual 
maintenance shutdown are excluded; ? Only a single product is filled in vials at this site over 38 
weeks; ? All available resources are channelled to producing this product; ? The manual 
packaging operational capacity is fixed at 350 units packed per operator per hour for either locally 
filled or imported semi-finished product; ? The quantity of the product filled is equal to the product 
to be packed; Collection of Process costing data Data on the cost of components used in 
manufacturing (filling and packaging); equipment costs and depreciation; manufacturing 
overheads and labour costs were collected by the researcher through interviews and company 
financial record extraction. Cost of Production The method used to calculate the costs of 
producing a single unit (dose) of a locally produced vaccine was similar for the semi-finished 
imported product although the inputs varied. Variable costs per unit (dose) were calculated by 
dividing the costs per batch by the number of units per batch; fixed costs were computed per 
annum. Total Fixed Costs were computed by adding direct and indirect costs. Total Fixed costs 
per dose were calculated based on the known total annual demand of this product at 4.5 million 
doses per year. Different scenarios were simulated under different demands such as at 
104 
 
theoretical capacity of Biovac. Locally produced vaccine cost inputs The cost of formulated bulk 
transportation, the cost of formulated bulk, the cost of raw materials, cost of product testing, 
equipment depreciation using the straight line method, direct and indirect labour and energy costs 
per batch including the packaging operations were taken into account in this calculation. Imported 
semi-finished vaccine cost inputs The costs of semi-finished product, transportation, raw 
materials, product testing, direct and indirect labour costs were taken into account when 
calculating the input costs. The cost of equipment depreciation was not calculated as the 
equipment used in manual operations was more than 10 years old and the remaining value was 
negligible. 3.5.2 Objective 2: Determination of favourable option to pursue for LFV and SFP Point 
of indifference or Pivot Point This is the point at which the total cost to produce a certain number 
of doses is irrelevant of whether the vaccine is manufactured locally or imported semi-finished. 
This point is significant in that it could be used to determine which option is more favourable 
under different market conditions (low or high market demand). On either side of this point one 
option (LFV or SFP) is expected to be more favourable than the other. In this study, the 
researcher is interested to determine the number of doses required to reach the point of 
indifference and extrapolate whether the point at which the LFV option is economically more 
viable than the SFP option. To determine this point, variable costs per dose and fixed costs (Total 
Cost) of each unit produced up to 5 million doses were calculated. A chart depicting Total Cost (y-
axis) vs. Number of doses (x-axis) was plotted on the same axis for both LFV and SFP using the 
formula: Y = mx + c, where Y = Total Cost of production; m = variable cost per dose (Slope); x = 
number of doses and c = Fixed Cost (y-intercept); The point at which the two curves cross each 
other is the indifference point. 3.5.3 Objective 3: Determination of the desirable market size for 
each option Break-even Point Analysis The desirable market size will be determined by the 
number of doses required to break-even. The break-even point is a neutral point where the cost 
of production equals the revenue generated. It is used to determine the point at which the number 
of units sold will cover the operational expenses and generate a profit. The selling price of the 
SFP and LFV was assumed to be the same as this is the single exit price on tender. The break-
even point was calculated using the variable cost per dose and fixed costs which in turn were 
used to compute the contribution margin. Using the contribution margin and total fixed costs, the 
Total Profit gained from each unit produced up to 5 million doses was calculated. A chart 
depicting Profit (y-axis) vs. Number of doses (x-axis) was plotted on the same axis for both LFV 
and SFP using the formula: Y = mx + c, where Y = Total Profit; m = Contribution Margin (Slope); x 
= number of doses and c = Total Fixed Cost (y-intercept); The break-even point was reached at a 
point where each curve crossed the horizontal axis. 3.5.4 Objective 4: Determination of the level 
of investment required for LFV & SFP The investment requirements for locally filled and imported 
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vaccines differ. This section will estimate the cost of setting up a facility from the ground up. With 
the Company having first built a facility suitable for imported vaccines (Cold Storage, Packaging 
and quality Control testing) then built a new facility for formulation and filling; the actual cost was 
accurately calculated from the data that was collected from the archival projects and financial 
records. The cost of bringing the product into the facility was estimated from technology transfer 
projects with external partners by analysing the actual project expenditure on each project from 
inception to submission of a product dossier for registration. In particular, the costs were analysed 
and grouped according to the following categories: ? Infrastructural Costs – Physical Buildings 
(Packaging, Formulation, Utilities, Warehouse and Cold Room Storage and Quality Control 
Laboratories) ? Plant & Equipment – Automated Filling Machines, Washers, Autoclaved and 
Utilities ? Technology Transfer Components – Product-specific Equipment, Qualification & 
Validation, Regulatory, Bulk Product Transportation and Consultant Fees The foreign currency 
fluctuations and today’s cost of borrowing were not taken into account 3.5.5 Objective 5: 
Assessment of the effect of changing variables on profitability Objectives 1 to 3 were concerned 
about understanding the production cost and market dynamics under static conditions. This 
objective aimed to test the resilience of either locally filled vaccine or semi-finished operations by 
introducing the stress factors which are known to occur in the vaccine business. Firstly, the semi-
finished product and formulated bulk are imported from a European supplier and are therefore 
subject to 33currency fluctuations between the South African Rand and the Euro.  
The  resilience to external forces had to be tested for the most favourable option as per 
objectives 2 and 3. Secondly, the prices of vaccines are known to drop either due to entry of 
competitor products or due to unaffordable prices (Spier and Milstien, 2009). It was therefore 
critical that both semi-finished and locally filled vaccines were subjected to these external factors 
and assess the impact on profitability and to determine which option is able to better withstand 
these factors. By using the production cost information from objectives 1 to 3, the cost of product 
(Formulated bulk and semi-finished product) was increased by 25% while the selling price which 
is currently known was reduced by 20% and the effects on profitability and resilience were 
analysed. The percentage manipulations were adjusted in parallel up to a point where only one 
option indicated viability under duress. 3.6 Data Analysis The data collected from multiple 
sources had to be coded and categorized to give meaningfulness. Data selection, coding and 
categorization is known as data reduction (Sekaran and Bougie, 2013). It helps to give ideas on 
how data may be displayed as well as to draw conclusions based on patterns. Once the data has 
been coded, the next stage in the analysis is data presentation as a matrix or graphical form to 
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illustrate the patterns as they are developing. Data Coding The unit of analysis in this study was 
the entire organization as this was a case study. As a result, an insurmountable amount of data 
was collected. Relevant data was selected and coded as either direct or indirect cost. These 
direct and indirect costs were further classified into either fixed or variable costs. Data 
Categorization The second stage of analysis was the mapping of the manufacturing processes for 
both imported semi-finished (SFP) and locally produced vaccines (LFV) with the production costs 
associated with both processes described and classified into cost centres. Through repetition of 
data from multiple sources, the main cost drivers emerged as transportation of semi- finished 
product (SFP) or formulated bulk (LFV) costs, raw materials, labour, equipment depreciation, 
utility and product testing costs. During this stage of data analysis, patterns and relationships 
between the data began to emerge which at times necessitated categories to be broken down 
into sub-categories. Data Display and Analysis The data that had been coded and categorised 
into cost pools 31was captured and displayed in a tabular matrix using Microsoft  
Excel Spreadsheet.  With further analysis, formulae and graphs were computed from the 
data to easily read patterns and make conclusions. Data Stress testing In order to test the 
robustness and the integrity of the model, the cost of formulated product and the selling price 
were deliberately increased and decreased by between 10 and 25%. Further analysis was 
conducted on the effect of this manipulation. 3.7 Issues of Trustworthiness Although case study 
research methodology is widely used in management studies and organizational theory (Schnell, 
1992) because of its flexibility in the use of multiple sources of data to enhance credibility (Baxter 
and Jack, 2008, Yin, 2012), the method may be subject to criticism. The researcher took careful 
consideration when conducting this study to ensure the credibility of the study. To enhance the 
6credibility of this study, the researcher used multiple sources of data  to converge 
them into the research. Within the context of this study, a focus group made up of company 
section heads that are familiar with the intricacies of vaccine production was formed. This group 
provided valuable information on the overview of the processes. Because of the level of authority 
within this middle management group, each member was able to select individuals from their 
teams who could be interviewed or guide the researcher into the facility to observe the processes 
as they unfold. The information that was provided by members of the focus group was verified 
through observations and review of manufacturing and financial records for accuracy. A series of 
meetings with the focus groups were setup as well as presentations to the research and 
development team (academic team) were used as a means to interrogate the robustness of the 
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research methodology and approach. Data relating to costs were collected from projects and 
verified against archived financial records whilst data on processes and process maps were 
verified through approved standard operating procedures and observation of the processes. An 
audit trail of the presentation slides to various groups (focus groups, management and research 
and development team), the meeting requests and summary of discussions were kept by the 
researcher for reference and as part of the audit trail. This team provided valuable input on the 
best approach and course to be taken in order to ensure the researcher remained within the 
scope of the study. 3.8 Ethical Considerations Ethical considerations were observed at all times 
when this research was conducted. Active research only commenced after the Ethical Clearance 
Certificate was issued by the University of KwaZulu-Natal. Permission to conduct the study was 
sought and granted in writing by the 38 Chief Executive Officer. In conducting this research study 
within a commercial entity, the researcher had to take great care not divulge company secrets 
such as supplier information, trade secrets and sensitive information without explicit permission to 
do so. The permission letter reiterated that access to confidential Company information needed to 
be treated in a confidential and appropriate manner as outlined in the Company’s Policies and 
procedure. As this was a case study research, observations took place within the work setting 
and it was imperative to demonstrate respect to the production schedule and request for 
permission to have access to restricted areas within the facility, Company records and time for 
interviews. Although this was a case study on the entity, key informants and the focus group 
members had the option not to participate and this was emphasized during on-going progress 
report- back meetings. 3.9 Limitations of the Study Assumption that only one product is produced 
on the site annually. The effect on the production costs if more products are added onto the 
facility was not assessed. The effect of foreign exchange currency fluctuations on the original cost 
when the equipment was purchased was not taken into account. Instead, the cost of production 
and other related costs will be reported in the local currency (the South African Rand). 3.10 
Summary This chapter discussed the case study research methodology that was employed by 
the researcher when conducting this study. The researcher began by stating the aim and the 
objectives of the study and described the location of the study as well as the manner in which the 
participants were selected. Research design methodology description including data collection 
strategies, detailed data collection procedures and data analysis description were discussed. 
Finally the issues of trustworthiness and ethical considerations employed in the study taken into 
account in the study were discussed towards the end of the chapter. Chapter 4 will present the 
findings resulting from data collected in this chapter. The findings will be presented systematically 
to align with the objectives as presented in this chapter. CHAPTER FOUR: Findings 4.1 
Introduction The aim of this study was to evaluate whether local production of vaccines, in South 
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Africa, is economically viable when compared to imported vaccines using Biovac as a case study. 
14This chapter presents and discusses the results of the data analysis  from 
Chapter 3. This study entailed the collection and sifting through tremendous amounts of data from 
different sources over a period of 4 months 27in order to achieve the goals and  
objectives of the study.  The results are narrated and presented in tabulation and 
graphical form as appropriate. This chapter is organized with the research problem in mind and 
with the findings presented in accordance to research questions raised in Chapters 1 and 3 as 
follows: ? Section 4.2.1 will report on the demographics of the Unit of Analysis ? Section 4.2.2 will 
report the findings on the unit cost of production; ? Section 4.2.3 will report findings on the point 
where local production is favourable over an imported vaccine (The point of indifference); ? 
Section 4.2.4 will report on the findings relating to market size for which one option is desirable 
over the other (Break-even Analysis); ? Section 4.2.5 will report the investment costs required for 
each option – Locally Filled Vaccine and Semi-finished Product; ? Section 4.2.6 will report the 
findings on the effects of changing key variables such as the cost of product and a drop in price 
on the profitability of either of the options. ? Section 4.2.7 will summarise the findings of this 
chapter and introduce Chapter 5. 4.2 Presentation of Findings 4.2.1 Demographics of the Unit of 
Analysis The 1Biologicals and Vaccines Institute of Southern Africa (Biovac) is  
a  pharmaceutical manufacturing company based in Cape Town with a workforce of 
approximately 180 employees. The core business of Biovac is vaccine manufacturing. The 
company was formed in 2003 as 1a Public Private Partnership (PPP) between the  
South African Government and The Biovac Consortium.  Since 2003, more than 
R700 million has been invested in infrastructural 40 and skills development in order to realize 
company’s ambitions of becoming a fully-fledged vaccine manufacturer on the African continent. 
Since inception, the Company has recruited a wide mix of skilled personnel to support the current 
operations of vaccine distribution, basic Research and Development as well as future expansion 
operations. By 2014, the skill set was mixed with Company employing 9 personnel with PhD 
qualifications on the high end and 30 with matriculation and below as summarised in Table 4.1 
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below. Table 4.1: Biovac Skill Set in 2014 (Permanent Employees) Qualifications No. of people 
Matric & Below 30 Certificates & Diplomas 34 Bachelor’s Degree 20 Honours Degree 10 Master 
Degree 13 PhD 9 The headcount per department is shown in figure 4.1 below. The figure shows 
that the highest numbers of people are employed in Production, Quality Control, Logistics, 
Engineering and Research and Development departments. Biovac Headcount per Dept - 2014 
Headcount per Dept. 18 16 14 12 10 8 6 4 2 0 Departments Figure 4.1: Biovac Headcount per 
Department Adapted from Biovac Presentation: Retention Policies and Models for the Local 
Workforce 4.2.2 Unit Cost of Production The determination of the unit cost of production was 
conducted in a multistep approach involving: 1) process flow mapping and identifying the relevant 
cost centre (pools), cost activities and classification; 2) Batch process information and theoretical 
capacity for aseptic filling and manual packaging operations; 3) Computation of cost activities and 
classification; 4) Indirect cost allocation of manufacturing and administrative overheads and; 5) 
the cost of producing a single unit of vaccine under various demand scenarios. Process Flow 
Mapping and Cost Categories The manufacturing process overview was developed from the 
description and identification of activities involved in both local filling and semi-finished 
importation operations. Due to the complexity of the vaccine manufacturing operations, data 
collected was reduced and categorized into main cost centre activities and further subdivided into 
relevant costs per activity. Each cost activity was classified as either fixed or variable as 
described in Table 4.2 below. Table 4.2: Process Steps for SFP and LFV Semi-Finished Product 
Locally Filled Vaccine Cost Centre/ Pool Cost Centre/ Pool Cost Activities Cost Classification 
Finished Product Handling Bulk Liquid Handling Transportation Raw Materials Labour Variable 
Variable Fixed Aseptic Filling Raw Materials Labour Eq. Depreciation Direct Electricity Variable 
Fixed Fixed Variable Viewing Viewing Labour Eq. Depreciation Fixed Fixed Labeling & Packaging 
Labeling & Packaging Raw Materials Labour Eq. Depreciation Direct Electricity Variable Fixed 
Fixed Variable Quality Control Quality Control Consumables Labour Commissioned Testing 
Variable Fixed Variable There are four steps involved in the processing of an imported vaccine 
and five for a locally produced vaccine. These steps are grouped vertically into cost centres. The 
manufacturing steps are similar between LFV and SFP operations with the additional aseptic 
filling step for the LFV. The cost centres for SFP are product handling from supplier to Biovac; 
product inspection; labelling and packaging and quality control testing. The LFV cost centres 
were found to be same as in SFP with the addition of the aseptic filling cost centre. In both SFP 
and LFV the common cost activities were: ? Transportation Costs – Freight Charges, Customs 
Clearance and Agents Fees ? Raw Materials (SFP or Formulated Bulk Liquid) – Cost of Product 
and Insurance ? Direct Electricity – power consumption required to power the equipment ? 
Quality Control Testing – consumables and testing commissioned testing ? Labour Costs – all 
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labour costs across the cost centres including indirect labour ? Equipment Depreciation – 
Significantly costly equipment depreciation (Automated filling lines, washers and autoclaves) 
Batch Process Information and Theoretical Capacity Calculations Aseptic Filling The company 
subscribes to batch manufacturing method of operation. In order to fill one batch of product, a 
single batch of formulated bulk liquid must be dispensed into single, sterile vials. The batch size 
for the product under consideration equals 83 litres of formulated bulk that is received by the 
Company ready for dispensing pending quality assurance approval. The required dose to be 
administered to a patient is 0.5 millilitres (ml) however 0.68 ml is the target fill volume in order to 
account for the residual volume of product that remains on the syringe when the vaccine is 
administered. A single batch of finished product filled from 83 litres of formulated bulk into single 
dose vials at a rate of 10,000 vials per hour is expected to have a theoretical yield of 
approximately 122,000 unit doses. With a 2% rejection rate allowed to account for start-up 
samples, product testing (quality control), in-process checks, product lost due to start-up and the 
product left in the 3 meter line between the formulated bulk tank and the filling line, the final 
quantity 43 expected to be transferred to packaging is approximately 119,000 doses. Although 
the actual filling time required to fill and empty the formulated bulk tank is approximately 12 hours, 
the total batch processing time (filling operations) requires approximately 19 hours to complete as 
shown in Table 4.3 below. Table 4.3: Batch Process Information (Aseptic Filling) Batch Process 
Information (Aseptic Filling) Formulated Bulk Size 83 Litres Fill Volume per dose 0.68 mL Batch 
Size 122059 units Batch Size (2% Scrap) 119618 units Filling Capacity 10000 units/hour Filling 
time 12 hours Setup Time 4 hours Cleaning Time 3 hours Total Process Time 19 hours It takes 
approximately 4 hours to prepare for the aseptic filling of a batch. This is the time it takes to 
perform the cleaning and sanitisation of the filling line, the aseptic connections between the filling 
line and the formulated bulk product and the time to allow the filling suite to return to a state of 
“rest”. Upon completion of the filling process, the disposable filling components are discarded as 
per approved procedures. The filling machine and the filling suite are cleaned over a period of 3 
hours. Theoretical Annual Filling Capacity The filling line has a theoretical capacity of 63.8 million 
batches per year at 10,000 vials per hour. This capacity is achieved over 38 production weeks 
and takes into account the machine will not be utilised during planned maintenance shutdown, 
Christmas holiday time and on public holidays. As presented in Table 4.4 below, 63.8 million 
doses equates to a total of 523 batches that could be filled on the vial filling line. Table 4.4: 
Theoretical Filling Capacity Theoretical Filling Capacity Production Weeks 38 Weeks Production 
Days 266 Days per Annum Production Hours 6384 Hours per Annum Annual Filling Capacity 
63,840,000 Doses per Annum No. of batches/annum 523 batches The annual demand for this 
product is 4, 500, 000 doses which equates to a spare capacity of 59.3 million doses. The annual 
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demand of 4.5 million doses is equivalent to 38 batches required to be filled per annum. Based on 
the theoretical capacity of the filling line and the stated demand, the utilization capacity of this 
filling line is approximately 7% per annum for this product. Packaging Operations The manual 
packaging process for both locally filled vaccine and the current semi-finished product is the 
same and take the same duration to complete both operations. Each unit filled or imported has to 
undergo a manual visual inspection before it can be labelled and packed. Table 4.5 below 
summarises the duration of the packaging process Table 4.5: Batch Process Information (Manual 
Packaging) Batch Process Information (Manual Packaging) Parameter Batch Size Daily Capacity 
Duration/ Quantity 119 618 Unit of measure Doses Visual Inspection Capacity/hour 2100 14 
hours Labeling Capacity/hour 6000 5 hours Packaging Capacity/hour 1750 9 hours Total Process 
Time 28 hours Batch processing Days 4 days The visual inspection process is performed by 7 
operators at an average of 300 vials viewed per hour and takes approximately 14 hours to 
complete. This equates to 2 working days on a single shift of 7 working hours (Excludes tea and 
lunch breaks). The labelling is carried out 45 using an old automatic labelling machine which has 
the capability to encode the batch and expiry date at an output of 6000 vials per hour over 5 
hours. The packaging operation takes approximately 9 hours when carried out by 8 operators 
with an average packaging rate of 250 vials per hour. The total packaging time is approximately 4 
days for a single batch of product. Cost Activity and Computation of Unit Cost of Production From 
data collection and process overview, the main cost drivers for both locally filled and semi-
finished vaccines were transport, raw materials, product cost (either formulated bulk or semi-
finished product), quality control testing and labour costs. Of these cost drivers, the cost of 
transport, raw materials and cost of product emerged the highest. Table 4.6 below presents a 
detailed account of the various costs associated with locally filled and semi-finished vaccines as 
per data collected. Table 4.6: Summary Costs behaviour per batch and per dose Summary Cost 
Behaviour Cost Drivers Locally Filled Vaccine Costs Semi-Finished Vaccine Costs Cost Activity 
Cost Type Per Batch Variable Costs/dose Fixed Costs per Annum Per Batch Variable Costs/dose 
Fixed Costs per Annum Transport Variable R 192,287 R 1.58 R 403,725 R 3.31 Raw Materials 
Variable R 280,340 R 2.34 R 63,566 R 1.06 Cost of Product Variable Direct Energy Variable R 
11,961,765 R 4,979 R 100.00 R 0.04 R 8,779,971 R 157.00 QC Testing Variable R 90,738 R 
0.74 R 22,392 R 0.18 Depreciation Fixed R 3,097,307 All Labour Fixed R 8,023,794 R 5,069,243 
Total variable Cost per Dose R 104.70 R 161.55 Total Direct Fixed Cost R 11,121,101 R 
5,069,243 Manufacturing Overheads R 14,065,742 R 2,168,850 Administration Overheads Total 
indirect cost R 84,269,765 R 98,335,506 R 54,318,980 R 56,487,830 Total Fixed Costs R 
109,456,607 R 61,557,073 Total Fixed Costs/dose (4.5 million doses) Total Fixed Costs/dose (2 
million doses) Total Fixed Costs/dose (76 million doses) R 24.32 R 54.73 R 1.71 R 13.68 R 30.78 
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R 0.96 The cost of transporting 83L formulated bulk from a supplier in Europe to Cape Town was 
R192, 287 whilst the 39cost of transporting semi-finished product from the  same 
supplier was 46 R403, 725. The cost of transporting semi-finished product is more than double 
the cost of transporting 83 Litres of formulated bulk for local filling operations. Transporting 83L 
from Europe to South Africa cost R1.58 per dose when compared to R3.31 for semi-finished 
vaccine. The cost of transport is made up of freight charges, customs clearance fees and agent 
forwarding charges. The cost of raw materials required to process a batch of a locally filled 
vaccine was R280, 340 whilst the cost of raw materials required for a semi-finished product was 
R63, 566. The costs of raw materials for a locally filled vaccine are more than four times the costs 
of raw materials required to complete a semi-finished product. The raw material costs for a locally 
filled vaccine are R2.34 per dose whilst for a semi-finished product the raw material costs are 
R1.06. This is a difference of only 50% between the dosage forms however; this is expected at a 
dose level since the raw material costs of a locally filled vaccine are in addition to those of an 
imported product. The cost of raw materials for semi-finished vaccines included the labels, 
cartons, package inserts and shippers. In addition, the raw materials for a locally filled vaccine 
includes glass vials, gamma irradiated rubber stopper and the aluminium seal cap. All these items 
are imported into the country. A single dose of semi-finished product costs R157 before 
processing. This translates to R8, 779, 971 per batch of 119,000 units. The cost of purchasing 
formulated bulk (83L) was calculated to be R11, 961,765 per batch which translates to R100 per 
dose filled locally. The unit cost per dose of a semi-finished product costs at least 50% more (at 
R157) than a locally filled vaccine at R100 per dose when compared to the semi-finished product 
at R157 per dose as per contract price. For both options of this product, the product cost 
accounted for more than 90% of the cost per dose. Direct energy costs to drive the filling line, 
autoclaves and automated washers were found to be significantly low at less than 5 cents per 
dose. Direct energy was only calculated for the locally filled vaccine and not on the manual 
packaging operation as there is only one low capacity labelling line used in this process and the 
power consumption is considered insignificant. The cost of quality control testing of a locally 
finished vaccine was four times that of a semi- finished vaccine. It cost R90, 738 to test a batch of 
a locally produced vaccine (R0.74 per dose) when compared to R22, 392 to test a batch of a 
semi-finished product (R0.18 per dose). The quality control testing for locally filled vaccine 
includes full batch testing whilst the semi-finished batch includes selected tests which are limited. 
Fixed depreciation costs using a straight-line method for the major equipment used directly during 
the filling process were calculated as fixed costs at R3 million whilst the total cost of labour that is 
directly involved in the production of the batch was R8 million for the locally filled vaccine and R5 
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million for the semi-finished vaccine. This is a cost difference of R3 million (60% difference) that is 
required per annum to produce vaccines locally. The total variable cost per dose for a locally filled 
vaccine is R104.70 when compared to R161.55 for the semi-finished product. This is a cost 
difference of R56.85 per unit between a locally filled vaccine and the imported product. However 
the total fixed costs for a locally filled vaccine are R109 million when compared to R61.5 million 
for the semi-finished product. The total fixed costs per dose for the locally filled vaccine at annual 
demand of 4.5million doses were R24.32 when compared to R13.68 for the semi-finished 
imported vaccine. This is a difference of almost 80% between the two products. At full theoretical 
capacity of 63.8 million doses per year, the fixed cost per dose drops from R24.32 to R1.71 for 
the locally filled vaccine and R13.68 to R0.96 for the imported vaccine. The fixed cost per dose 
for both products drop significantly with an increase in the number of doses produced. At 2 million 
doses (approximately half the annual demand), the fixed cost per dose are more than double 
those of the annual demand. 4.2.3 Objective 2: Level of economic activity favourable to LFV vs. 
SFP The second 28objective of this study was to determine the level of  economic 
activity for which local production (LFV option) is preferred when compared to the importation of 
SFP. This was achieved by first determining the point at which the total cost of producing a LFV is 
less than the total cost of producing a SFP. Figure 4.2 below is a graphical representation of the 
total costs incurred in the production of LFV and the SFP when plotted against the number of 
doses of vaccines sold. 48 Millions R 600 Indifference Point SFP R 500 LFV R 400 Total Cost of 
Prodcution 7R 300 R 200 R 100 LFV Preferred R0 0 0.5  1 1.5 2 2.5 3 3.5 Number of 
Vaccine Doses Millions Figure 4.2: Point of Indifference In figure 4.1 above, the cost behaviours 
of LFV and SFP are plotted on the same axis. The total cost of production is plotted along the Y-
axis and the number of vaccine doses is plotted along the X-axis. The Y-intercept for each curve 
represents the respective fixed costs of each option. The curve depicting SFP is plotted in blue 
and labelled SFP whilst the curve depicting LFV is plotted in dark red and labelled LFV. The 
slopes of each of the curves represent the variable cost per dose which translates to the total cost 
of production for each vaccine sold. The variable cost per dose for SFP (R161.55) is higher than 
for LFV (R104.70) hence the cost of production increases at different rates which are shown by a 
steeper curve for the SFP when compared to the LFV curve. The black dotted line indicates the 
point at which the LFV and SFP curves intersect at 800,000 doses. At this point it does not matter 
whether this product is imported semi-finished or is manufactured locally since the costs of 
production is the same. This point is also referred to as the point of indifference. It is observed 
from the curves that the total fixed cost of a LFV is initially higher than the fixed cost of a SFP up 
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to 800, 000 doses (point of indifference). Beyond this point, the costs of local vaccine production 
remain below the costs of importing a SFP. That is, beyond 800, 000 doses it becomes more 
favourable to locally produce the vaccine than to import it semi-finished. This does not mean that 
either option will generate positive revenue (profit) beyond 800, 000 doses. When taking into 
account the break-even analysis of each option as calculated in table 4.6 below, the break-even 
point for LFV is 1.3 million doses and 2. 6 million doses for the SFP. Therefore this confirms that 
at 800,000 doses sold the company would be operating at a loss for both options. 4.2.4 Objective 
3: Determination of the desirable market size (Break-even Point) The selling price for both locally 
filled vaccine (LFV) and semi-finished product (SFP) is the same at R185.00 per dose (current 
selling price of SFP). Table 4.7 summarises the break even analysis for the LFV and the SFP. 
Table 4.7: Break-even Analysis of LFV vs. SFP LFV SFP Sales/Dose R 185.00 R 185.00 Variable 
cost/Dose R 104.70 R 161.55 Contribution Margin R 80.30 R 23.45 Total Fixed Costs R 
109,456,607 R 61,557,073 Doses to Break-even 1,363,150 2,625,234 Total Costs per dose 
(F+V) R 129.03 R 175.23 Profit per dose (4.5 million dose) R 55.97 R 9.77 The variable cost per 
dose of LFV is significantly lower than for the SFP at R104.70 and R161.55 respectively. The 
lower variable cost per dose corresponds with a higher contribution margin of R80.30 for the LFV 
when compared to a much lower contribution margin of R23.45 for the SFP. The total fixed costs 
for each option vary significantly with fixed costs accounting for R109.5million for LFV when 
compared to R61.5million for SFP. The break- even point for both LFV and SFP was found to be 
below the annual demand of 4.5million doses. The number of doses required to break-even for 
the LFV was 1.3million compared to 2.6million for the SFP. The total cost per dose for LFV was 
lower at R129.03 when compared to R175.23 for the SFP. This resulted in a significant profit per 
dose of R55.97 per dose of locally produced unit when compared to R9.77 per dose. An analysis 
of 2million doses results in a loss for the SFP and a profit of R25.57 for the LFV. Figure 4.3 below 
is a graphical presentation of the results on the effect of profit generated per dose sold for the 
LFV and the SFP. Millions R 350 R 300 Break-even Point for LFV Break-even Point for SFP LFV 
13R 250 R 200 R 150 Profit R 100 R 50 SFP R 0 -R 50 4.5million Doses -R 100 -R  
150  0 1 2 3 4 5 6 Number of Vaccine Doses Millions Figure 4.3: Break-even Analysis of 
LFV vs. SFP By plotting the curve depicting Profit on the Y-axis against the number of doses sold 
the curve above emerges. The Y-intercept for each curve represents the fixed costs. The slopes 
of each of the curves represent the contribution margin per dose which translates to profit 
generated with each sale. The break-even point for both LFV and SFP is the point where each 
curve crosses the X-axis at zero. This point is shown on the graph by the black dotted line. Below 
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the X-axis there is no profit generated hence the numbers are negative and above the X-axis 
there is profit generated hence the numbers are positive. The annual demand for this product on 
the South African market is 4.5 million doses and this point is marked on by the red dotted line. 
The fixed costs for LFV are more than those of the SFP however; the slopes of each curve differ 
markedly. That is, the LVF curve is steeper than the SFP curve which means the higher the 
contribution margin, the steeper the curve and the faster the rate of profit generation. By 
observing the two curves, it takes less than a million doses for the LFV and SFP curves to cross 
each other and reach a point where the cost of importing the SFP equals the cost of producing 
locally. However, both LFV and SFP options are not profitable at this point. At the LFV break-
even point of 1.3million doses, the SFP option is not generating a profit and is still at a loss of 
approximately R30 million. When the SFP reaches break-even point at 2.6million doses, the LFV 
option has already generated a profit of approximately R90 million. At the annual demand of 4.5 
million doses, the profit generated by the LFV is approximately R250 million compared to a profit 
of approximately R45million generated by the SFP option. 4.2.5 Investment costs The analysis of 
the investment costs showed that more than R745 million has been invested into establishing 
local manufacturing operations. A further breakdown of the costs reveals that R375 million is 
required for investment into semi-finished operations as opposed to a total of R745 million 
required for local vaccine filling operations. From the findings, almost twice (1.98 times) the 
investment amount is required for locally filled vaccine operations than semi- finished. The 
investment amounts exclude the cost of labour that was incurred from 2003 to 2014. Because 
Biovac was established on an existing site (formerly, The State Vaccines Institute) the costs of 
acquiring the land, excavations and electrification is excluded from the calculated investment 
costs. The major investment costs for semi-finished product were attributable to setting up of the 
Cold Room Storage infrastructure, Quality Control laboratories, Packaging Halls and the 
Administration buildings. Of these costs, the Quality Control laboratory constituted the bulk of the 
costs at R240 million whilst the construction of the warehouse building was the least. The 
warehouse cost included the refrigeration infrastructure for vaccine storage. The major 
investment costs are summarised in Table 4.8 below. Table 4.8: Investment Cost Summary Cost 
Category Item Description Item Cost API, Formulation & Filling R300 million Infrastructure Quality 
Control Laboratories R240 million Packaging Hall 100 million Warehouse & Utility R30 million 
Automated Filling Line R34 million Plant & Equipment Washers & Autoclaves R12.5 million 
Cleanroom Structures R2.5 million Technology Transfer Product for Local Filling R17 million The 
investment cost of setting up local filling operations alone were R300 million excluding the 
equipment to be used inside the Cleanrooms. The cost of constructing the formulation and filling 
suites was more than the combined cost of setting up operations for a semi-finished product. Of 
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this amount (R300 million), approximately 10% was allocated to the purchasing of a high speed 
automated aseptic filling machine at a cost of R34 million. Less than 5% of the cost went to the 
purchasing of autoclaves and automatic washers which are crucial in ensuring consistent 
cleaning and disinfection of pathogens before and after filling operations. 4.2.6 Effect of changing 
Cost of Product and Selling Price Increasing Cost of Product Figure 4.4 below demonstrates the 
effect of increasing the cost of formulated bulk by 25% on the profitability of local vaccine filling 
operations. Millions R 200 R 150 Break-even point 1: LFV Break-even point 2: LFV LFV R 100 
Profit R 50 R 0 SFP -R 100 Break-even Point 1:SFP -R 150 0 1 2 Number of Vaccine Doses 3 4 
5 6 Millions Figure 4.4: Effect of increasing Cost of Product on profitability for LFV The findings 
show that increasing the cost of formulated bulk by 25% caused the break-even point curve to 
shift to the right from 1.3 million doses (Break-even point 1:LFV) to 1.98 million doses (break-
even point 2: LFV). Notably, the new break-even point for LFV is reached before the break-even 
point for SFP (Break-even point 1: SFP) which occurs at 2.6 million doses. A 25% increase in the 
cost of formulated bulk product resulted in a drop in profit per dose for LFV from R55.97 to 
R30.97 which equates to a profit drop of R25 per dose (45% decline). This results in a net profit 
of 16% from local filling operations as opposed to a profit of 12% from semi-finished product. 
Consequently the total profit that can be realized from local filling operations is approximately 
R140 million compared to approximately R45 million that could be generated from semi-finished 
operations. Figure 4.5 below shows the effect of increasing the cost of formulated bulk product by 
25% on the point of indifference. This figure indicates that local filling operations are favourable 
over semi-finished operations even with a 25% increase in the cost of product. Millions R 800 
Point of Indifference 1 R 700 Point of indifference 2 7R 600 R 500 Total Cost R 400 R  
300 R 200 R 100 R 0 0  1 2 3 4 5 Number of Vaccine Doses Millions Figure 4.5: Point of 
Indifference after increasing Cost of Product for LFV Figure 4.5 shows the effect of increasing the 
cost of product on the indifference point as a shift to the right from the original 800, 000 doses to 
fewer than 1.6 million. On the contrary, by increasing the cost of semi-finished product by 25%; 
the break-even point was reached at 7.9 million doses which are beyond the annual demand for 
this product. This suggests that local vaccine filling operations are favourable over semi-finished if 
the demand is expected to be more than 1.6 million doses per annum. With the current demand 
of this product currently estimated to be 4.5 million doses, local production is favourable. 
Reduction in Selling Price: The selling price of a semi-finished vaccine was R185 per dose. 
Findings showed that dropping the selling price of a semi-finished product by 10% from R185 to 
R175.75 per dose required 4.3 million doses to break even as opposed to 2.6million doses if the 
117 
 
selling price remained unchanged. In contrast, a 20% reduction in the selling price of a locally 
filled vaccine from R185 to R148 required 2.5 million doses to break even as per break-even 
analysis curve in Table 4.9 and Figure 4.6 below. Table 4.9: Break-even Analysis after a drop in 
product selling price Break-even Analysis after Selling Price Reduction LFV SFP Sales per Dose 
R 148.00 R 175.75 Variable cost/Dose R 104.70 R 161.55 Contribution Margin R 43.30 R 14.20 
Total Fixed Costs R 109,456,607 R 61,557,073 Doses to Break-even 2,528,052 4,335,549 Total 
Costs per dose (F+V) R 129.03 R 175.23 Profit per dose (4.5 million dose capacity) R 18.97 R 
0.52 The findings in Table 4.9 showed that the profit per dose generated by local filling operations 
after a 20% reduction in the selling price is 32 times more than the profit per dose generated from 
semi-finished product operations. The findings reveal that a 20% selling price reduction results is 
a drop of almost 50% (from R80 to R43) for the locally filled vaccine operations and remained 
profitable. This is in contrast to a drop of 60% in profit margin from only a 10% drop in the selling 
price for the semi-finished product. These findings are consistent with those observed on the 
effect of increasing the cost of product in that in both instances; locally produced vaccine option is 
more resilient to price fluctuations. Semi-finished product is sensitive to external market forces 
which can easily render the operations to be unprofitable in the long term. Figure 4.6 below 
illustrates the effect of reducing the selling price by 20% for locally filled vaccine and 10% for 
semi-finished product. Millions R 150 R 100 Original LFV break-even LFV Break-even after 20% 
price reduction LFV R 50 SFP Break-even after 10% price reduction Profit R0 SFP -R 50 -R 100 
Point of indifference -R 150 0 1 2 3 4 5 6 Number of Vaccine Doses Millions Figure 4.6: Effect of 
reducing Selling Price on profitability Figure 4.6 shows that locally filled vaccine operations break-
even ahead of semi-finished product operations. The effect of the price reduction is a shift to the 
right in break-even points of both options (LFV & SFP) but the point of indifference is reached 
around 1.6 million doses indicating that local filling operations are favourable when the demand is 
more than 1.6 million doses. Under the selling price reduction scenarios described above, it was 
also noted that there is virtually no profit generated by the semi-finished operations at maximum 
annual demand of 4.5 million doses. This again is in contrast to a modest profit of approximately 
R50 million generated from local filling operations. 4.3 Summary This chapter analysed the 
findings on semi-finished and local vaccine filling operations. The findings showed that local 
vaccine filling, compared to semi-finished product, generates higher profits and is more 
favourable as a form of local production when the demand for this vaccine exceeds 800, 000 
doses per annum. The findings also revealed that the low margins generated from semi-finished 
operations may be responsible for the high sensitivity to price fluctuations for this manufacturing 
option. As shown in the study, a 10% reduction in the selling price renders semi-finished 
operations unprofitable whereas the local filling operations are able to withstand price drop of 
118 
 
20% and still remain profitable. In this study, it was shown that local filling operations do not rely 
on economies of scale (or large markets) to be profitable; however when it comes to semi-
finished product economies of scale may cushion the operations against operational losses due 
to external market forces. Chapter 5 will provide a discussion of the findings from this Chapter. 
CHAPTER FIVE: 24Discussion 5.1 Introduction The aim of this study was to  
evaluate economic viability of  a locally filled vaccine when compared to the same vaccine 
that is currently imported as a semi-finished product for labelling, packaging and distribution. The 
objectives were to determine the production costs for both options followed by a thorough 
analysis on which option is favourable to pursue under which conditions. A case study approach 
was followed in conducting this study in order to gain an in-depth contextual analysis of the 
Biovac processes and cost factors using multiple sources of data. This chapter will discuss the 
findings in relation to the key consideration that were highlighted in the 14literature  
review in chapter 2 within the context of Biovac. In particular the  production costs, skills 
availability, economies of scale and their effect on profitability and finally the findings on the 
investment cost requirements will be discussed. The Chapter will conclude with a summary. 
5.1.1. Cost of Production and Price of Finished Product Literature review in Chapter 2 highlighted 
the drivers behind the support for local production as heavy disease burden, lack of access to 
affordable medicine, security of supply and the socio-economic benefits that stand to be realized. 
Those who argued against local production (Kaplan and Laing, 2005; Bate, 2008) cited lack of 
skilled personnel, economies of scale (small markets), cost disadvantages and lack of 
competitiveness of the local pharmaceutical industry. That is, the viability of local production rests 
on the ability of local manufacturers to produce quality medicine at competitive or better prices 
than imported medicine. Within the context of this study, the production costs of a locally filled 
vaccine were compared to the costs of a semi-finished product to determine the viability of local 
vaccine production in South Africa. In-bound transport Costs The cost of transporting formulated 
bulk product is significantly less than the cost of transporting semi-finished product for labelling 
and packaging. Formulated bulk product is transported in a 100L stainless steel vessel that is 
inside a self-cooling container. On the other hand, the filed vials are packed in trays which are 
stacked inside insulated shipper boxes that 59 are filled with dry ice. Dry ice is used to ensure 
that that cold chain is maintained from the supplier to Biovac. As a result, shipment of semi-
finished product is bulky and requires a standard shipping container. Because the packaging 
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configuration of formulated bulk takes up less space and requires less pre-shipment handling, it is 
expected that the shipment costs would be less. Cape Town is a port of entry for Formulated bulk 
and semi-finished products which are then transported for 15 kilometres to Biovac in a 
refrigerated truck. The shipping costs would be expected to be more if either the formulated bulk 
or the semi-finished product were to be delivered to a land-locked country. This additional cost of 
transport would be added to the price of medicine. All else being equal, it is likely that the cost of 
the same product in a landlocked country would be more than it would be in South Africa. Cost of 
Testing (Quality Control) The cost of testing a locally filled vaccine is substantially more than 
testing a 35semi-finished product. The semi-finished product is  delivered with a 
certificate of analysis that confirms that all tests have been performed in accordance to procedure 
with only the potency and product identification that remain to be tested on finished product. 
Formulated bulk product requires additional testing steps from delivery to finished product. These 
steps include bulk sample testing, in-process and finished product testing which includes sterility 
testing and potency at each step of the process. It is therefore expected that the testing costs 
would be more for locally filled vaccines when compared to semi-finished product. In instances 
where the laboratory infrastructure is not in place to complete all tests required, the Company 
may send certain samples to external, approved laboratories to conduct such tests on behalf of 
the Company. External testing comes at a cost, therefore, a cost-benefit analysis on which tests 
are to be carried out in-house or to be outsourced is usually done based on the available skill, 
complexity of the test, cost of equipment and frequency of the testing requirement. Raw Materials 
Costs The costs of raw materials that are required to process formulated bulk are twice as much 
as those required for processing semi-finished product. Semi-finished product is delivered as 60 
naked vials (unlabelled product) and undergoes labelling and final packaging. Over and above, 
the locally filled vaccine requires specialised type of glass vials, gamma-irradiated rubber 
stoppers and aluminium seals which are imported abroad in foreign currency. Once the product is 
filled, it undergoes the same process as a semi-finished product. The cost of raw materials per 
dose is however not twice as much for locally filled vaccine versus semi- finished product 
because the total cost is an average of total cost divided by the number of units filled. The 
importation of glass vials and rubber stoppers mean that these items are subject to foreign 
currency fluctuations and therefore the cost may vary throughout the year. Cost of Production – 
Locally Filled vaccine vs. Semi-finished Product When analysing the cost of product, the following 
becomes evident: The cost of semi-finished product is R157 per dose as per contract which 
translates to R8.7 million per batch. The cost of formulated bulk product is R11.9 million as per 
contract which translates to R100 per dose of filled product. The cost per dose of locally filled 
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vaccine is expected to be lower than semi- finished product as expected. Formulated bulk cost 
more than the semi-finished product however the variable cost per dose of a locally filled vaccine 
is far less the semi-finished product. Semi-finished product and LFV present different sets of 
challenges that may have an effect on the cost of each option. Firstly, the risks of product failure 
due to sterility and low potency remain with the supplier of the semi-finished product up to the 
point of delivery to Biovac. Over and above, the product supplier would have incurred additional 
cost of quality assurance on the process as well raw materials used in the product also remain 
with the supplier. Secondly, the same risk of batch failure due to sterility pose a major concern as 
the responsibility shifts from the product supplier to the manufacturer. Vaccine manufacturing 
requires aseptic handling which means there is no terminally sterilisation step once the product is 
in the final container. The manufacturer not only has to be vigilant about product handling to 
prevent loss of potency and product contamination during processing but also has to prove 
through validation that the product can be handled from delivery right through processing into 
finished product. Another finding that may appear as a cause for concern is the low utilization 
capacity of 5.6% which suggests that the filing suites will be utilized for an equivalent of only a 
few weeks in a year. Even when taking into account aseptic validation activities that take place 
during year, the utilisation capacity remains low. This presents an opportunity to bring additional 
products through contract manufacturing of other compatible products and indicates that the filling 
line is not a bottleneck. This will help to improve the higher utilisation capacity. 5.1.2. Availability 
of Skilled Labour and Cost of Labour Personnel employed at Biovac possess a skill base that 
ranges from very low skill with no formal qualification all the way up to Master’s and PhD level. 
The spread of skill and expertise support the low tech, tertiary operations with semi-skilled 
personnel through to aseptic filling operations with skilled personnel and research and 
development with highly skilled personnel with Honour’s, Master’s and PhD degrees. The 
Universities of Stellenbosch, Cape Town and the Western Cape are some of the tertiary 
institutions providing support to Biovac in skills development and other research collaborations. 
The labour requirements for labelling and packaging of semi-finished product operations is less 
than the requirements for LFV in terms of the operator skill and the simplicity of the operations. 
The skill requirement for tertiary production operators is low-tech and does not require a tertiary 
qualification. On the other hand secondary production (aseptic formulation and filling) requires a 
higher level of expertise especially in microbiology background. This is evident in the mix of skill 
set that is utilised for local filling operations. As long as Biovac is able to recruit and retain the 
right kind of skilled personnel and continually train them in topics such as validation, aseptic 
processing, cGMP and quality assurance; local production operations will receive the required 
support and ensure that local filling operations remain sustainable. 5.1.3. Economies of Scale on 
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Profitability and Sustainability Under current conditions, local vaccine filling from imported bulk is 
favourable if the demand is estimated beyond 1.3 million doses. For the product under study, the 
demand for semi- finished product is currently at 4.5 million doses per annum and therefore this 
option is favourable. The semi-finished product seemed to be highly sensitive to price fluctuations 
and with a slight drop in the selling price resulting in non-profitability. This is concerning when 
taking into account that this product is imported in foreign currency and hence is subject to 
currency fluctuations. Secondly, with vaccine prices known to drop with time as more competition 
enters the market (Spier and Milstien, 2009), the sensitivity of the semi-finished product to price 
does not seem to favour this option for long term sustainability Therefore, the findings support 
local production of this vaccine. The economies of scale for this product appear to be 
exaggerated with profitability being achieved with 1.3 million doses which coincides with a point 
where the number of doses for imported vaccine is not even profitable. The argument for 
economies of scale was raised in Chapter 2 and a concern was raised by the researcher that 
there is no definition or an indication on what constitutes favourable economies of scale. This 
finding is 34in line with a study that was conducted  in Ghana by Chaudhuri (2013) 
which also showed that local production in small countries with small economies can be profitable 
despite the cost disadvantages. The findings confirmed the issue of high fixed costs in vaccines 
(Baumann, 2009) in that the fixed cost per dose reduced with the increasing number of doses. 
This effect of this phenomenon was more noticeable with semi-finished product. This suggest that 
although the definition of economies of scale is not very clear; when it comes to the profitability of 
semi- finished product operations the more doses that can be sold the lower the fixed cost per 
dose that can be realised. Perhaps one way to improve profitability would be to expand to 
regional markets. For South Africa, expansion into the Southern African Developing Countries 
(SADC) region which includes Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, and 
Mozambique would unlock untapped markets. This will also increase the current production 
utilisation capacity of 5.6% to beyond 15%. Local production is able to repay the investment costs 
in approximately 4 years with a profit margin of R55/dose for LFV. Even when the selling price 
drops by 20% LFV is still favoured over SFP. 5.1.4. Investment Costs Infrastructural Costs The 
findings in Chapter 4 confirmed that there are different levels of investment requirements for 
secondary and tertiary production operations. The infrastructural investment began a decade ago 
and to date more than R700 million has been invested into the reestablishment of local vaccine 
manufacturing. The setup costs for tertiary operations (labelling and packaging) were 
substantially low at R375 million when compared to R745 million total investment cost for 
secondary and tertiary operations. This implies that the requirements for local vaccine filling 
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operations are twice as much as the requirements for semi-finished operations. This was not 
surprising as the infrastructural cost of the formulation and filling suites alone were R300 million 
excluding plant and equipment. Vaccines are sensitive to heat and therefore the investment into 
the warehouse and cold room storage is required upfront before any labelling and packaging can 
take place. Being heat sensitive, testing for potency on delivery and of finished product is critical 
to prevent processing of product that may not meet the quality standard hence the quality 
assurance infrastructural requirement. Quality control laboratories require sophisticated 
equipment which also adds to the cost of the product. The presence of the cold chain and testing 
infrastructure not only does it allow for labelling and packaging operations to continue but serve 
as building blocks for more products to be brought into the facility. In addition it serves as a 
footprint for expansion into more complex operations such as formulation and filling whilst 
generating revenue. The model of backward integration which was adopted by Biovac showed 
that other countries who are interested in establishing local pharmaceutical manufacturing can 
begin by investing in simpler operations to generate revenue and increase the level of investment 
into more complex operations over time. The findings revealed that the profit margins from semi-
finished operations are lower than those for semi-finished product which translates to the ability to 
recoup the investment costs from operations. The findings showed that importing this vaccine will 
generate a profit of 10% before distribution and marketing costs whilst the local filling operations 
will generate 64 about 43% before distribution and marketing costs. It is clear from the findings 
that local filling operations, under current conditions, are highly favourable for this product over 
the imported vaccine. From an investment point of view, local filling operations indicate a better 
return on investment and a high probability to being able recoup the investment costs. This 
means the formal banking sector is likely to fund this kind of operation. This finding is supported 
by the analysis into the effect of price fluctuations which showed that a 10% drop in the selling 
price resulted in a break-even point of 4.3million doses for the semi-finished product as opposed 
to the local filling operations. This means it would take more than a decade to recoup the 
investment costs of simple tertiary production operations. On the other hand, even with a drop in 
selling price of as much as 20% for a locally filled vaccine this option remains favourable over the 
SFP both in terms of the point of indifference and break-even. Technology Transfer Costs This 
refers to the costs associated with bringing a new product into the facility. There are three 
considerations to be taken into account when selecting a technology transfer partner to ensure a 
mutual benefit. Firstly, the selection of the product(s) to be produced in the facility must be 
compatible with the available infrastructure in order to contain investment costs. Secondly, 
because pharmaceutical production is highly regulated, the product may not be sold to the market 
before licensing and registration approval from the local regulatory agency has been obtained. 
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Finally, whilst technology transfer may speed up the process knowledge and improve personnel 
skill level, it cost money and someone has to pay for it. Selecting a mutually compatible partner is 
critical to ensure fair distribution of costs. For example, this technology transfer required an 
investment of approximately R17 million. However this cost could have been in excess of R30 
million without the technology transfer partner bearing the costs of active raw materials and 
training. Transferring technical know-how requires competent project management skills as this is 
an immense investment undertaking before the product can be sold into the market. 5.2 
Summary The findings indicate that local vaccine filling operations from formulated bulk product is 
more favourable over imported semi-finished vaccine for labelling and packaging when the 
estimated demand exceeds 800, 000 doses. The profitability of local filling operations is reached 
at 1.3 million doses. This is less than half the annual demand of 4.5 million doses for this product. 
In contrast, the profitability of an imported semi-finished vaccine is reached at 2.6 million doses 
which is twice number of doses. In addition, at 4.5 million doses the semi- finished product is 
expected to generate a profit of approximately R50 million compared to a convincing R250 million 
for locally filled vaccine. Although the investment requirements for local vaccine filling operations 
were found to be approximately twice as much as those required for semi-finished product 
operations, the profit margins justify the investment undertaking. Furthermore, the semi-finished 
product seemed to show noticeable sensitivity to price fluctuations which is a concern for a 
product that is imported in foreign currency and is subject to exchange rate uncertainties. Finally, 
the concept of economies of scale in relation to profit generation seems to be over exaggerated 
as shown by the findings of this study as well as the study that was conducted in a smaller market 
in Ghana. CHAPTER SIX: Recommendations and Conclusions 6.1 Introduction The aim of this 
study was to evaluate, using Biovac as a case study, whether local vaccine production is 
economically viable when compared to importation of semi-finished product. The objectives were 
to determine the costs of production of each option and to assess which option was favourable 
under which conditions and to determine the investment requirements for each of the options. 
This Chapter provides the implications of this research as well as recommendations for future 
studies based on the findings. 6.2 Significant Conclusions from the Study The major conclusion 
from this study is that local vaccine production may be economically viable and more preferable 
to imported semi-finished product. The cost of formulated bulk and semi-finished product 
constituted more than 80% of the total cost of production however; the profit margins from local 
vaccine filling operations were shown to be substantially higher than those that stand to be 
realised from processing semi-finished product. As a result of low profit margins that are 
generated from semi-finished product, this manufacturing option is the least favourable between 
the two and is sensitive to price fluctuations. The conclusion is that this option may not be viable 
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for long sustainability of the organization. The second conclusion from findings showed that local 
production operations of high-end multivalent vaccines are economically viable even with low 
volumes. This finding must be interpreted with caution as it does not reveal that whilst being 
cheaper and profitable; the risk of batch failure shifts from the supplier to the local manufacturer. 
This may have massive financial implications which the local manufacturer may not have been 
exposed to when processing semi-finished product. Therefore significant amount of time in 
training and validation may be required to ensure the risk of batch failure due to process 
inconsistencies is minimised. Although the study did not assess economic viability from antigen 
production and formulation, the findings suggest that local filing from locally produced antigens 
may be even cheaper. This takes into account that local production will eliminate transport and 
formulated bulk costs however; this level of operation will require additional product handling and 
expose the organization to even higher risks of batch failure over and above the skill 
requirements for processing product at this level. It is within this context that a conclusion can be 
drawn that security of supply may take years to be realised, if not decades, as Africa continues to 
be dependent on imported formulated bulk to carry out local filling operations. This suggests that 
the African continent still remains vulnerable to supply shortages. This is contrary to the notion of 
establishing local manufacturing operations to reduce dependency on imports. 6.3 Implications of 
this Research This study provides an assessment tool for Biovac management to use when 
assessing the viability of a project proposal from a potential technology transfer partner. With the 
production costs associated with processing imported semi-finished product and local filling from 
formulated bulk know, determining the number of doses required to break-even (profitability) and 
the extent of the profitability (at anticipated demand) of the proposed option is now possible. This 
will allow management to strategize on which vaccines or compatible products to pursue and 
more importantly which information to use in the assessment. The findings from this study 
suggest that economies of scale are a key consideration for profit generation and may not 
necessarily be an absolute requirement for countries or governments who want to produce locally 
to meet local demand. As shown by the findings, the break-even point of a locally produced 
vaccine with an annual demand of 4.5 million doses could be reached with 1.6 million doses sold. 
However, economies of scale cannot be disregarded as they can provide a cushion against 
external forces such as a drop in the selling price or an increase in the cost of product as per the 
findings on the resilience of the semi-finished product option. With The African Union supporting 
local production across Africa as a means to stimulate industrial development and economic 
growth, other countries that may be interested in pursuing vaccine production and sterile 
manufacturing can use this study as a baseline to 68 gauge the level of investment required for 
such an undertaking. Other countries will be able to use findings from this study on manufacturing 
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costs to make decisions which cost factors to subsidise in efforts to lower costs to the end user. 
6.4 Recommendations to solve the research problem This case study focused on multivalent 
vaccine production to draw conclusion on the viability of local vaccine filling operations. This 
presented a limitation in that the study did not consider whether a low cost vaccine with a lower or 
higher demand will also be a viable option to pursue when compared with imported semi-finished 
product. However, this study made it possible to determine economic viability of any operations. 
For Biovac to get a complete picture on which vaccines to continue importing or to consider 
manufacturing them locally, through technology transfer, an internal study must be carried out to 
include monovalent and low cost vaccines. Carrying out a study of this nature will allow Biovac to 
develop a matrix of the type of products to be pursued for local production based on set of well-
defined criteria. Most importantly a study assessing the effect of adding other products on the 
existing infrastructure will be of benefit in that it can increase the utilization capacity which is 
currently below 10%. 6.5 Recommendations for Future Studies This study was a first of its kind 
on the African continent with regards to vaccine production but the findings and conclusions were 
drawn from a single case study. Due to the limitations of the study and a single unit of analysis, 
the findings may be difficult to apply generically across other pharmaceutical manufacturing 
operations. The focussed on the production costs to evaluate viability, perhaps other studies 
could focus more on other types of costs to evaluate the combined effect of mixed costs on the 
viability of local operations. Despite the limitations of the study, the findings showed some 
correlation with literature on the exaggeration of the effect of economies of scale. For example, 
the finding showing possibility profitability with relatively low volumes of vaccines sold correlated 
with the study conducted by Chaudhuri (2013) in Ghana which also showed similar results. 
Perhaps more 69 studies could be conducted to define what constitutes economies of scale in 
order to remove ambiguity in the current interpretation and definition. Finally, the duration of the 
technology transfer for this product was almost 3 years due to regulatory requirements for 
validation prior to product licensing. Perhaps a study focussing on comparing the opportunity 
costs the due to time lost while waiting for regulatory approval and licensing for either semi-
finished or locally filled vaccine may justify or prove to the contrary the viability of local production. 
The study will need to focus from an investment point of view. 6.6 Summary The aim of the study 
to evaluate economic viability of local vaccine production was fulfilled. The research methodology 
and approach used to address the objectives was able to collect relevant data. From the findings 
presented in Chapter 4 and analysed in Chapter 5 the conclusion that is drawn from this study is 
that the local vaccine filling operations are a viable option when compared to imported semi-
finished product under the conditions stated in the previous chapters. The recommendations 
made will enable Biovac to expand on the findings of this research 4 6 7 8 9 10 11 12 13 14 15 16 
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